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Abstract
Abstract
About fifteen years ago, the complete sequence of the human genome had been decoded.
Great hopes were pinned on this major achievement of modern science. However, in fact
genes are merely the building plan of a cell, and it is their products, the proteins, that ex-
ecute all functions in biological processes. Hence now proteomics, the branch of science
investigating proteins, is a great new hope.
During the last couple of years, mass spectrometry has evolved to be the main work-
horse of proteomics research. Mass spectrometry-based proteomics has developed into a
versatile tool for investigating a wide variety of questions. Next to studying the protein
inventory of cells, mass spectrometry can be used to measure the quantity of each pro-
tein, to decode interaction networks between proteins, to detect chemical modifications
attached to proteins, and much more.
In this PhD work, I have applied mass spectrometry-based proteomics to all of the afore-
mentioned applications. In my first and main project, I have developed a new concept for
efficiently mapping protein-protein interactions in yeast. Following up on this work, I
have contributed to a collaborative effort to further develop the yeast interaction method
into a high-throughput pipeline. Furthermore, I have successfully applied my knowledge
about interactomics in a collaboration project on human histone variants. I have also
applied mass spectrometry to explore protein modifications. In the first such project, I
showed that mass spectrometry even allows to unravel completely new and previously
unknown modifications, by discovering the modification that activates elongation factor
P in certain bacteria. Finally, I investigated glycation, a protein modification relevant in
diabetes, following the recent trend of mass spectrometry moving into clinical applica-
tions.
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Zusammenfassung
Vor ungefähr fünfzehn Jahren wurde die Sequenz des menschlichen Genoms entschlüs-
selt. Diese Errungenschaft der modernen Wissenschaft war mit vielen Hoffungen ver-
bunden. Allerdings sind die Gene nur der Bauplan einer Zelle. Tatsächlich werden alle
Funktionen in biologischen Prozessesen von den Produkten der Gene, den Proteinen
ausgeführt. Daher ist nun die Proteomforschung, die sich mit der Untersuchung von Pro-
teinen beschäftigt, ein großer neuer Hoffnungsträger.
Während der letzten Jahre hat sich die Massenspektrometrie zur meistgenutzten Metho-
de in der Proteomforschung herausgebildet. Massenspektrometrie-basierte Proteomfor-
schung is heute eine flexible Technologie, mit der eine Vielzahl von Fragen beantwor-
tet werden kann. Diese Technik kann nicht nur dazu verwendet werden, das Protein-
Inventar einer Zelle zu bestimmen, sondern auch die Menge jedes einzelnen Proteins.
Außerdem können Interaktions-Netzwerke zwischen Proteinen entschlüsselt werden,
chemische Modifikationen an Proteinen entdeckt werden, und vieles mehr.
In der vorliegenden Doktorarbeit habe ich massenspektrometrische Methoden in al-
len zuvorgenannten Einsatzgebieten angewendet. In meinem Hauptprojekt habe ich ein
Konzept zur effizienten Analyse von Protein-Protein Interaktionen in Hefe entwickelt.
In einer Weiterführung dieser Arbeit trug ich dazu bei, die Hefe-Interaktionsmethode
in eine Hochdurchsatzmethode weiterzuentwickeln. Des weiteren habe ich mein Wis-
sen über Proteininteraktionen erfolgreich in ein Kollaborationsprojekt über menschli-
che Histonvarianten eingebracht. Neben der Analyse von Proteininteraktionen habe ich
massenspektrometrische Methoden auch zur der Analyse von Proteinmodifikationen
verwendet. Im ersten derartigen Projekt habe ich die Modifikation entdeckt, durch die
Elongationsfaktor P in bestimmten Bakterien aktiviert wird. Somit konnte ich zeigen,
dass die Massenspektrometrie es sogar ermöglicht bis dato unbekannte Modifikationen
zu erforschen. Schließlich habe ich eine Proteinmodifikation namens Glykierung unter-
sucht, die zur Pathologie von Diabeteserkrankungen beiträgt. Dieses Projekt folgt dem
derzeitigen Trend, massenspektrometrie-basierte Proteomforschung nun auch zur Be-
antwortung von klinischen Fragestellungen anzuwenden.
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1 Introduction
1.1 Proteins –The functional units of life and their investigation
The term ‘protein’ was first introduced by Gerardus Johannes Mulder in 1839, who in
turn got the suggestion for this naming from Jöns Jakob Berzelius. Based on his exper-
iments on the composition of various proteins like albumin, fibrin and casein, Mulder
had developed the theory that there must be a common substance in all proteins that
otherwise differ only in their sulfur and phosphorus content. Berzelius suggested to call
this common substance ‘protein’ as deduced from the Greek word ‘πρωτειoς’ meaning
‘fundamental’. Although the conclusions that Mulder drew from his experiments were
incorrect owing to the limited methodologies at that time, the term ‘protein’ is actu-
ally very well deserved. Indeed proteins are fundamental for all living organisms. They
provide structure, transport other molecules, catalyze reactions, forward signals, and
basically execute or at least participate in every single biological process in living organ-
isms. The totality of proteins that a particular cell, tissue or organism is expressing at a
given point in time and under given conditions has been termed the proteome, in ana-
logy to the genome, the totality of genes in a given organism. The branch of science that
is trying to investigate the whole protein content of cells, tissues and organisms is called
proteomics.
Owing to the complex and dynamic nature of the proteome, its investigation is inher-
ently complicated and needs specialized methods [1]. These methods need to fulfill two
main criteria to successfully identify proteome changes between samples. Firstly, they
need to provide sufficient depth in order to access the whole dynamic range of exist-
ing proteins. The dynamic range is defined as the difference in abundance between the
lowest and the highest abundant protein and reaches around seven orders of magnitude
in cells [2]. Secondly, they need to be of a quantitative nature, as often not the identity
but the amount of individual proteins changes in a cell upon perturbation [3]. The first
technique trying to monitor whole proteome changes was two-dimensional gel electro-
phoresis (2D-GE) [4]. However, with 2D-GE only the most abundant proteins could be
detected, meaning such screens could not really decode a proteome with all its compo-
nents. Back then, determining the identity of the protein spots in the gel was also cum-
bersome as no fast and sensitive method for protein identification existed [1]. Hence,
the introduction of mass spectrometry (MS) into the field of proteomics in the 1990s
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presented a giant leap forward. Due to the development of soft ionization methods like
matrix-assisted laser desorption/ionization (MALDI) [5] and particularly electrospray
ionization (ESI) [6], proteins could now be analyzed by MS, which had not been pos-
sible before. This major achievement in protein science was also recognized by the Nobel
committee, which awarded part of the 2002 Nobel prize in chemistry for those protein
ionization techniques.
After many genomes of lower complex organisms had already been sequenced, around
the year 2000 the entire human genome sequence was finally decoded in a large col-
laborative effort [7, 8]. The resulting protein sequence databases are now the basis for
identifying proteins in a rapid and routine manner by combining MS data acquisition
with database searching.
The introduction of mass spectrometry into the field of proteomics enabled the detection
first of hundreds then of thousands of proteins in a single experiment, and the numbers
have been growing ever since.
1.2 Mass spectrometry-based proteomics
Mass spectrometry is an analytical method that determines the mass of ionized analytes
in the gas phase. A mass spectrometer consists of five basic parts: (1) An ion source
transferring the analyte into the gas phase (2) some kind of ion optics guiding the ions
through the mass spectrometer, (3) a fragmentation device, (4) a mass analyzer that de-
termines the mass-over-charge ratio (m/z) of the ionized analyte, and (5) a detector that
measures the number of analytes at each m/z ratio. For a long time, mass spectrometers
were successfully used in the analysis of small molecules. However, to use mass spectro-
metry for the analysis of proteins a major obstacle had to be overcome. Being fairly large
and heat-labile biomolecules, proteins were incompatible with MS using the ionization
techniques available at that time. However, this issue was solved by the introduction
of new ionization strategies called MALDI and ESI. Proteins could now successfully be
transferred from a solid matrix or a liquid, respectively, into the gas phase and hence
analyzed by MS. ESI in particular was a huge success story for proteome analysis as
it allowed on-line coupling of high pressure liquid chromatography (HPLC) to mass
spectrometry, which in turn allows ‘presorting’ of peptides and therefore much greater
analysis depth. Since then, many technical developments have been implemented to
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improve mass spectrometry-based proteomics, and a variety of different methodologies
and applications have evolved [9].
1.2.1 Basic principles
Two important basic concepts in MS-based proteomics are top-down and bottom-up
analysis. In the top-down approach, full length proteins are ionized and analyzed by
tandem MS. The proteins can be measured in a denatured state, or as natively folded
proteins, which even enables the analysis of whole protein complexes (Native MS [10]).
Top-down techniques have two major advantages: (1) The whole protein sequence is
accessible for analysis, hence full sequence coverage can in principle be achieved. (2) All
protein isoforms can be detected, i.e. all splice variants and all modifications with their
localization. However, mass spectra of full length proteins are exceedingly complicated
and not easy to interpret, therefore generally top-down approaches can only be applied to
purified proteins or very low complexity mixtures. It is difficult to couple top-down MS
with liquid chromatography, because whole proteins require long analysis times in the
mass spectrometer in order to achieve the mass accuracy and resolution needed for their
identification [11]. Furthermore, the size of the protein itself is a limiting factor: the larger
the protein, the harder it is to analyze by MS. Despite these issues, some remarkable
results have recently been achieved using standard (recent review: [12]) and native top-
down methods (recent review: [13]).
The second, easier and much more widely used MS-based proteomic approach is bottom-
up or shotgun proteomics (see Figure 1, page 4). In this concept, the proteins are cleaved
into smaller peptides using specific proteases. The most commonly used protease for
this task is trypsin [9]. Tryptic peptides are of an ideal length for HPLC separation, MS
analysis and efficient fragmentation. Trypsin specifically cleaves on the C-terminal side
of lysine and arginine residues, two basic amino acids that can carry a positive charge on
their side chains [14]. Therefore digestion with trypsin facilitates efficient ionization of
the peptides, which enables their analysis by MS. Some other proteases are also suitable
for cutting proteins into small peptides, e.g. LysC, GluC, chymotrypsin, AspN and ArgC
[15–17]. Finally, other proteases like outer membrane protease T cut proteins into rela-
tively long peptides or protein fragments, an approach in between the other two called
middle-down proteomics [18].
Bottom-up proteomics is typically used to analyze highly complex mixtures, like whole
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cell lysates. Of course digesting such complex protein mixtures results in even more
complex peptide mixtures, therefore HPLC is essential to reduce this complexity. For
this purpose, the peptide mixture is loaded onto a chromatographic column packed with
a material the peptides interact with, usually a hydrophobic reverse phase material e.g.
C18. The peptides bind to the C18 material with different strengths according to their
chemical properties, and can gradually be released from the column by increasing the
organic content of the chromatography solvent.
ESI
HPLC
time
cells/tissues/
bodyuids...
proteins peptides
extraction digestion
bottom-up
protein assembly
mass spectrometer
Full MS MS2precursor
selection,
isolation,
fragmentation
data dependent acquisition
cycles of full MS scans followed by 
MS2 scans of the n most intense peaks
peptide masses (m/z),
peptide intensities
peptide fragments 
Full MS
MS2 MS2 MS2 MS2
top1 top2 ... top n
m/z m/z
if desired:
fractionation/
enrichment
if desired:
fractionation/
enrichment
A: Sample preparation
B: Liquid chromatography – tandem mass spectrometry
C: Spectra interpretation
Figure 1: Standard shotgun proteomics workflow. A Every proteomics experiment starts with the
extraction of proteins from the corresponding sample. Depending on the application, the resulting
protein mixture can be fractionated or enriched for a certain protein population. In the next step, the
proteins are digested into peptides, usually using trypsin. The resulting peptide mixture can also be
fractionated or enriched for a certain population, e.g. modified peptides. B Since the resulting peptide
mixture is still highly complex, peptides are usually separated by HPLC. From the chromatography
column, the peptides can be directly sprayed into the mass spectrometer and transferred to the gas
phase by ESI. MS data is usually acquired in a data-dependent fashion. C From the full scan, the top
n peptide features are selected for fragmentation and further analyzed in MS2 scans. Computational
software can then identify the measured peptides from the acquired data and reconstruct the
corresponding proteins. Adapted from [19].
Nevertheless, not one but many peptides elute from the chromatography column at a
given point in time. To identify the eluting peptides, in most cases data-dependent ac-
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quisition (DDA) is used, which works as follows: First the mass spectrometer acquires a
full scan (also called MS scan or survey scan) monitoring all peptide features that elute
from the HPLC column at a given point in time. The full scan is usually recorded at high
resolution and it hence measures very accurately the mass and intensity of every peptide.
The accurate mass of a peptide is however not sufficient for its identification, since dif-
ferent amino acid sequences can result in the same peptide mass. Therefore the peptides
have to be fragmented in order to acquire sequence information. For that purpose in
DDA the top n most abundant peptides features from the full scan are sequentially iso-
lated and fragmented, acquiring so called MS2 scans or fragmentation scans. The MS2
scans can be recorded either at low resolution e.g. in a linear ion trap (high-low strategy),
or at high resolution e.g. in an Orbitrap analyzer (high-high strategy). After all top n fea-
tures have been analyzed, the instrument records the next full scan and the cycle starts
anew. To fragment as many peptides as possible, the cycle time should be adapted to the
standard peak width of the chromatography setup. The number of top n features that
can be fragmented within one cycle depends strongly on the instrument speed. For this
reason, the scan speed of a mass spectrometer is of crucial importance for proteomic
analysis of complex samples. Even though DDA methods are very efficient for analyzig
complex mixtures, they still miss many lower abundant peptide features, a phenomenon
known as the undersampling problem. The number of detectable peptides in a standard
single-shot measurement of a HeLa cell lysate was estimated to be more than 100.000,
however only around 10.000 of them could be identified (see Figure 2) [20].
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Figure 2: Under-
sampling in data-
dependent acquisition
The grey histogram de-
picts all peptide features
detected in digested
HeLa cell lysate. The
red histogram shows
those features that were
targeted for fragment-
ation using a top 10
method. Finally, the green
histogram shows those
peptides features that
could be identified in the
end. Adapted from [20].
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One approach to overcome the undersampling issue and to achieve a higher dynamic
range and sensitivity is data-independent acquisition (DIA) [21]. However, also DIA app-
roaches can naturally not achieve a higher dynamic range than what is given by the in-
strument. In DIA, not only a selection, but in fact every detectable feature is fragmented
(all-ion-fragmentation). The resulting MS2 spectra are inherently highly complex and
multiplexed, hence DIA requires very sophisticated data analysis. To at least partially
reduce this complexity, one of the most well-known DIA approaches called ‘SWATH’
fragments mass windows of a fixed width instead of the entire mass range [22]. This
is done by rapidly scanning through the whole mass range in consecutive mass isola-
tion windows of typically 25 Da. In SWATH, the data-independent acquisition is then
combined with targeted data analysis. This means only a certain number of peptides
with known fragmentation behavior (which has to be established beforehand) is effec-
tively followed. In this way, the method achieves high quantification accuracy for the
targeted peptides. However, so far SWATH cannot compete with DDA for whole pro-
teome analyses in terms of proteome coverage, which also holds true for all other DIA
approaches.
Fragmentation techniques
Several methods can be used to fragment peptides into smaller parts in order to obtain
sequence information. In the most classical fragmentation technique, collision-induced
dissociation (CID), the peptide ions are accelerated to high kinetic energy and then col-
lided with an inert gas like nitrogen, helium or argon [23]. CID was initially performed
in triple quadrupole instruments (beam-type CID). Later also linear trap quadrupole
(LTQ) cells were used for CID fragmentation, however, this trap-type CID approach
suffers from a low mass cutoff problem. Because the generation and the detection of the
ions happens within the same device (tandem-in time principle), not all created peptide
fragments can be efficiently stabilized after fragmentation and product ions below a cer-
tain mass cutoff are lost. Higher-energy collisional dissociation (HCD) is an advanced
version of CID, featured in Orbitrap instrumentation and typically performed in a spe-
cialized octopole collision cell [24]. In principle HCD strongly resembles beam-type
CID and hence also allows low mass fragment ions to be observed, because the genera-
tion and the detection of the ions is separated in space (tandem-in space principle). Both
CID and HCD techniques preferentially fragment peptides at the peptide bonds, leading
to the formation of so called b-and y-ions (see Figure 3A, page 7).
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Electron-capture dissociation (ECD) on the other hand induces fragmentation by let-
ting peptide ions interact with free electrons [25]. Finally, electron-transfer dissociation
(ETD), an advanced version of ECD, induces fragmentation by colliding the peptides
with anthracene or fluoranthene anions [26]. The latter two techniques primarily lead
to the formation of c- and z-ions (see Figure 3A).
While ECD and ETD have advantages for longer peptides or even entire proteins (top-
down) or peptides carrying labile modifications, CID and HCD are more powerful for
effective fragmentation of short tryptic peptides and peptides carrying stable modifi-
cations [27]. Hence CID and HCD are the most widespread techniques for fragmenting
peptides in shotgun proteomics. HCD is becoming more widely adapted, because the
resulting spectra additionally contain the informative low-mass region. This is particu-
larly important for reporter-based quantification techniques that require this low mass
range to be observed (see section 1.2.4).
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Figure 3: Peptide fragmentation. A The most sequence informative fragments are obtained by
peptide backbone fragmentation. Depending on the fragmentation technique, different fragments
are observed. Corresponding to the cleavage site and which terminus they retain, they are designated
as a, b, c and x, y, z-ions (Roepstorff-Fohlmann-Biemann nomenclature [28, 29]). B Theoretically,
complete sequence coverage can be obtained by fragmenting a peptide, in this example by HCD,
resulting in a complete y-and b-ion series. The y-ions are numbered consecutively from the original C-
terminus, the b-ions are numbered consecutively from the original N-terminus. The difference between
consecutive ions (bm and bm+1 and yn and yn+1,respectively) yield the masses of the corresponding
amino acids. Next to the y and b ions, in HCD often an a2 ion is observed. Adapted from [30].
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Fragmentation behavior of peptides in HCD
The fragmentation of peptides in HCD is charge directed and results in a variety of frag-
ment types. Some of the most relevant fragments observed in HCD will be explained in
the following.
In general, the most sequence informative fragments are those obtained by peptide back-
bone fragmentation designated a, b and c for those retaining the N-terminus and x, y
and z for those retaining the C-terminus (see Figure 3A, page 7) [30]. In low-energy
fragmentation techniques such as in CID/HCD, the lowest energy pathway is naturally
favored, which is the breakage of the amide bonds leading to the formation of b-and
y-ions. In principle it is possible to determine the complete amino acid sequence of a
peptide in this way, provided breakage occurs at every amide bond (de-novo sequencing
by MS; see Figure 3B, page 7). However, since every molecule is ideally breaking only
once, a relatively high number of peptide ions needs to be collected and fragmented for
this purpose. Hence in practice, complete b-and y-ion-series are rarely observed in high
complexity samples, necessitating the use of database searching for peptide identifica-
tion.
How the b-and y-ions are created can at least qualitatively be explained by the mobile
proton model (see Figure 4, page 9) [31, 32]. The prerequisite for peptide fragmentation
is protonation during ionization. The proton(s) are initially sitting on basic residues of
the peptide, e.g. the terminal amino group or arginine and lysine side chains. Hence
tryptic peptides usually carry at least two charges [30]. After ionization, the protons
are initially quite tightly bound to the basic residues. However, during fragmentation
the peptide ions are excited, and as their internal energy increases, one proton becomes
’mobile’ and can move to energetically less favored protonation sites, such as the nitro-
gens of the backbone amide bonds (see Figure 4, page 9). Protonation on the amide
nitrogen leads to a considerable weakening of the amide bond, however, direct bond
cleavage is disfavored in the low energy fragmentation regime. Instead, the dissociation
of the peptide into two parts occurs via more complex rearrangement reactions. Pro-
tonation on the amide nitrogen makes the carbon atom of the amide bond a likely target
for nucleophilic attack. Consequently it is attacked by the oxygen of the N-terminally
neighboring amide bond (red arrow in Figure 4, page 9). This leads to the formation of
an oxazolone ring structure and dissociation of the peptide bond, resulting in a b- and
a y-fragment. Which one of the two is actually observed depends on which one retains
the proton; this in turn depends on the proton affinity of the two fragments.
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Other ’sequence informative’ backbone fragments can also occur in HCD, e.g. a-ions
that are generated from b-ions via the loss of CO. However, this mostly occurs for the
b2-ion leading to a characteristic a2/b2-fragment ion pair in HCD spectra [33]. Many
other fragments are produced by losing small neutral molecules, mostly water and am-
monia [32]. This leads to the formation of [MH-H2O]+, [MH-NH3]+, [yn-H2O]+, [yn-
NH3]+,[bm-H2O]+, and [bm-NH3]+ ions. Water can be lost from the C-terminal COOH
group or the aspartic and glutamic acid COOH groups, and from serine and threonine
side chains; ammonia can be lost from the N-terminus and the side chains of arginine,
asparagine and glutamine. Other frequently observed neutral losses in HCD spectra in-
clude CH4SO from oxidized methionine, CH3NO from glutamine or asparagine, and
C2H4O from threonine [33]. Furthermore, HCD fragmentation produces internal frag-
ments that result from b-or y-ions undergoing a second cleavage. Such internal frag-
ments are characteristic for HCD, a beam type fragmentation method, and occur much
less in trap-type CID.
As mentioned before, another characteristic of HCD is a number of fragments in the
low mass range, that cannot be observed in trap-type CID. These include immonium
ions originating from arginine, lysine, phenylalanine, tryptophane, tyrosine, histidine,
glutamine, and glutamic acid. A special case is the immonium ion generated by phos-
photyrosine, which can be used as a reporter ion to verify the existence of this PTM [33].
Finally, side chain fragments of several amino acids can be observed in the low mass
9
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range.
Detailed knowledge about peptide fragmentation behavior can be used to explain more
peaks in fragmentation spectra and gain more confidence in identifications. This was re-
cently demonstrated by developing an ‘expert system’ for computer-assisted annotation
of MS2 spectra [34]. In this study, including other fragment types just discussed in addi-
tion to the classic b-and y-ions increased the intensity coverage of fragment peaks from
56% to 86% in a typical shotgun experiment.
Mass analyzers
Five basic types of mass analyzers are used for proteomics experiments: Quadrupole ana-
lyzers, ion trap analyzers, time-of flight (TOF) analyzers, Fourier-transform ion cyclo-
tron resonance (FT-ICR) analyzers [35], and Orbitrap analyzers [36]. While quadrupole
and TOF analyzers continuously scan incoming ions (beam-type analyzers), ion trap,
FT-ICR and Orbitrap analyzers capture certain ion populations and perform sequen-
tial processes on them (trap-type analyzers). The different mass analyzers have differ-
ent properties, with the key parameters being resolution, sensitivity, mass accuracy and
speed.
The resolution, calculated as the m/z value divided by the the width of the peak at half of
its height, is a measure of how well two different peaks of slightly different m/z ratios can
be detected as such. Ion traps and quadrupoles typically have a low resolution (~1000),
TOF instruments perform better (>10.000), however, by far the highest resolving power
is provided by FT-ICR and Orbitrap analyzers (>100.000). For the latter two, this high
resolution can be achieved because both measure frequencies of circulation ions, which
can be measured in a highly accurate fashion [30]. The Orbitrap mass analyzer provides
this high resolution at a much lower price and footprint than the FT-ICR instruments,
which are equipped with expensive ultra strong magnets. Therefore nowadays the Or-
bitrap is the preferred high-resolution analyzer.
The sensitivity of a mass analyzer is dependent on the detection principle. Standard ion
traps and linear ion traps [37] employ electron multipliers as detectors, which are cap-
able of detecting single ions and therefore highly sensitive. Detection based on Fourier
transformation usually requires a few more charges to distinguish a signal from the noise.
However, in the Orbitrap analyzer single ion detection is in principle feasible due to im-
proved electronics and thermal stability [38].
The mass accuracy describes how far an experimentally determined mass deviates from
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the real (theoretically calculated) mass. In general, it depends on the resolution of a mass
analyzer, hence high-resolution analyzers can achieve parts-per-million (ppm) mass accu-
racy. The Orbitrap has been reported to even achieve sub-ppm mass accuracy [39].
The scan speed is roughly inversely correlated with resolution. Therefore, FT-ICR analy-
zers are usually slowest, ion traps and Orbitraps are much faster, and beam-type analy-
zers (quadrupoles and TOFs) are the fastest.
Nowadays, the dominant types of mass spectrometers for shotgun proteomics are hybrid
instruments combining several mass analyzers. The most frequently used mass spectro-
meters of this type are quadrupole TOF instruments, quadrupole ion trap instruments
and finally quadrupole Orbitrap instruments. Quadrupole Orbitrap mass spectrometers
are particularly powerful, because the quadrupole supplies fast and accurate mass selec-
tion, and the Orbitrap mass analyzer combines outstanding resolution with high sensi-
tivity, mass accuracy, and scanning speed.
1.2.2 Orbitrap mass spectrometry
The Orbitrap mass analyzer was used in all of the following work, hence this section will
provide more details about this particular device and the instrument family that evolved
around it. The Orbitrap was invented by Russian physicist Alexander Makarov and first
described in 2000. Its working principle is based on trapping ions by making them orbit
around and along a central spindle-shaped electrode (electrostatic ion trap, see Figure 5
A, page 12) [40]. While the frequency of rotation around the central electrode is depend-
ent on several factors, like the initial ion velocity and the initial radius, the frequency of
the harmonic oscillations along the the axis of the field (designated z-axis in Figure 5A)
is only dependent on the m/z value. This axial frequency can be measured using image
current detection on the segmented outer electrodes in a highly accurate fashion, and by
Fourier Transformation (FT) transformed into a mass-to charge signal (see Figure 5B,
page 12) [41]. Already the first Orbitrap from 2000 provided high mass resolution (up to
150.000), extremely high mass accuracy (around 5 ppm) as well as high dynamic range
[40]. In the following years, the Orbitrap was even further improved. In FT-ICR ana-
lyzers, the resolution can only be increased by using a stronger magnet, which quickly
raises the prices for such instruments. In an electrostatic trap like the Orbitrap on the
other hand, the field strength can be increased by either applying higher voltages, or by
changing the geometry of the trap [42]. The first Orbitrap cell being improved by one of
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these principles was the ‘High-Field Orbitrap’ cell first incorporated into an instrument
in 2012 [43]. This high-field Orbitrap is smaller than the standard Orbitrap (20 mm in-
ner diameter vs. 30 mm inner diameter) and features around two-fold higher resolution.
Along with the improved high-field Orbitrap cell, an enhanced Fourier Transform (eFT)
algorithm was introduced that further improves resolving power. Starting in the same
year, the standard Orbitrap became available with a higher central electrode voltage (now
5 kV instead of 3.5 kV). Finally, in 2014 both improvements were combined in the ‘Ultra
High Field Orbitrap’ that is now available in the latest generation of instruments and
achieves very high resolution at a very high scan speed (Specified resolution at m/z 200
is 240.000 with a transient length of 512 ms [44]).
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Figure 5: The basic principles of the Orbitrap mass analyzer. A Cross-section schematic represent-
ation of the Orbitrap analyzer. The Orbitrap consist of an outer barrel-shaped electrode and an inner
spindle-shaped electrode. Ion populations are injected tangentially to the outer electrode, stabilized
by the electric field and forced into circular motion around the inner electrode in ion packages (colored
circles). The ions also oscillate harmonically from right to left within the Orbitrap along the z-axis
(colored arrows). Adapted from [36, 40]. B Fourier Transformation converts the detected image current
first into frequencies and then into m/z signals.
The first instrument featuring an Orbitrap mass analyzer was introduced by Thermo
Fisher in 2006, and since then a whole family of Orbitrap mass spectrometers has evolved.
The data in this thesis were produced on four different machines, which represent the
progress of the Orbitrap instrumentalization over the last years: The ‘LTQ Orbitrap’ [45],
the ‘Orbitrap Elite’ [43], the ‘Q Exactive’ [46] and finally the ‘Q Exactive HF’ [44, 47]. The
four different machines and the differences between them are explained in Figure 6 on
page 13.
In general, Orbitrap instrumentation is exceptionally well suited for investigating com-
plex proteome samples, and together with improvements on the chromatography side
this mass analyzer has advanced the entire MS-based proteomics field, making high-
resolution mass spectrometry a standard in many laboratories.
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Figure 6: Schematic representations of the four types of Orbitrap mass spectrometers used in
this work. The first instrument ever to feature an Orbitrap mass analyzer was the LTQ Orbitrap [45]. It
is equipped with a linear ion trap for the generation of peptide fragments by CID. The fragmentation
spectra are also acquired in the linear ion trap and have low resolution. The second machine used in this
work was the Orbitrap Elite. It features a High-Field Orbitrap with eFT, an improved dual linear ion trap,
improved ion optics, and HCD and ETD as additional fragmentation techniques [43]. The next machine,
the Q Exactive, is a much simpler and smaller (benchtop) mass spectrometer, yet extremely powerful.
It features a high voltage Orbitrap analyzer and HCD as the only fragmentation technique. Therefore
in this instrument both full scans and fragmentation scans are always read-out in the Orbitrap with
high resolution [46]. Finally, the most recently developed machine is the Q Exactive HF. Compared to
the classic Q Exactive, it features improved ion optics, an improved selection quadrupole, and most
importantly an Ultra High Field Orbitrap analyzer [44, 47].
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1.2.3 Bioinformatic data analysis and computational proteomics
High-resolution mass spectrometry-based proteomics experiments produce a tremend-
ous amount of data. Already a single two hour measurement of a digested HeLa lysate
contains around 90.000 spectra, and the corresponding raw file has a size of around
2 GB. Therefore efficient data analysis software is required to analyze and interpret the
data. Regardless of the software that is used, the bioinformatic workflow can be divided
into several parts.
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Peak detection: First of all, the peptides features in the full scans have to be identified,
which requires sophisticated 3D peak detection algorithms. For each detected peptide
feature, the mass-over-charge ratio and the intensity are determined.
Peptide identification: To identify peptides, the corresponding fragmentation spectra are
used. However, the sequence information in these spectra is in most cases not sufficient
to directly read out the peptide sequence, therefore basically all bottom-up approaches
make use of protein sequence databases, e.g. FASTA files [48] obtained from UniProt
[49]. Theoretical peptide lists are generated by in-silico digesting the proteins in the ap-
propriate database with the same protease that has been used in the experiment. The
obtained theoretical peptides are then in-silico fragmented using the appropriate frag-
mentation method. Experimentally obtained peptide and fragment m/z values are then
compared to the theoretical ones. Several algorithms are available for this purpose, the
most commonly used ones are SEQUEST [50], Mascot [51] and the Andromeda search
engine [52] integrated in the MaxQuant environment [53]. In most cases, the search em-
ploys a target-decoy principle, by searching not only against the real database, but also a
decoy database that contains reversed nonsense versions of the true peptide sequences
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[54]. The hits to both databases are then sorted according to their score, and a cutoff is
placed at a point where a certain number of hits to the decoy database have accumulated
(see Figure 7 A, page 14). Typically this cutoff is set at 1% of hits to the reverse database
leading to a 1% false discovery rate (FDR) at the peptide level.
Protein assembly: The next step is to assemble the identified peptide sequences into pro-
teins (see Figure 7 B, page 14). This step is of crucial importance and at the same time not
trivial, as the same peptide sequence can be present in different proteins and especially in
different isoforms of the same protein [55]. Such peptides are referred to as non-unique
peptides, while the ones unequivocally identifying a protein are referred to as unique
peptides. There are different ways to deal with this problem. In the MaxQuant software
for example, two proteins are joined into a ‘protein group’ whenever the set of identified
peptides is the same or completely contained within the set of peptides from the other
protein, because there is not enough evidence to report them as separate proteins [53].
Ideally, an FDR cutoff of 1% is also applied on the protein level, again by using a target-
decoy principle, to avoid reporting of false positive protein identifications as much as
possible.
Protein quantification: Proteins are quantified using different strategies that will be dis-
cussed in the following section (Section 1.2.4).
Next to these standard steps, the data can also be searched for posttranslational modi-
fications (PTMs). Usually the modification one wants to look for is known, and usually
the residues at which this modification is naturally attached to are also known. In this
case, the corresponding mass difference introduced by the PTM is considered in the
database search as a variable modification. Some artificial modifications are deliberately
introduced during sample preparation, e.g. disulfide bridges are usually reduced and
subsequently alkylated. This leads to all cysteine residues being modified by carbamido-
methylation, which is then considered as a fixed modification in the search. The identi-
fication of peptides carrying such known modifications is usually straightforward. Most
of the time, also the exact modification site can be determined by examining the frag-
mentation spectra of the modified peptides (see also section 1.3.2)
A completely different and unbiased strategy to identify PTMs was introduced with the
ModifiComb algorithm [56] and is available in the MaxQuant software as an option
called dependent peptide search. In this approach, no information about any modifi-
cation is passed on to the search engine, hence in the first instance all modified peptides
are not identified (see Figure 8, page 16). After this first search, the algorithm compares
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all identified peptides with all unidentified peptides, and determines the mass difference
∆M for each peptide pair. Now the fragmentation spectra of the peptide pairs are com-
pared. If some of the peaks in the unidentified spectrum are shifted by the exact same
peptide mass difference ∆M, while some other fragments are identical, the unidentified
peptide is assumed to be a modified version of the identified peptide. Depending on
which peaks are shifted, the most likely position for the modification can be determined.
Because the identification of the modified peptide is dependent on the identification of
the unmodified counterpart, it is called dependent peptide, while the unmodified pep-
tide is called the base peptide. I have used the dependent peptide search approach in this
thesis to identify the modification that activates elongation factor P (see chapter 2.2.1).
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Figure 8: In the ‘dependent peptide’ search approach, no a priori information about potential
modifications is passed on to the software. Hence in the first instance, all modified peptides are not
identified. By performing pairwise comparisons between all peptide features, some of the unidentified
peptides can be determined to be modified versions of identified peptides. Adapted from [56].
1.2.4 Protein quantification by mass spectrometry
As outlined before, it is of crucial importance to not only determine the identity of
proteins present in a particular sample, but also the amount of each protein. Only if
this quantitative information is acquired, biologically meaningful statements about pro-
teome changes between samples of any kind can be made. Therefore, several MS-based
quantification methods have been developed, either for relative quantification comparing
protein amounts between samples, or for absolute quantification measuring the exact ab-
solute amount of a protein in a sample.
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The challenge for all MS-based quantification approaches is that MS by itself is not a
quantitative technique. Due to varying length and amino acid composition, tryptic pep-
tides have different chemical properties and charge states. This results in different ‘flya-
bilities’ i.e. different ionization efficiencies and behavior in the MS. Therefore the in-
tensity in the mass spectrometer is not directly proportional to the peptide amount, and
quantification cannot rely on comparing different peptides with each other. Instead,
quantification is based on comparing the intensities of identical peptides originating
from different samples representing e.g. a diseased state and the corresponding con-
trol. In the bottom-up approach, quantitative values are initially obtained for peptides,
but the quantitative information about all peptides originating from one protein can
then be combined to obtain a quantitative value for this protein. In this way one can
determine proteins changing in abundance between two samples, and hence identify
important players in the process under investigation.
Overview of quantification approaches
An overview of the most important quantification approaches is given in Box 1 (page
18). There are two basic principles for MS-based protein quantification. In label-based
quantification approaches the sample and the control are differentially labeled. For this
purpose, a different number of stable (i.e. nonradioactive) ‘heavy’ isotopes are intro-
duced, mostly 13C, 15N and 2H/D, resulting e.g. in a ‘light’ control and a ‘heavy’ sample.
Most importantly, the introduction of stable isotopes does not change the physiochem-
ical properties of the peptides, but only their mass. Hence they behave the same as their
natural counterparts in the cell, during sample preparation and during HPLC separation,
but can be distinguished during MS measurement. After the labeling step, the samples
can be mixed and analyzed together in one liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) run. Depending on the labeling strategy and the available num-
ber of differential labels, more or less samples can be combined (called multiplexing),
and up to 54 different samples have already been multiplexed [57]. Dependent on the
number of samples to be compared, the labeling results in multiple peaks for every pep-
tide, separated by a characteristic mass difference, with each peak originating from one
sample. In this way, the intensities of these peaks can easily be compared for each pep-
tide.
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Box1: Quantification Approaches
Approach Principle Name Type Reference
Label-based Metabolic labeling SILAC relative [58]
Super-SILAC relative [59]
15N relative [60, 61]
Chemical labeling TMT relative [62]
iTRAQ relative [63]
mTRAQ relative [64]
Dimethyl relative [65]
Spike-in Absolute-SILAC absolute [66]
PrESTs absolute [67]
AQUA absolute [68]
QconCAT absolute [69]
PSAQ absolute [70]
FlexiQuant absolute [71]
Label-free Spectral counting relative [72]
Intensity-based relative [73, 74]
iBAQ absolute [75]
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The table on top lists the most important quantification approaches with the corresponding references. Quantific-
ation approaches can be divided in label-based and label-free approaches. Label-based approaches can be further
subdivided into metabolic labeling, chemical labeling and spike-in techniques. Quantification can either be relat-
ive, comparing relative protein amounts between different samples, or absolute, determining the absolute protein
concentration in a sample. The figure illustrates how quantitative information is extracted in the different quanti-
fication approaches (Adapted from [19]). In standard label-based methods, the intensities of differentially labeled
peptides is compared within the same LC-MS/MS run. In label-based methods that use reporter techniques, the
labels are ‘isobaric’ i.e. indistinguishable in the full scan, however create reporter ions of differential mass upon
fragmentation, whose intensities are extracted from the MS2 scans. Finally, in label-free methods, the intensity of
the same peptide in different LC-MS/MS runs is compared.
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The isotopic labels can be introduced in two ways, either metabolically or chemically.
In metabolic labeling, the stable isotopes are introduced in the living cell or organism
through its metabolism, by feeding heavy-isotope-modified amino acids. Our group
has pioneered the most well-known of the metabolic labeling approaches, called stable
isotope labeling with amino acids in cell culture (SILAC) [58]. In chemical labeling tech-
niques, the stable isotopes are added in chemical reactions during sample preparation
either at the protein or the peptide level. In general, isotopic labeling approaches are
very robust and accurate, especially metabolic labeling approaches where samples are
combined at the very beginning of the workflow and hence no artificial changes are in-
troduced (see Figure 9).
Cells/tissue etc.
(Purication/fractionation) 
(Purication/fractionation) 
Proteins
Peptides
MS analysis
Metabolic 
labeling
Chemical 
labeling
Label-free
approaches
Data analysis
Figure 9: Parallel/separate sample processing in the three major quantitative workflows. In
metabolic labeling approaches, samples are combined at the very first step of the sample processing
workflow, directly after culturing/obtaining the samples. Therefore, all experimentally introduced
changes affect both samples in the same way, leading to highly accurate quantification results.
Chemical labeling is either performed at the protein or at the peptide level, therefore samples have
to be processed in parallel for some steps, resulting in less accurate quantification. In label-free
quantification procedures, the complete sample preparation is done in parallel, hence a highly
reproducible workflow is a prerequisite to obtain reliable quantification results. Adapted from [76].
The second approach for MS-based quantification is called label-free quantification. As
the name suggests, no labels are introduced, therefore samples can naturally not be
mixed. Instead the control and the sample are analyzed in separate runs, and after MS
measurement, peptides abundances are calculated from the acquired data using differ-
ent approaches. Because samples are only combined at the stage of data analysis (see
Figure 9), it is considered the least accurate quantification approach. However, relatively
high accuracy quantification can still be achieved if highly reproducible sample prepar-
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ation and LC-MS/MS measurement are ensured and powerful data analysis algorithms
are applied that correct for the remaining variability. The work presented in this thesis
was exclusively acquired using label-free quantification, hence label-free approaches will
be discussed in more detail in the next section.
Label-free quantification
Label-free quantification (LFQ) is a purely computational approach, which has several
basic advantages. (1) It can be applied to virtually any kind of sample, even clinical
samples derived from patients [77]. (2) It is experimentally much easier to apply as no
labeling has to be performed, and usually it is also less expensive. (3) It can be applied
to an unlimited number of samples, while the highest number with labeling approaches
for direct comparisons is 10 conditions in parallel with TMT 10-plex [78]. On the other
side, due to the completely parallel sample processing, LFQ approaches usually require
more replicates (at least triplicates), excellent reproducibility of the whole LC-MS/MS
pipeline and sophisticated data analysis to yield accurate results.
The first, relatively simple LFQ approach was described in 2004 and used the number of
acquired fragmentation spectra as a semi-quantitative approximation for protein abund-
ance [72]. Although the number of acquired MS2 spectra is indeed directly related to the
abundance of a peptide, this spectral counting (SC) approach suffers from several weak-
nesses. First of all, protein size naturally introduces a bias, as large proteins produce
more peptides than smaller ones. Furthermore, the chromatography and the resulting
peak width have a strong impact on the results. Small differences are hard to detect in
SC approaches, and a relatively high number of MS2 spectra per protein is required for
this purpose [79]. Finally, in shotgun proteomics usually dynamic exclusion is used to
prevent highly abundant peptides from being sequenced over and over again, however,
this leads to underestimation of these highly abundant proteins in the SC approach.
Another counting approach is based on the number of identified peptides per protein
[80]. In this protein abundance index (PAI) approach, the results are normalized for the
protein size, by calculating the ratio of experimentally observed peptides to the theo-
retically observable ones for each protein. The PAI method was later extended resulting
in the ‘exponentially modified PAI’ (emPAI) approach (emPAI= 10PAI-1), in which it was
empirically found that the resulting score is directly proportional to the protein abund-
ance and can hence even be used for estimating absolute protein amounts [81].
The above-mentioned methods based on counting MS2 spectra or peptides naturally
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result in discrete numbers, and completely ignore a wealth of information contained
within the measured peptide intensities. When low-resolution mass spectrometry was
the standard, counting approaches yielded valuable results. However, today more pro-
mising intensity-based approaches have become feasible, yielding more accurate quan-
tification results. Intensity-based LFQ approaches require high resolution both in the
time and in the mass dimension, because the different peptide peaks have to be clearly
resolved. Hence they benefit greatly from the recently developed nano-scale ultra high
performance liquid chromatography (UHPLC) platforms and high-resolution mass ana-
lyzers like the Orbitrap.
Intensity-based LFQ approaches rely on the fact that the peak intensities of individual
peptide signals are linearly correlated with the peptide concentration over a wide range
of concentrations [73]. The first intensity-based approaches simply used the summed
peak area of all peptides belonging to one particular protein [73]. A more sophisticated
intensity-based LFQ approach is the MaxLFQ algorithm [74] available in the MaxQuant
software environment [53]. In this approach, first all peptide features are detected in
all LC-MS/MS runs to be compared. Then, the retention times of all runs are aligned
to make them comparable at all and correct for small variations in chromatography.
After that, matching between runs can be performed, an operation transferring iden-
tifications from one run where a peptide feature was identified to another run where the
same peptide feature was also present, but not selected for fragmentation and hence not
identified [82]. Matching between runs requires highly accurate masses and corrected
retention times of the peptides, and resolves some of the stochastic nature of sequen-
cing in shotgun approaches. This allows to extract the maximum amount of quantitative
information available on peptide level, which is highly beneficial for following protein
quantification. The raw intensities are then normalized, to correct for small differences
introduced during the parallel sample handling. For this purpose, a certain number of
proteins that are assumed to be unchanging between all samples is required. Finally, pro-
tein intensities are calculated from the peptide intensities by taking all available pairwise
peptide ratios between all samples into account. After that, the resulting ‘LFQ intensit-
ies’ represent excellent approximations for the protein amounts observed in the different
samples, and MaxLFQ has proven to be superior to spectral counting and summed in-
tensity approaches [74].
Label-free quantification can also be used for absolute quantification. In principle, even
spectral counting approaches and the emPAI method can be used for this purpose. A
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more sophisticated method combining intensity-based and peptide counting approaches
is intensity-based absolute quantification (iBAQ) [75]. In this approach, the protein in-
tensity is normalized by the number of theoretically observable peptides, and scaled
using spiked-in commercially available protein standards. The newest method for ab-
solute LFQ is the so-called ‘proteomic ruler’ concept. In principle it is similar to the
iBAQ method, but instead of spiked-in protein standards the data is scaled using his-
tones whose signal is proportional to the DNA content and hence the number of cells in
the sample [83].
In general, newly improved label-free quantification approaches provide a good accuracy
despite the parallel sample handling, and present a viable alternative to all label-based
approaches. This will have a large impact on MS-based proteomics in general, because
quantitative data can now easily be achieved without large efforts, even in large-scale
studies comparing hundreds to thousands of conditions or patients.
1.3 Applications of mass spectrometry-based proteomics
Mass spectrometry-based proteomics can be applied to a wide range of biological ques-
tions, the most obvious one being investigating whole proteomes. The first proteome
ever that came close to being complete was that of budding yeast published in 2008,
where the authors found evidence for 4399 proteins in haploid and diploid yeast [84].
Three years later, proteomes of a human cancer cell line were published, containing more
than 10.000 proteins [15, 85]. Recently, two big drafts of the entire human proteome
were published, acquired by combining data from many different human cell types and
claiming to have evidence for up to 18.000 proteins [86, 87]. However, the notion of a
‘complete’ human proteome is inherently difficult. To detect all existing proteins with all
their isoforms is nearly impossible, because some of them will only be expressed at very
specific cases under very specific conditions and in very specific cell types.
Many scientific problems indeed benefit from investigating a specific sub-proteome in-
stead of the whole proteome. This sub-proteome can consist of a specific cellular com-
partment. For example, for investigating nuclear processes often nuclear extracts are
prepared. Another obvious application that requires the extraction of a sub-proteome
is interaction proteomics. For investigating protein-protein interactions one wants to ex-
tract the part of the proteome that interacts with the corresponding protein of interest.
Finally if one is interested in a particular posttranslational modification (PTM), extrac-
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tion of the part of the proteome that bears this particular modification is of course highly
beneficial.
Mass spectrometry-based proteomics has matured during the last years, and has now
reached a stage where it can be applied to actual patient material. This field, called clinical
proteomics, tries to assist in diagnosis and even treatment of various diseases. Although
being one of the most challenging applications of mass-spectrometry-based proteomics,
it also offers the most reward and promise for the future.
Three of the just described applications, namely interaction proteomics, PTM-related
proteomics and clinical proteomics are part of this PhD work. Therefore they will now
be described in more detail.
1.3.1 Investigating protein-protein interactions by mass spectrometry
The interaction of proteins with other proteins, but also with nucleic acids, lipids, meta-
bolites, small molecules etc. is the basis of life at the molecular level. This section will
mainly focus on the investigation of protein-protein interactions, however examples for
the other types of interactions will also be shortly discussed at the end.
Proteins interact with each other to form sometimes small and defined, sometimes very
large multiprotein complexes. Investigating these protein complexes and also their in-
terconnections can provide meaningful information about biological processes and the
functions of proteins inside the cell. Next to more indirect techniques such as phage
display [88] and protein-fragment complementation assays such as the yeast two-hybrid
(Y2H) approach [89–91], mass spectrometry has become the method of choice for ana-
lyzing protein complexes under near physiological conditions.
To investigate protein-protein interactions by mass spectrometry, the protein of interest
first has to be immobilized. It is bound to a certain matrix, usually via an antibody either
directed against the protein itself, or against a protein tag that has been fused to it. Sub-
sequently, the bound protein is used as a bait to fish for prey interacting proteins by
incubating it e.g. with cell lysate. After a washing step that removes some of the unspe-
cific binders, the remaining bound proteins are released from the matrix and identified
by LC-MS/MS. This workflow is commonly known as affinity purification mass spectro-
metry (AP-MS) [92].
When AP-MS was first developed, quantitative MS measurements were not yet available.
Therefore the affinity purification workflow relied on dual affinity tags like the tandem
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affinity purification (TAP) tag, which enabled two consecutive rounds of purification
[93]. Combined with specific elution steps and stringent washing, this procedure yiel-
ded relatively clean protein complexes, which was pivotal as all proteins subsequently
identified by MS were considered to be interactors. The TAP technique was applied to
generate the first large-scale interaction datasets in the model organism budding yeast
[94–96]. However, the TAP technique and similar procedures suffer from several issues.
Firstly, due to the stringent nature of the two-step purification, weak or transient inter-
actors are mostly lost in the process. Secondly, unspecific binders can still not completely
be removed, hence a high false-positive rate has to be expected. To deal with these false
positives, proteins appearing in empty control pulldowns or in more than a certain per-
centage of all pulldowns were often simply put on a ‘contaminant blacklist’. This naturally
decreases the true positive rates as many proteins are simply not considered, and is also
not a suitable technique to efficiently identify unspecific binders.
ratio
-lo
g 
p 
va
lu
e
0
prey
tag
bait
back-
  ground
prey
bait
back-
  ground
quantitative
mass spectrometry
specic interactors
background binders
specic
pulldown
control
pulldown
statistical analysis
The quantitative AP-MS workow
Figure 10: Investigating protein-protein interactions by quantitative AP-MS. In quantitative AP-
MS strategies, a specific pulldown is compared with a control pulldown where the bait protein is not
tagged. Through a washing step, the interactors of the bait are enriched in the specific pulldown.
This enrichment is then reflected in the quantitative MS readout. Using statistical tests like the t-test,
the enriched interactors can easily be identified as such and distinguished from the unchanging
background binders centered around zero. Adapted from [19].
Many of the aforementioned issues could be improved or even completely solved by the
introduction of quantitative mass spectrometry. By comparing quantitative amounts of
proteins in a specific and a control pulldown, interactors can be distinguished from un-
specific binders that are unchanging between the two pulldowns (see Figure 10). The
fact that unspecific binders can now easily be identified as such and do not have to be
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removed from the dataset has induced a reversal of trend in the workflow. Instead of
purifying protein complexes as much as possible, fast and low stringent single-step puri-
fications are employed (for more information see also Results section 2.1.1). This in turn
minimizes the loss of weak and transient interactors.
A critical point in every interaction experiment is the expression level of the bait [97].
Ideally, one should use the endogenous protein as a bait, e.g. by using an antibody di-
rected against the protein itself. This ensures correct localization of the bait and correct
amounts of the bait compared to its interaction partners. Developing specific antibodies
for every bait protein of interest is however hardly feasible in large-scale studies. Hence,
in most cases tagged proteins are used, enabling the use of generic purification protocols
for a large number of bait proteins. Another advantage of using tagged proteins is that a
very simple control is at hand: the same strain/cell line, but with an untagged bait (see
Figure 10, page 24). Next to the green fluorescent protein (GFP)-tag, which can addi-
tionally be used for protein localization, popular tags in larger scale AP-MS studies are
the aforementioned TAP-tag and the FLAG-tag [98, 99]. In simple organisms like yeast,
the tag can be directly introduced into the endogenous locus of the protein ensuring en-
dogenous expression. In human cells this is much more complicated, therefore mostly
alternative approaches are used. One strategy to achieve at least very close to endoge-
nous expression is to use bacterial artificial chromosomes (BAC) as vectors. BACs can
accommodate large pieces of DNA, even whole human genes with all their regulatory
elements, are easily modified to contain the tag, and can be stably expressed in human
cells. Hence they allow expression of e.g. a GFP-tagged version of the bait under endo-
genous control [100], as in the quantitative BAC-GFP interactomics (QUBIC) approach
[101].
Quantification in pulldown experiments can be performed as explained before, using
label-based or label-free approaches. However, to capture a reasonable large part of
an interactome, a large number of pulldowns has to be performed and compared on a
quantitative level. Hence label-free techniques, which have no limitations regarding the
number of samples, are gaining strong momentum in interaction proteomics. In pull-
downs, relatively large ratios are usually expected, which can easily be detected by label-
free methods. Intensity-based LFQ, in particular, has been shown to perform as well
as SILAC quantification for pulldowns [101, 102]. As LFQ approaches require a highly
reproducible sample preparation workflow to produce accurate quantification results,
they benefit from high-throughput parallel sample processing platforms. In the QUBIC
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pipeline, for example, all pipetting steps were performed on a robotic platform, ensuring
very high reproducibility of the pulldowns [101]. Similar LFQ workflows for investiga-
ting protein interactions in yeast will be explained in Results sections 2.1.1 and 2.1.2. Such
fast sample preparation methods now leave the mass spectrometric measurement as the
bottleneck of the interaction pipeline. However, with the newest generation of Orbitrap
mass spectrometers and the advancing field of single-shot proteomics, much shorter
measurement times are possible, as also described in Results section 2.1.2. Very soon it
will be possible to obtain high coverage interactomes of many organisms in a quantita-
tive manner, with manageable effort and in a relatively short time. These datasets will be
highly valuable resources for biology and systems biology research.
Figure 11: Constructing protein-
protein interaction networks from
quantitative AP-MS data The output of a
quantitative AP-MS experiment is a large
data matrix of all the different bait pro-
teins vs. all the identified prey proteins.
The quantitative data contained in the
matrix have to be extracted with appro-
priate statistical methods to identify in-
teracting proteins. From that information,
interaction networks can be constructed
that reveal the composition of protein
complexes, their interconnectivity, and
possibly also their topology. Adapted
from [19].
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Large-scale quantitative AP-MS experiments yield a large data matrix as schematically
depicted in Figure 11, from which interacting proteins can be extracted and entire in-
teraction networks can be generated. Such quantitative networks contain a wealth of
information, for example about the interconnectivity of proteins. Some proteins in the
network are ‘interaction hubs’, i.e. they have multiple connections to other proteins and
take part in many different biological processes, while others interact only with one or
few proteins hinting at a very specialized role. To some extent, is is also possible to de-
termine the strength of the individual interactions: strong enrichment in the pulldown
is indicative of a strong interaction, whereas mild enrichment is indicative of a weaker
or more transient interaction (see also Results section 2.1.1). Furthermore, the stoichio-
metries within the complexes can be estimated by using absolute quantification methods
like iBAQ [103]. Finally, if enough entry points for a complex are included in the dataset,
it can be possible to determine alternative subcomplexes and complex topologies.
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A different approach to decipher the complex topology is the use of chemical cross-
linkers, that ‘freeze’ protein complexes in a certain moment in time (see Figure 12) [104–
106]. The crosslinkers are bispecific and have a defined length determined by a spacer
group, hence they can only link regions of proteins that are in a certain proximity to each
other. The treated proteins are then digested as usual and the crosslinked peptides are
identified by mass spectrometry, which determines spacial constraints that can hint at
interaction surfaces within the protein complex. However, identifying crosslinked pep-
tides is not trivial and the fragmentation spectra are inherently more complex, hence the
technology needs more improvement before it can be applied in a generic way and in
a large-scale manner. Crosslinking approaches using unspecific crosslinkers like form-
aldehyde can also be used to retain transient interactors, and therefore yield functionally
relevant information that may be more difficult to obtain in standard AP-MS experi-
ments [107].
 
chemical
crosslinker
digestion
identify
cross-linked
peptides
build
topological
model
Crosslinking of protein complexes
Figure 12: Investigating the interac-
tion topology of protein complexes by
chemical crosslinking and AP-MS. A
bispecific chemical crosslinker targeting
defined chemical groups is added to the
cells to freeze complexes in their current
state. The standard proteolytic diges-
tion then results in crosslinked peptides
that can be identified by MS. According
to which peptides between two proteins
are found to be crosslinked, a topological
model can be built. Adapted from [19].
The previously described principles of AP-MS are of course not limited to investigating
protein-protein interactions, but can be extended to any kind of bait that can be im-
mobilized on a solid support. For example, peptides can be easily synthesized, linked to
a matrix and used to screen for interactors. Even more interestingly, both a modified and
unmodified version of the peptide can be synthesized, to screen for proteins specificly
recognizing a certain PTM. This approach has for example been successfully applied to
histone modifications and specific phosphorylation events [108–110]. Also DNA (e.g. in
[111, 112]) and RNA (e.g. in [113, 114]) molecules can be used as baits to screen for pro-
tein interactors. Finally, in a field called chemical proteomics, small molecules are used
as baits to screen for drug-binding proteins. Hence chemical proteomics can be used
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to identify drug targets and potential off-targets leading to side effects [115], to decipher
a drug’s mechanism of action and even to assess binding characteristics. The inhibitor
coupled to the solid support can also be unspecific e.g. targeting kinases in general [79].
In this approach the interaction with different kinase inhibitors is then tested via com-
petition with the affinity matrix, as proteins binding to the free inhibitor will not bind
to the matrix anymore, and hence be detected with lower abundance in the pulldown.
A similar approach has been used to study the dissociation constants between proteins
and kinase inhibitors, by adding different concentrations of free inhibitor [116]. More
recently, it has also been applied to study histone deacetylase (HDAC) inhibitors and
their selective targeting of different HDAC complexes [117].
In summary, MS-based proteomics has established itself as a valuable tool for investi-
gating the interactions of proteins with all kinds of other molecules. Especially if proper
MS quantification is applied, the acquired data contains a wealth of information that can
help to identify previously unknown functions of proteins, or to understand biochemical
processes both in a physiological and pathological state.
1.3.2 Investigating posttranslational modifications by mass spectrometry
Posttranslational modifications are important key players of cellular control. They allow
the propagation of signals inside the cell so that it can react to a rapidly changing envi-
ronment or to changes in the internal state. Classically, signaling was thought to occur
via isolated ‘pathways’, i.e. linear cascades of different proteins propagating signals e.g.
from the cell membrane to the nucleus. Nowadays it is acknowledged that in reality sig-
naling pathways are extensively connected and in fact organized in incredibly complex
signaling networks that integrate stimuli [118]. Therefore to understand such widespread
networks, it is highly beneficial to analyze PTMs in a global and unbiased manner rather
than looking at individual modified proteins.
PTMs can have various effects on the protein carrying the modification, i.e. change its
structure, stability, activity, localization and interaction partners. The functional im-
portance of PTMs has become evident in many cases where their deregulation has been
linked to a disease [119]. Currently, about 300 different PTMs have been described to
physiologically occur on proteins [120]. However, of this large number only very few
PTMs are studied routinely and thoroughly. To date, the PTMs that have been targeted
in most studies are phosphorylation, acetylation, glycosylation, ubiquitinylation, and
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methylation (e.g. [121–129]).
Although many techniques exist to identify PTMs in small focused studies, high-reso-
lution mass spectrometry is currently the main technique for detecting and quantify-
ing protein modifications on a proteome-wide scale. Usually, standard bottom-up ap-
proaches are used for this purpose. The introduction of MS-based methods to the PTM
field has in some cases multiplied the number of known sites 10 to 100-fold compared
to traditional methods [130].
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Figure 13: Investigating PTMs by LC-MS/MS. Adapted from [19]. A After digesting the proteins into
peptides, the peptides carrying the modification of interest can be enriched using specific enrichment
strategies. This in turn increases the chance for their comprehensive identification. B After adding
the mass of the modification of interest and the potentially modified amino acid(s) to the database
search, modified peptides can be easily identified. Both the mass of the entire peptide as determined
in the full scan, as well as the mass of some fragments in the MS2 scan will be shifted by a certain mass
difference ∆M. Because only some of the peptide fragments are shifted by the corresponding ∆M, the
site of the modification can also be determined.
Despite numerous success stories, the bottom-up MS-based investigation of PTMs re-
mains challenging for several reasons. (1) Usually only a fraction of a protein is modified,
hence PTMs are often present in substoichiometric amounts making them hard to detect
in complex mixtures. (2) Depending on the modification, the fragmentation spectra of
modified peptides can be complicated and difficult to interpret. (3) If a modified peptide
contains several potentially modified residues, it is often challenging or even impossible
to determine the exact site. (4) Although PTM crosstalk is an important regulatory mech-
anism [131], multiple PTMs simultaneously occurring on the same protein can often not
be detected as such in bottom-up approaches based on short tryptic peptides. (5) The
database search space for peptide identification is drastically increased, especially if a
PTM can be located on several amino acids and/or the search includes several PTMs at
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a time. (6) Finally, quantification is based on single peptides, potentially leading to miss-
ing values and some inaccuracies. Many of the aforementioned issues can successfully
be solved. To overcome the substoichiometric nature of many PTMs, prefractionation
techniques and specific enrichment procedures, for example based on antibodies, ionic
interactions and chromatography (see Figure 13A, page 29), have been introduced [132].
High-resolution MS combined with efficient fragmentation and solid data analysis soft-
ware can in most cases identify PTMs with high confidence and even directly locate the
site of the modification (see Figure 13B, page 29). PTM crosstalk can be more closely in-
vestigated using alternative proteases creating other and/or longer peptides than trypsin,
or using top-down approaches. Quantification can strongly be improved by introducing
several replicates per sample, normalizing for changes in the abundance of the corres-
ponding proteins, and applying robust data analysis strategies.
Like for unmodified peptides, quantification of PTM sites can be performed either in
a label-free format or using the standard metabolic and chemical labeling techniques.
Regarding chemical labeling, however, it needs to be considered that many chemical
labeling agents target lysines, which might interfere both with tryptic cleavage and the
analysis of PTMs localized on lysine, like acetylation, ubiquitination and methylation.
Following the general trend in quantitative proteomics, label-free techniques are gaining
momentum also for the analysis of PTMs. Recently a label-free ultra-deep phosphopro-
teome of a human cancer cell line covering more than 50.000 distinct phosphopeptides
was published [133].
After the detection of PTMs on a proteome-wide level has become feasible, the next
logical step is to monitor the dynamics of signaling networks upon stimulation, per-
turbation or under various growth or stress conditions. Highly interesting insights have
for example already been obtained by performing time-course experiments in response
to certain stimuli like epidermal growth factor (EGF) and transforming growth factor β
(TGF-β) [134, 135].
Another intriguing possibility is to determine PTM site occupancies, i.e. to determine the
fraction of a protein that is modified. If the dectected occupany is high, this can hint at a
functional site, whereas low occupancy can hint at non-specific and hence less function-
ally important origin [136]. Site occupancies can be determined whenever a stimulus is
applied, then only three pieces of quantitative information are required: the change in
abundance of the modified peptide, the change in abundance of the corresponding un-
modified counterpart, and the change in protein abundance [137]. Phosphorylation site
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occupancies have been determined on a proteome-wide scale using SILAC and recently
also LFQ technologies [133, 137].
High quality quantitative data with a high coverage of sites can be the basis for analyzing
further characteristics of a certain PTM. From the sequence around the modification
site, specific motifs can be determined, that in turn can point to the modifying enzyme.
By integrating other orthogonal data, like interaction, localization, or structural data, a
deeper understanding of the PTM under investigation can be obtained.
In summary, MS-based PTM analysis is increasingly revealing an unexpectedly large
number of naturally occurring protein modifications. With the development of more
enrichment techniques, additional PTMs will become accessible for proteome-wide in-
vestigation. By providing quantitative information about PTM sites, MS-based prote-
omics can now be used to decipher signaling processes both in the healthy and in the
diseased state.
1.3.3 Mass spectrometry-based clinical proteomics
MS-based proteomics technologies have improved tremendously over the last years, and
increasingly powerful sample preparation techniques, instrumentation and data analysis
software are available today. Hence it is now becoming feasible to apply mass spectro-
metry to adress questions of clinical and medical relevance. This field of research called
clinical proteomics has a variety of goals, ranging from better characterization of patho-
logical processes on a molecular level to diagnosis, monitoring and optimized treatment
of diseases.
The most popular application of MS-based clinical proteomics is the search for protein
biomarkers that can pinpoint the presence or reflect the stage of a particular disease, or
can be used to classify patients into treatment-relevant subgroups. Biomarkers can be
specific cells, (mutated) genes, proteins, lipids, metabolites, or other small molecules,
many of which are routinely monitored in standard blood tests. Nevertheless, it is the
protein domain that is ultimately affected in a disease, therefore finding protein bio-
markers is particularly promising. Several protein biomarkers are already routinely used
in the clinic, like C-reactive protein that pinpoints the presence of general inflammation
[138], troponin I that indicates a myocardial infarction [139], and prostate-specific anti-
gen that is a marker for prostate cancer [140]. The search for protein biomarkers is facing
three major challenges. The first one is the extreme complexity and dynamic range of
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the biological material that is the source for biomarker search. The second is the low
abundance of many disease-relevant biomarkers, making their discovery reminiscent of
finding a needle in the haystack. Finally, the large variability between human individuals
and also individual disease characteristics further complicates the situation [141].
Blood is the ultimate source for biomarker discovery. Human blood plasma does not
only contain the classical plasma proteins, but also so-called tissue leakage proteins. As
blood is in contact with every single tissue in the body, it contains small amounts of
proteins from all of these tissues, representing both physiological and pathological pro-
cesses. Therefore blood plasma most likely represents the most comprehensive human
proteome [142]. Blood is also the most sampled biofluid, taken from patients at almost
every routine check-up, and a vast infrastructure exists for its storage and analysis. Al-
though the collection of blood in an invasive procedure, it is still very easily accessible
compared to e.g. tissue biopsies. Unfortunately, although being such a promising source
for protein biomarkers, blood plasma is also the most challenging material for proteomic
analysis. The dynamic range in plasma spans an enormous ten to eleven orders of mag-
nitude from the highest to the lowest detected protein so far [143]. It is dominated by
very few proteins like albumin present at extremely high concentrations, covering up the
low abundant tissue leakage proteins of interest and the even lower abundant cytokines
(see Figure 14 A, page 33). This dynamic range is far higher than the dynamic range pro-
teomic technologies can capture; even up-to-date mass spectrometers only reach around
six orders of magnitude at best [144].
The pipeline for the development of a new protein biomarker can be divided in several
phases (see Figure 14 B, page 33). Particularly in the later phases of biomarker veri-
fication, validation and assay development, large numbers of patient-derived samples
need to be processed to deal with the natural human and disease variability. At these
later stages, so-called immunoaffinity-based MS (IA-MS) approaches are and routinely
used. IA-MS methods enrich the protein of interest using antibodies, followed by tar-
geted MS analysis, and have already been successfully applied to quantify various pro-
tein biomarkers [145–150]. However the focus of IA-MS and other classic ligand binding
assays like the enzyme-linked immunosorbent assay (ELISA) onto one or several can-
didates makes them unsuitable for phase one, the unbiased discovery of new protein
biomarkers. This currently leaves classic data-dependent LC-MS/MS approaches as the
main technique for this purpose [141].
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Figure 14: Clinical plasma proteomics. (A) The dynamic range of plasma demonstrated on 34
exemplary plasma proteins. Adapted from [143]. (B) The phases of biomarker discovery and the
number of samples required. Adapted from [141].
The search for protein biomarkers still faces many problems, some of them already men-
tioned, and currently only about one new protein biomarker is introduced per year [141].
Several ideas how to improve this fact have been proposed. Of course methods to more
comprehensively cover the blood plasma proteome are highly desirable in this respect.
Higher proteome coverage can be achieved by extensive fractionation, however, this in
turn multiplies the number of samples, and hence reduces the throughput drastically.
Another method to achieve better coverage of lower abundant plasma proteins is to de-
plete the top abundant ones, reducing the dynamic range by one to two orders of mag-
nitude.
A different approach is to actually move away from the plasma at least for the discovery
phase, and use tissues or other biofluids. Often ‘proximal fluids’, i.e. body fluids that are
located more closely to the actual site of the disease, are highly attractive for biomarker
discovery [141]. Examples for such proximal fluids are urine for diabetes, kidney disease,
bladder cancer etc., cerebrospinal fluid for diseases affecting the brain, bronchoalveolar
lavage fluid for lung diseases, and so on. In many cases, the fold difference between the
diseased state and the healthy state is higher in proximal fluids, making them a good
source for protein biomarker discovery [151, 152]. After identifying a biomarker in a
proximal fluid, the final clinical test can in many cases still be developed for the more
easily accessible blood.
Genetic and environmental variations introduce noise between samples, which com-
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plicates the discovery of new biomarkers. One way to reduce this noise is to use model
systems for the discovery phase. Genetically homogenous animals, but also cell lines,
can be a good choice for a disease model in this regard.
Finally, ultra high performance mass spectrometers with high resolution, mass accuracy
and scan speed can greatly enhance the results in clinical experiments [141]. Therefore
the latest generation of Orbitrap instruments (see chapter 1.2.2) is particularly suited for
clinical proteomics.
So far, the success of discovery proteomics for finding new biomarker candidates has
fallen short of expectations. However with the improved technologies and instruments
that are now available, this will likely change in the future. Furthermore, MS-based
proteomics is already successfully applied in many functional clinical studies evaluating
altered protein-protein interactions or posttranslational modifications in various disease
contexts. In many cases, the protein level itself is not affected in a disease, but rather
the level of a particular PTM on that protein. The role of PTMs in the pathogenesis
of many diseases has recently become more and more acknowledged [136]. In some
types of cancer, for example, mutated kinases with higher/lower activity lead to altered
phosphorylation levels on their target proteins, which in turn alters their activity and
ultimately causes the disease. A well-known example is the constitutively active tyr-
osine kinase Bcr-Abl, which is created by a translocation between chromosomes 9 and
22 and leads to leukemia [153]. Other PTMs like acetylation, ubiquitination, SUMOyla-
tion, glycosylation, glycation and many more can also have a strong impact on the de-
velopment of diseases [154]. Protein glycation, a modification relevant in diabetes, will
be the topic of Results section 2.2.2 in this thesis. MS-based proteomics is currently the
only available tool for investigating large-scale variations at the PTM level, both in the
physiological and pathological state.
In summary, mass spectrometry holds great promise for clinical applications and will
in the future contribute to better diagnose, classify and monitor patients, and to provide
optimized treatment strategies for individual patient needs in the context of personalized
medicine.
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1.4 Aims of the thesis
In this thesis, I have developed and applied state-of-the-art mass spectrometry-based
proteomics technologies for investigating protein-protein interactions and posttransla-
tional modifications.
I started out with developing a method for investigating protein-protein interactions in
budding yeast. The basis for this first and main project was the quantitative BAC-GFP
interactomics (QUBIC) [101] methodology from our group, which I transferred from the
human to the yeast system. Budding yeast is an attractive model organism for human
biology and offers several appealing advantages for investigating interactions. Being a
relatively simple organism, yeast can easily be genetically modified, hence endogenous
bait expression is possible by tagging the bait proteins directly in their genetic loci. Other
genetic alterations are also possible, like knocking out individual complex members to
determine complex topologies.
Developing the interaction pipeline for yeast required establishment of the culture con-
ditions and the input amounts, as well as the sample preparation methodology. The im-
munoprecipitation step had already been optimized for GFP-tagged human proteins in
the QUBIC project, and was found to be equally suited to enrich GFP-tagged yeast pro-
teins and their interaction partners. After the wetlab workflow was established, I found
that every single pulldown contained almost 2000 proteins, representing about half of
the entire yeast proteome. This was a striking discovery, as such a large number of back-
ground binders had not even been observed in the human pulldowns. Therefore, the
next goal was to develop dedicated data analysis techniques, to detect the few true inter-
actors among the majority of unspecific binders. Since the data was acquired with label-
free quantification, distinguishing enriched interactors from unchanging background
proved to be relatively straightforward. However, we found that we can make additional
use of the large background to improve data quality and obtain high confidence inter-
action partners. Together with Marco Hein, whose main project was the application of
the QUBIC pipeline for mapping the human interactome, I developed several strategies
to extract the maximum amount of information contained within the background.
The resulting yeast interaction pipeline stands in stark contrast to classical pulldown
experiments where unspecific binders are removed by stringent washing and multiple
purification steps, which however leads to the loss of weaker or more transient interac-
tion partners. Since our pulldowns are hardly ‘purifications’ anymore, I termed the new
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methodology ‘affinity enrichment mass spectrometry’ (AE-MS) to distinguish it from
the classical ‘affinity purification mass spectrometry’ (AP-MS) approaches.
After I had established the pipeline for investigating protein-protein interactions in yeast,
my work was continued within the group. Since the yeast interactome in exponentially
growing yeast is already quite well understood, the next objective is to investigate this
interactome under various conditions and perturbations. To do so, new methods to
detect true interactions under close to physiological conditions in a fast and reprodu-
cible manner are required. Hence, the aim of this second project was to transform the
AE-MS interaction pipeline into a high-throughput format. We first wanted to decrease
the time spent on sample preparation and adapted most steps accordingly to a 96-well
format. With the drastically reduced sample preparation time, the measurement time of
the samples in the mass spectrometer (two hours in the first yeast interaction pipeline)
became the major obstacle to increase sample throughput. We hence explored much
shorter gradients, and even further reduced the analysis time by implementing a double-
barrel column setup driving two analytical columns in parallel. Finally, we were able to
measure 96 pulldowns in only about one day with this new high-throughput methodo-
logy, and still achieved remarkable coverage for the targeted complexes.
On the side, I applied my expertise of protein-protein interactions in a fruitful colla-
boration project on human histone variants. Canonical human histones can be replaced
by several variants, and this occurs at very specific places in the genome and leads to
various functional differences. One way to determine how these variants are targeted
to specific chromatin locations and how they exert their differential function, is to in-
vestigate which proteins they interact with. Hence the aim of this third project was to
identify differential interaction partners of specific H2A variants as compared to the ca-
nonical histone H2A. We first performed pulldown experiments of mononucleosomes
containing GFP-tagged histone variants in HeLa cells, and identified some highly inter-
esting interaction partners that are now being followed-up by my collaboration partners
(ongoing project). Additionally, we also performed similar pulldowns of H2A variants
in melanoma cells in collaboration with a third group (presented in this thesis). In this
project, our interaction analysis was able to identify the protein Brd2 as a specific interac-
tion partner of H2A.Z containing nucleosomes. After various additional experiments to
validate and characterize this protein, Brd2 emerged as a potential target for the therapy
of malignant melanoma.
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Next to investigating protein-protein interactions, I started to become interested in PTMs,
with this interest being triggered by another intriguing collaboration project. The ques-
tion in this fourth project was how elongation factor P (EF-P), a protein required for
efficient translation, is activated in a certain branch of bacteria. While for many bacteria
the activation of EF-P is known to occur by modification of a specific lysine residue,
other bacteria display an arginine residue in the homologous position. Since arginine is
not one of the commonly modified amino acids, the question whether it is modified at
all, and if so by what entity, was intriguing. Using phylogenetic tree analysis, my colla-
boration partner in this project had already identified the potential modifying enzyme.
However, what kind of modification this protein might transfer to EF-P in order to ac-
tivate it, remained completely elusive. Hence, the aim of this project was to investigate
whether the potential modifying enzyme actually modifies EF-P, whether modification
really occurs on the arginine in question or elsewhere, and finally what the activating
modification actually is. Using MS-based proteomics and the ‘dependent peptide’ search
technique, I successfully identified the previously unknown modification that activates
EF-P. This project was the first high profile application of the dependent peptide search
in our group.
In the fifth and last project, I focused on a clinical question and investigated protein glyc-
ation, a posttranslational modification highly relevant in the diagnosis, monitoring and
pathology of diabetes. While this modification is extensively studied on a few specific
proteins like hemoglobin, no real comprehensive dataset on glycated proteins in blood
plasma, the most affected biofluid, currently exists. Hence, the aim of this project was
to develop a method to identify glycated proteins from plasma with high confidence us-
ing mass spectrometry. In a first step, I wanted to evaluate the specific behavior of this
particular modification during HCD fragmentation and the feasibility to study protein
glycation on our specific MS instrumentation both in vitro on model proteins and in
vivo in actual plasma. In the future, we will apply the acquired knowledge to investigate
glycation directly in patient samples.
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2 Results
2.1 Development and application of mass spectrometry-based methods for
investigating protein-protein interactions in yeast and human
A deeper understanding of protein-protein interactions can help to answer key ques-
tions in biology. Although methods to identify interaction partners of proteins have
been available for some time, mapping the interactome is by far not completed. Espe-
cially weaker or transient interaction partners often escape detection, hence methods
to preserve such proteins are urgently required. In my first project focusing on interac-
tions, I took one step in this direction by developing an efficient yeast pulldown pipeline
with very low purification stringency. This led to a background of unprecedented size,
and necessitated the development of specialized data analysis techniques described in
the first publication of this section.
In the second publication, we took the now established yeast interaction pipeline to the
next level, by drastically increasing the sample throughput. To do so, we implemented
improvements in the sample preparation workflow as well as in the LC-MS/MS mea-
surement techniques and the data analysis.
While large-scale quantitative interaction networks and methods to acquire such inter-
actomes are highly valuable resources to the scientific community, biologists often focus
on very few proteins of their interest. In the third project, I showed that our method-
ologies are equally well suited for small-scale studies. In this publication, I successfully
applied our label-free pulldown technology to find interaction partners of human his-
tone H2A variants in the context of malignant melanoma.
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2.1.1 Affinity enrichment mass spectrometry (AE-MS) as a novel concept for investigating
protein-protein interactions
Keilhauer, E. C., Hein, M. Y. & Mann, M.
Accurate Protein Complex Retrieval by Affinity Enrichment Mass Spectrometry (AE-
MS) Rather than Affinity Purification Mass Spectrometry (AP-MS).
Molecular and Cellular Proteomics 2015 Jan; 14(1); 120-135.
The quantitative BAC-GFP interactomics (QUBIC) pipeline developed in our group
already represented a powerful workflow for investigating protein-protein interactions
in a mammalian cell culture system under near physiological conditions [101]. In the
first project of my PhD, I wanted to transfer this pipeline to the yeast system. In contrast
to the BAC cell lines, that provide very close to endogenous expression of bait proteins,
in yeast genes can be directly tagged in their genetic locus, thereby providing true endo-
genous expression. Conveniently, an endogenously tagged yeast library employing the
GFP-tag had already been created by the Weissman group, initially for protein localiza-
tion studies, and could be used for my experiments [155]. Since the QUBIC pipeline is
based on the GFP-tag, parts of the workflow could be reused for the yeast pulldowns.
However, a different upfront lysis protocol based on mechanical beadbeating had to be
developed and optimized. Furthermore, I constructed a dedicated control strain with
the same genetic background as the strains of the GFP-library, thereby obtaining an op-
timal control for my interaction experiments.
Surprisingly, I found that the yeast pulldowns behaved differently from the human pull-
downs, in that they produced an even larger background (ca. 1.800 protein as opposed
to ca. 800 proteins). Hence, dedicated data analysis methods were required to extract
true interactors. Together with Marco Hein, who was at the same time applying the
QUBIC pipeline for mapping the human interactome, I developed a powerful data ana-
lysis pipeline for this purpose. Although the background in the yeast and human system
was somewhat different, we found the basic strategies to pull out the proteins of interest
to be universally applicable. Finally, I showed that the large number of unspecific binders
detected in our pulldowns does not present a hindrance to data analysis, but on the con-
trary can be leveraged in a very efficient way. Since the pulldowns are highly similar to
each other, we found that a dedicated control strain is actually not necessary to interpret
the results, but that pulldowns can simply be compared against each other instead. We
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also propose a way to efficiently group candidate proteins in ‘weak’ and ‘strong’ interac-
tors based on their reproducible enrichment in the pulldown and their intensity profile
across all runs.
Since such low-stringency single-step pulldowns do not present real ‘purifications’ any-
more, I termed the novel method affinity enrichment mass spectrometry (AE-MS), to
clearly distinguish it from the classic AP-MS protocols mostly based on stringent TAP-
tag purification technology. I successfully evaluated this novel concept on a variety of
well-known yeast complexes from various cellular compartments, and achieved unpre-
cedented coverage from single pulldowns for many of them.
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Accurate Protein Complex Retrieval by Affinity
Enrichment Mass Spectrometry (AE-MS)
Rather than Affinity Purification Mass
Spectrometry (AP-MS)*□S
Eva C. Keilhauer‡, Marco Y. Hein‡, and Matthias Mann‡§
Protein–protein interactions are fundamental to the under-
standing of biological processes. Affinity purification cou-
pled to mass spectrometry (AP-MS) is one of the most
promising methods for their investigation. Previously, com-
plexes were purified as much as possible, frequently fol-
lowed by identification of individual gel bands. However,
todays mass spectrometers are highly sensitive, and pow-
erful quantitative proteomics strategies are available to dis-
tinguish true interactors from background binders. Here we
describe a high performance affinity enrichment-mass
spectrometry method for investigating protein–protein in-
teractions, in which no attempt at purifying complexes to
homogeneity is made. Instead, we developed analysis
methods that take advantage of specific enrichment of in-
teractors in the context of a large amount of unspecific
background binders. We perform single-step affinity enrich-
ment of endogenously expressed GFP-tagged proteins and
their interactors in budding yeast, followed by single-run,
intensity-based label-free quantitative LC-MS/MS analysis.
Each pull-down contains around 2000 background binders,
which are reinterpreted from troubling contaminants to cru-
cial elements in a novel data analysis strategy. First the
background serves for accurate normalization. Second, in-
teracting proteins are not identified by comparison to a
single untagged control strain, but instead to the other
tagged strains. Third, potential interactors are further vali-
dated by their intensity profiles across all samples. We
demonstrate the power of our AE-MS method using several
well-known and challenging yeast complexes of various
abundances. AE-MS is not only highly efficient and robust,
but also cost effective, broadly applicable, and can be
performed in any laboratory with access to high-resolution
mass spectrometers. Molecular & Cellular Proteomics
14: 10.1074/mcp.M114.041012, 1–16, 2015.
Protein–protein interactions are key to protein-mediated
biological processes and influence all aspects of life. There-
fore, considerable efforts have been dedicated to the map-
ping of protein–protein interactions. A classical experimental
approach consists of co-immunoprecipitation of protein com-
plexes combined with SDS-PAGE followed by Western blot-
ting to identify complex members. More recently, high-
throughput techniques have been introduced; among these
affinity purification-mass spectrometry (AP-MS)1 (1–3) and the
yeast two-hybrid (Y2H) approach (4–6) are the most promi-
nent. AP-MS, in particular, has great potential for detecting
functional interactions under near-physiological conditions,
and has already been employed for interactome mapping in
several organisms (7–15). Various AP-MS approaches have
evolved over time, that differ in expression, tagging, and
affinity purification of the bait protein; fractionation, LC-MS
measurement, and quantification of the sample; and in data
analysis. Recent progress in the AP-MS field has been driven
by two factors: A new generation of mass spectrometers (16)
providing higher sequencing speed, sensitivity, and mass ac-
curacy, and the development of quantitative MS strategies.
In the early days of AP-MS, tagged bait proteins were
mostly overexpressed, enhancing their recovery in the pull-
down. However, overexpression comes at the cost of obscur-
ing the true situation in the cell, potentially leading to the
detection of false interactions (17). Today, increased MS in-
strument power helps in the detection of bait proteins and
interactors expressed at endogenous levels, augmenting the
chances to detect functional interactions. In some simple
organisms like yeast, genes of interest can directly be tagged
in their genetic loci and expressed under their native pro-
From the ‡Department Proteomics and Signal Transduction, Max
Planck Institute of Biochemistry, Martinsried, Germany
Received, May 7, 2014 and in revised form, October 17, 2014
Published, MCP Papers in Press, November 2, 2014, DOI 10.1074/
mcp.M114.041012
Author’s Choice—Final version full access.
Author contributions: E.C.K. and M.M. designed research; E.C.K.
performed research; M.Y.H. contributed new reagents or analytic
tools; E.C.K., M.Y.H., and M.M. analyzed data; E.C.K. and M.M. wrote
the paper.
1 The abbreviations used are: AP-MS, Affinity purification mass
spectrometry; AE-MS, Affinity enrichment mass spectrometry; GFP,
Green fluorescent protein; (Co-)IP, (Co-) Immunoprecipitation; Y2H,
Yeast two-hybrid; BAC, Bacterial artificial chromosome; QUBIC,
Quantitative BAC green fluorescent protein interactomics; TAP, Tan-
dem affinity purification; LFQ, Label-free quantification; MaxLFQ,
MaxQuant Label-free quantification; CAA, Chloroacetamide; ES, Ex-
perimental series; FDR, False discovery rate; SC, Synthetic complete;
YPD, Yeast extract peptone dextrose; BSCG, Bait specific control
group; NPC, Nuclear pore complex; SPB, Spindle pole body.
tapraid4/zjw-macp/zjw-macp/zjw00115/zjw4939-14a xppws S3 2/12/14 15:57 4/Color Figure(s) F1–5 ARTNO: M114.041012
•
Research
Author’s Choice © 2015 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at http://www.mcponline.org
Molecular & Cellular Proteomics 14.1 1
AQ: A
Fn1
43
2 Results
moter. In higher organisms, tagging proteins in their endoge-
nous locus is more challenging, but also for mammalian cells,
methods for close to endogenous expression are available.
For instance, in controlled inducible expression systems, the
concentration of the tagged bait protein can be titrated to
close to endogenous levels (18). A very powerful approach is
BAC transgenomics (19), as used in our QUBIC protocol (20),
where a bacterial artificial chromosome (BAC) containing a
tagged version of the gene of interest including all regulatory
sequences and the natural promoter is stably transfected into
a host cell line.
The affinity purification step has also been subject to sub-
stantial changes over time. Previously, AP has been com-
bined with nonquantitative MS as the readout, meaning all
proteins identified by MS were considered potential interac-
tors. Therefore, to reduce co-purifying “contaminants,” strin-
gent two-step AP protocols using dual affinity tags like the
TAP-tag (21) had to be employed. However, such stringent
and multistep protocols can result in the loss of weak or
transient interactors (3), whereas laborious and partially sub-
jective filtering still has to be applied to clean up the list of
identified proteins. The introduction of quantitative mass
spectrometry (22–25) to the interactomics field about ten
years ago was a paradigm shift, as it offered a proper way of
dealing with unspecific binding and true interactors could be
directly distinguished from background binders (26, 27). Im-
portantly, quantification enables the detection of true interac-
tors even under low-stringent conditions (28). In turn, this
allowed the return to single-step AP protocols, which are
milder and faster, and hence more suitable for detecting weak
and transient interactors.
Despite these advances, nonquantitative methods—often
in combination with the TAP-tagging approach—are still pop-
ular and widely used, presumably because of reagent ex-
penses and labeling protocols used in label-based ap-
proaches. However, there are ways to determine relative
protein abundances in a label-free format. A simple, semi-
quantitative label-free way to estimate protein abundance is
spectral counting (29). Another relative label-free quantifica-
tion strategy is based on peptide intensities (30). In recent
years high resolution MS has become much more widely
accessible and there has been great progress in intensity-
based label-free quantification (LFQ) approaches. Together
with development of sophisticated LFQ algorithms, this has
boosted obtainable accuracy. Intensity-based LFQ now offers
a viable and cost-effective alternative to label-based methods
in most applications (31). The potential of intensity-based LFQ
approaches as tools for investigating protein–protein interac-
tions has already been demonstrated by us (20, 32, 33) and
others (34, 35). We have further refined intensity-based LFQ in
the context of the MaxQuant framework (36) using sophisti-
cated normalization algorithms, achieving excellent accuracy
and robustness of the measured “MaxLFQ” intensities (37).
Another important advance in AP-MS, again enabled by
increased MS instrument power, was the development of
single-shot LC-MS methods with comprehensive coverage.
Instead of extensive fractionation, which was previously
needed to reduce sample complexity, nowadays even entire
model proteomes can be measured in single LC-MS runs (38).
The protein mixture resulting from pull-downs is naturally of
lower complexity compared with the entire proteome. There-
fore, modern MS obviates the need for gel-based (or other)
fractionation and samples can be analyzed in single runs.
Apart from avoiding selection of gel bands by visual exami-
nation, this has many advantages, including decreased sam-
ple preparation and measurement time, increased sensitivity,
and higher quantitative accuracy in a label-free format.
In this work, we build on many of the recent advances in the
field to establish a state of the art LFQ AE-MS method. Based
on our previous QUBIC pipeline (20), we developed an ap-
proach for investigating protein–protein interactions, which
we exemplify in Saccharomyces cerevisiae. We extended the
data analysis pipeline to extract the wealth of information
contained in the LFQ data, by establishing a novel concept
that specifically makes use of the signature of background
binders instead of eliminating them from the data set. The
large amount of unspecific binders detected in our experi-
ments rendered the use of a classic untagged control strain
unnecessary and enabled comparing to a control group con-
sisting of many unrelated pull-downs instead. Our protocol is
generic, practical, and fast, uses low input amounts, and
identifies interactors with high confidence. We propose that
single-step pull-down experiments, especially when coupled
to high-sensitivity MS, should now be regarded as affinity
enrichment rather than affinity purification methods.
EXPERIMENTAL PROCEDURES
Yeast Strains—For all experiments GFP-tagged yeast strains orig-
inating from the Yeast-GFP Clone Collection were used, a library with
4156 GFP-tagged proteins representing about 63% of S. cerevisiae
open reading frames (39). The haploid parental strain of this library,
BY4741 (ATCC 201388), served as an initial control strain and to
construct the strain pHis3-GFP-HIS3kMX6 (short name pHis3-GFP).
To do so, we used the His3 locus in BY4741, which is nonfunctional
because of a deletion of several amino acids in the middle of the
coding sequence. We amplified a cassette containing a GFP gene
without start codon and a His3 gene of Saccharomyces kluyveri under
control of the TEF promoter and terminator out of the vector pFA6a-
GFP(S65T)-HIS3kMX6. This cassette was integrated into the His3
locus of BY4741 directly after the original His3 promoter and start
codon by homologous recombination, replacing the rest of the non-
functional His3 sequence. As a result, our pHis3-GFP strain is able to
synthesize histidine and expresses moderate amounts of cytosolic
GFP just as the tagged library strains.
Culture of Yeast Strains and anti-GFP Immunoprecipitation—
Tagged yeast strains, the parental strain BY4741 and the control
strain pHis3-GFP were first grown on plates (YDP plates for BY4741,
SC-His plates for all other strains) and then in YPD liquid medium at
standard culture conditions. Cell growth was regularly examined by
measuring OD600 nm. Yeast cells were grown until they reached
an OD600 nm of around 1, followed by harvesting culture volumes
High Accuracy Label-free Quantitative AE-MS in Yeast
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equaling 50 ODs. For biochemical triplicates (experimental series 1
(ES1)), three times 50 ODs were harvested out of the same culture and
from then on processed separately. For biological quadruplicates
(experimental series 2 (ES2)), four different colonies were picked on
different days and processed separately from the beginning. Yeast
cell pellets were dissolved in 1.5 ml lysis buffer (150 mM NaCl, 50 mM
Tris HCl pH 7.5, 1 mM MgCl2, 5% glycerol, 1% IGEPAL CA-630
(SIGMA-ALDRICH GmbH, Taufkirchen, Germany), Complete® prote-
ase inhibitors (Roche Diagnostics Deutschland GmbH, Mannheim,
Germany), and 1% benzonase (Merck KGgA, Darmstadt, Germany)),
transferred into FastPrep® tubes (MP Biomedicals GmbH, Es-
chwege, Germany) containing 1 mm silica spheres (lysing matrix C,
MP Biomedicals), frozen in liquid nitrogen and stored at 80 °C until
lysis. The frozen samples were thawed and then lysed in a Fast-
Prep24® instrument (MP Biomedicals) for 6  1 min at maximum
speed. Lysates were cleared by a 10 min centrifugation step at 4 °C
and 4000  g; and 800 l of the clear lysates were transferred into a
deep-well plate for immunoprecipitation. IP of yeast protein com-
plexes was essentially performed as described before for a mamma-
lian cell culture system (20). IPs were performed on a Freedom EVO®
200 robot (Tecan Deutschland GmbH, Crailsheim, Germany)
equipped with a MultiMACS™ M96 separation unit (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) that contains a strong perma-
nent magnet. (Miltenyi Biotec also supplies equipment for performing
the same pull-downs in a manual fashion.) The basic steps of the IP
protocol are as follows: First the lysates are mixed with 50 l mag-
netic MACS Anti-GFP MicroBeads (Miltenyi Biotec) and incubated
for 15 min at 4 °C. Because of the favorable kinetics of the mi-
crobeads, tagged proteins are efficiently captured in only 15 min (40).
Then the Multi-96 separation columns are equilibrated with 250 l
equilibration buffer (same as lysis buffer). After that, the lysates are
added to the columns with the magnet turned on, retaining the
magnetic MicroBeads on the column. Once all the liquid has passed
through the columns, they are first washed with 3  800 l ice cold
wash buffer I (0.05% IGEPAL CA-630, 150 mM NaCl, 50 mM Tris HCl
pH 7.5, and 5% glycerol), then with 2  500 l of wash buffer II (150
mM NaCl, 50 mM Tris HCl pH 7.5, and 5% glycerol). Afterward 25 l
of elution buffer I (5 ng/l trypsin, 2 M Urea, 50 mM Tris HCl pH 7.5,
and 1 mM DTT) are added and the columns are incubated for 30 min
at room temperature. In this “in-column digest,” the proteins are
partially digested to allow elution from the columns, and reduced by
DTT. Subsequently the resulting peptides are eluted and alkylated
with 2  50 l elution buffer II (2 M Urea, 50 mM Tris HCl pH 7.5, and
5 mM CAA), and collected in a 96-well plate.
The plate was incubated at room temperature overnight to ensure
a complete tryptic digest. The next morning the digest was stopped
by addition of 1 l Trifluoroacetic acid (TFA) per well. The acidified
peptides were loaded on StageTips (self-made pipette tips containing
two layers of C18) to desalt and purify them according to the standard
protocol (41). Every sample was divided onto two StageTips to give
one “working” StageTip and one “backup” StageTip. The StageTips
were stored at 4 °C until the day of LC-MS/MS measurement.
LC-MS/MS Measurement—Samples were eluted from StageTips
with 2  20 l buffer B (80% ACN and 0.5% acetic acid). The organic
solvent was removed in a SpeedVac concentrator for 20 min, then the
remaining 4 l of peptide mixture were acidified with 1 l of buffer
A*(2% ACN and 0.1% TFA) resulting in 5 l final sample size. 2 l of
each sample were analyzed by nanoflow liquid chromatography on an
EASY-nLC system (Thermo Fisher Scientific, Bremen, Germany) that
was on-line coupled to an LTQ Orbitrap classic (Thermo Fisher Sci-
entific) through a nanoelectrospray ion source (Thermo Fisher Scien-
tific). A 15 cm column with 75 m inner diameter was used for the
chromatography, in-house packed with 3 m reversed-phase silica
beads (ReproSil-Pur C18-AQ, Dr. Maisch GmbH, Germany). Peptides
were separated and directly electrosprayed into the mass spectrom-
eter using a linear gradient from 5.6% to 25.6% acetonitrile in 0.5%
acetic acid over 100 min at a constant flow of 250 nl/min. The linear
gradient was followed by a washout with up to 76% ACN to clean the
column for the next run. The overall gradient length was 134 min. The
LTQ Orbitrap was operated in a data-dependent mode, switching
automatically between one full-scan and subsequent MS/MS scans
of the five most abundant peaks (Top5 method). The instrument was
controlled using Tune Plus 2.0 and Xcalibur 2.0. Full-scans (m/z
300–1650) were acquired in the Orbitrap analyzer with a resolution of
60,000 at 400 m/z. The five most intense ions were sequentially
isolated with a target value of 1000 ions and an isolation width of 2
m/z and fragmented using CID in the linear ion trap with a normalized
collision energy of 40. The activation Q was set to 0.25, the activation
time to 30 ms. Maximum ion accumulation times were set to 500 ms
for full scans and 1000 ms for MS/MS scans. Dynamic exclusion was
enabled; with an exclusion list size of 500 and an exclusion duration
of 180 s. Standard MS parameters were set as follows: 2.2 kV spray
voltage; no sheath and auxiliary gas; 200 °C heated capillary temper-
ature and 110 V tube lens voltage.
Raw Data Processing—All raw files were analyzed together using
the in-house built software MaxQuant (36) (version 1.4.0.6). The de-
rived peak list was searched with the built-in Andromeda search
engine (42) against the reference yeast proteome downloaded from
Uniprot (http://www.uniprot.org/) on 03–20-2013 (6651 sequences)
and a file containing 247 frequently observed contaminants such as
human keratins, bovine serum proteins, and proteases. Strict trypsin
specificity was required with cleavage C-terminal after K or R, allow-
ing up to two missed cleavages. The minimum required peptide
length was set to seven amino acids. Carbamidomethylation of cys-
teine was set as a fixed modification (57.021464 Da) and N-acetyla-
tion of proteins N termini (42.010565 Da) and oxidation of methionine
(15.994915 Da) were set as variable modifications. As no labeling was
performed, multiplicity was set to 1. During the main search, parent
masses were allowed an initial mass deviation of 4.5 ppm and frag-
ment ions were allowed a mass deviation of 0.5 Da. PSM and protein
identifications were filtered using a target-decoy approach at a false
discovery rate (FDR) of 1%. The second peptide feature was enabled.
The match between runs option was also enabled with a match time
window of 0.5 min and an alignment time window of 20 min. Relative,
label-free quantification of proteins was done using the MaxLFQ
algorithm (37) integrated into MaxQuant. The parameters were as
follows: Minimum ratio count was set to 1, the FastLFQ option was
enabled, LFQ minimum number of neighbors was set to 3, and the
LFQ average number of neighbors to 6, as per default. The “protein-
Groups” output file from MaxQuant is available in the supplement
(supplemental Table S1), as well as all spectra for single-peptide-
based protein identifications (supplemental Spectra).
Data Analysis—Further analysis of the MaxQuant-processed data
was performed using the in-house developed Perseus software (ver-
sion 1.4.2.30). The “proteingroups.txt” file produced by MaxQuant
was loaded into Perseus. First, hits to the reverse database, contam-
inants and proteins only identified with modified peptides were elim-
inated. Then the LFQ intensities were logarithmized, and the pull-
downs were divided into ES1 and ES2 and from then on analyzed
separately. Samples were first grouped in triplicates or quadrupli-
cates and identifications were filtered for proteins having at least three
or four valid values in at least one replicate group, respectively. For
every bait a separate grouping was defined, and the data was indi-
vidually filtered for proteins containing at least two (ES1) or three (ES2)
valid values in the specific bait pull-downs. After this, missing values
were imputed with values representing a normal distribution around
the detection limit of the mass spectrometer. To that end, mean and
standard deviation of the distribution of the real intensities were
High Accuracy Label-free Quantitative AE-MS in Yeast
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determined, then a new distribution with a downshift of 1.8 standard
deviations and a width of 0.25 standard deviations was created. The
total matrix was imputed using these values, enabling statistical anal-
ysis. Now a student’s t-tests was performed comparing the bait
pull-down (in replicates) to its individual bait specific control group
(BSCG). This BSCG contained all other pull-downs in the data set
except those of known complex members. This whole procedure of
individual filtering, imputation and t test was repeated for every bait.
The resulting differences between the logarithmized means of the two
groups (“log2(bait/background”) and the negative logarithmized p
values were plotted against each other using R (version 2.15.3) in
“volcano plots.” We introduced two different cutoff lines with the
function y  c/(x - x0), dividing enriched proteins into mildly and
strongly enriched proteins (c  curvature, x0  minimum fold change).
The positions of the cutoff lines were defined for each experimental
series separately by first plotting the distribution of all observed
enrichment factors and deriving the standard deviation of this distri-
bution. The x0 parameter for the inner curve and outer curve was then
set to one and two standard deviations (rounded to one significant
digit), respectively (supplemental Fig. S6B and S6F). The curvature
parameters were obtained by overlaying all plots within one series,
using only pull-downs of functional baits and rather small defined
complexes (ES1: all but CDC73, PUP1, and PUP2; ES2: all but NUP84
and NUP145). The c parameter of the outer line was then adjusted to
optimally separate true interactors from false positives (for more
details see supplemental Fig.S6C, 6D, 6G, and 6H). The curvature of
the inner line was then set to half of the curvature of the outer line.
Cut-off parameters for ES1 were x0  0.9 and c  4 for the inner
curve, and x0  1.8 and c  8 for the outer curve. Cutoff parameters
for ES2 were x0  0.5 and c  4 for the inner curve, and x0  1 and
c  8 for the outer curve. For all enriched proteins outside the inner
cutoff line, we calculated the Pearson correlation of their LFQ
intensity profile across all runs to the LFQ intensity profile of the
corresponding bait. Enriched proteins were assigned to interactor
confidence classes A, B, or C according to their position in the
volcano plot and their correlation value. Cutoffs for the correlation
scores were defined for both series individually by analyzing all
correlations within one series using a quantile–quantile plot (Q–Q
plot), which compares the real distribution of all correlation values
to a theoretical normal distribution (supplemental Fig. S6E and 6F).
The correlation cutoff was 0.55 for experimental series 1and 0.35
for experimental series 2. Note that these cutoff criteria do not
represent absolute fixed values, but rather help to interpret the
individual pull-down result.
RESULTS
Establishing a High Performance AE-MS Method for De-
tecting Interactions in Yeast—First, we set out to develop a
generic and robust, yet high performance affinity enrichment-
mass spectrometry (AE-MS) method for investigating protein–
protein interactions in yeast. This organism is amenable to
genetic and biochemical approaches and has already served
as a model in many of the classical interactome studies. We
chose to work with a GFP-tag system, because this tag is well
tolerated and highly specific antibodies have been generated.
Furthermore, a library of GFP-tagged yeast strains is com-
mercially available, covering about 4000 open reading frames,
and also offering localization data (34). The GFP-tagged bait
proteins in this library are expressed at endogenous levels, a
great advantage for detecting functional interactions. We
chose a subset of 36 strains from this library, containing
tagged bait proteins that are members of characterized com-
plexes from various cellular compartments and cover the
entire abundance range of the yeast proteome (supplemental
Fig. S1).
Next, we wished to construct a control strain that was as
genetically similar to the strains of the library as possible. Be-
cause the parental strain of the GFP-library, BY4741, is histidine
auxotroph and does not express GFP, we reintroduced the
HIS3 selection marker gene and a GFP gene into the dysfunc-
tional HIS3 locus of BY4741 (Experimental Procedures). The
resulting control strain can be grown under the same conditions
as the strains of the GFP library, expresses moderate amounts
of cytosolic GFP and was termed pHIS3-GFP.
An overview of our AE-MS workflow is depicted in Fig. 1.
We combined a mild detergent-based lysis buffer with exten-
sive bead beating to efficiently extract yeast proteins without
disrupting interactions. We investigated the needed input
amounts, and found that a 50 ml yeast culture volume with an
OD600 nm of 1.0 provided ample material for an IP experiment
even with very low expressed baits. Starting from these initial
50 ODs of yeast cells allowed us to save material as backup
at various stages of the sample preparation. The final amount
injected into the mass spectrometer corresponded to only
about 5.3 ODs; a very low amount of starting material, espe-
cially considering that baits were not overexpressed. The
single-step affinity enrichment was performed with highly
specific monoclonal anti-GFP antibodies coupled to magnetic
microbeads in a flow-through column format using mild wash-
ing conditions to preserve weak or transient interactions (Ex-
perimental Procedures). The whole pull-down procedure was
rather short, taking only about 2.5 h from lysis to elution.
Proteins were eluted by in-column predigestion with trypsin,
then digested to completion overnight. For all complexes
tested, we found that the resulting peptides could be analyzed
without any prefractionation in single-shot LC-MS/MS runs on
Orbitrap instrumentation, which considerably shortens overall
experiment time, provides greater reproducibility especially in
a label-free format and higher sensitivity. All experiments were
performed in several replicates; either biochemical triplicates
(experimental series 1, ES1) or biological quadruplicates (ex-
perimental series 2, ES2).
Raw data were analyzed using MaxQuant (36), providing
ppm level mass accuracy, confident identification of proteins
(False Discovery Rate of less than 1%), and accurate intensi-
ty-based label-free quantification, thanks to recently devel-
oped sophisticated normalization and matching algorithms
(37). Remarkably, all our pull-downs resulted in the identifica-
tion of thousands of unspecific binders in addition to the
specific interactors, leading to quantification of about half of
the yeast proteome in every single sample. On the one hand,
this was because of the low stringent single-step protocol in
which we attempt enrichment instead of proper purification of
protein complexes. On the other hand, it resulted from the
high instrument sensitivity of the LTQ Orbitrap instrument,
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and was also promoted by the “match between runs” algo-
rithm in MaxQuant. Matching between runs transfers identifi-
cations from one MS run to another run, where the same
peptide feature was present, but not selected for fragmenta-
tion and hence not identified. High confidence matching is
enabled by the high mass precision of the Orbitrap and
achieved using unique m/z and retention time information of
the features, after the retention times of all runs have been
aligned (43). Processing with matching between runs in-
creased the number of available quantifications in the com-
bined (ES1ES2) unfiltered LFQ matrix of 196 samples times
2304 proteins from 45 to 80%. The very large number of
proteins quantified per IP prompted us to establish novel data
analysis strategies, exploiting the information-rich intensity-
based LFQ data, as described in the following sections.
AE-MS Produces Internal Beadomes for Every Pull-down—
Together, our pull-downs identified a large set of background
binders specific for the affinity matrix and conditions used in
our experiments. As these proteins are usually detected be-
cause they bind to the beads used in the purification, the
totality of them has been called the “bead proteome” or
“beadome” (44, 45). Instead of having to determine this
beadome from separate control experiments, here we detect
it as a byproduct in the specific pull-downs (“internal
beadome”). In total, after standard filtering (Experimental Pro-
cedures) of the data we quantified 2245 different protein
groups in the combined ES1 and ES2 experimental series
(Fig. 2A). Per pull-down, we quantified on average 1860 pro-
teins in ES1 and 1825 proteins in ES2. Only a tiny fraction of
the detected proteins in each pull-down were actual interac-
tors of the corresponding tagged protein. For example, using
MCM2 as bait recovered the six MCM complex members
along with 1891 unspecific background proteins on average.
These six proteins constituted only 0.3% of all identified pro-
teins and only 1.3% of the summed LFQ intensity in the
corresponding pull-downs, although the bait was among the
highest intense proteins.
The unspecific binders identified in our internal beadome
cover the entire abundance range, with only a small bias
toward more highly abundant proteins when compared with
the yeast proteome as a whole (46) (Fig. 2B). GOBP and
GOCC term analysis by category counting of the identified
proteins did not indicate cellular functions or compartments
that are strongly over-or underrepresented (supplemental Fig.
S2A). However, the intensity at which we detect proteins in
the beadome is dependent on two factors: their abundance in
the proteome and their affinity to the beads. Whereas low
abundant proteins are generally not found at high intensities in
the beadome, the intensities of high abundant proteins can
vary from high to low signals (supplemental Fig. S2B and 2C).
Pearson correlation between beadome intensity and pro-
teome copy numbers was 0.53 for both ES1 and ES2. Next,
we performed 2D enrichment analysis (47), in which we com-
pared protein annotations between beadome and proteome in
an intensity-dependent fashion. The major protein classes
that showed higher intensities in the beadome than what
would be expected from their cellular abundance were RNA or
DNA related (e.g. ribosome, spliceosome, nucleolus, and DNA
recombination). This confirms former findings that ribosomal
proteins have a high affinity to the beads. Interestingly, pro-
teins in metabolic categories, which are ubiquitously present
in pull-downs because of their high abundance, tended to be
de-enriched (supplemental Fig. S2D and 2E). We conclude
that the beadome is in essence a scaled down version of the
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proteome, albeit with some preferences related to general
protein binding properties.
The reproducible identification of unspecific binders across
all runs is of course correlated with their intensity; higher
intense background binders are more likely to always be
detected, whereas background binders that are close to the
level of detection may only be identified in some of the runs.
Therefore, the LFQ intensity matrix contains missing values
among the lower intense proteins (marked gray in Fig. 2A). To
enable statistical analysis, such missing values can be “im-
puted.” Therefore, after discarding proteins that are not re-
producibly detected in at least one replicate group, we
imputed the remaining missing values using a normal distri-
bution around the detection limit of the mass spectrometer.
These simulated low intensity values fit well into the profiles of
the low abundant proteins, and because of its randomness,
imputation does not create artifacts in t-tests or in intensity
profile analyses. A comparison of the data set processed with
and without matching identifications between runs, and the
result of imputation are illustrated in supplemental Fig. S3.
Most of the background proteins are characterized by
highly similar intensities in nearly all of the pull-downs within
an experimental series, and we denote these as typical back-
ground binders. Both in ES1 and ES2 for about 90% of all
detected proteins the standard deviation of their intensity
profile was lower than 1.5 log2 LFQ intensity units; and for
about 70% even lower than 1 (Fig. 2C). As expected, this
analysis also confirms that proteins with higher intensity tend
to have more stable background profiles. Next to the typical
background binders, we also found a small number of pro-
teins with irregular profiles. Those atypical background bind-
ers are usually among the lower intense proteins. Both types
of unspecific binders can readily be distinguished from a
specific interactor, whose profile ideally fluctuates mildly
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around an average background intensity and only deviates
from that behavior in specific pull-downs, where it is detected
reproducibly and at higher intensities. The relationship of
mean LFQ intensity and standard deviation of the intensity
profile as well as the profiles of some typical and atypical
unspecific binders are further documented in supplemental Fig.
S4. Again, there is a clear trend that the intensity profiles of
higher intense proteins have a smaller standard deviation.
Among the proteins with the highest standard deviation (1.5
log2 LFQ intensity units) many bait proteins and interactors are
found.
A closer look at the heat map in Fig. 2A reveals the back-
ground in ES1 and ES2 to be slightly different. Sample prep-
aration was similar in both experiments; however, ES1 and
ES2 were measured on two different LC-MS systems of the
same type but at different time periods, which introduces
noticeable variation of the corresponding background. The
variation between pull-downs is lower in ES2 because sam-
ples were measured directly after each other in contrast to
ES1 where samples were measured in blocks according to
baits. Because of the slight variations in the background
signature between ES1 and ES2, data analysis was performed
separately for each experimental series. The differences be-
tween ES1 and ES2 allowed us to study the influence of these
workflow parameters.
Exploiting the High Coverage Background for Identifying
Protein Complexes—Evidently, the extremely large number of
unspecific binders detected in addition to the specific inter-
actors in AE-MS represents a completely different experiment
readout than that of classic AP-MS protocols. This large back-
ground needs specialized data analysis, which is; however, not
aimed at removing the unspecific binders, but instead exploits
them for high confidence detection of interactors. We recog-
nized four different ways in which the unspecific binders de-
tected in our pull-downs can be used beneficially.
First, they form the basis for intensity-based LFQ in Max-
Quant. To produce reliable and accurate quantification re-
sults, the normalization procedure performed in MaxQuant
requires a background proteome that is assumed to be un-
changing. This function is provided here by a large number of
unspecific binders identified in all samples. Normalization can
then correct for differences in sample loading and sample
concentration, which is a prerequisite to making the pull-
downs comparable at all and constitutes the basis for further
data analysis.
Second, the unspecific binders can serve as a quality con-
trol. We observed that deviation of the detected background
binders from the standard behavior can indicate insufficient
quality of a specific pull-down, which easily became apparent
by hierarchical clustering of the data matrix. As an example,
see the vertical stripe close to the middle of ES2 in Fig. 2A,
which is a replicate of a pHIS3-GFP pull-down. Close inspec-
tion of the raw data revealed generally low peptide intensities
and polymer contamination in this sample. In another case, a
difference in background signature was not because of sam-
ple quality, but seemed to be because of the nature of the
tagged complex: All six proteasome pull-downs reproducibly
featured a slightly but clearly different background than the
other pull-downs. This can be explained by the fact that
proteasome subunits have high cellular copy numbers and are
part of a very large complex; together this alters conditions on
the beads, “crowding out” some of the normally observed
background binders.
Third, the high number of unspecific binders reproducibly
quantified in all samples resulted in very high correlations
between different pull-downs. In Fig. 2D, these correlations
are plotted for two tagged strains, SET1-GFP and PAF1-GFP,
and the control strain pHIS3-GFP. Within triplicate pull-
downs, the average Pearson correlation coefficients were al-
ways greater than 0.977. Between the different strains, cor-
relation was always higher than 0.935, indicating that the
intensities of the background proteins in the three yeast
strains are highly similar. In fact, the correlation of SET1-GFP
to PAF1-GFP was even higher than the correlation of SET1-
GFP to the control strain pHIS3-GFP (0.945 versus 0.937). The
proteins most changing in intensity between the two pull-
downs were the expected SET1 and PAF1 interactors (Fig.
2E). These findings led us to investigate the possibility of
comparing pull-downs not to an untagged control strain as it
is usually done, but instead to compare them to each other,
which will be further explored in the next section.
Finally, we reasoned that next to the pair-wise correlation of
samples across all protein intensities, pair-wise correlation of
intensity profiles across all samples should contain meaning-
ful information. Specifically, intensity profiles of true interac-
tors across all pull-downs, when compared with the intensity
profile of the corresponding bait, should be correlated. The
characteristic profile of interactors compared with the un-
changing profile of typical background binders or the random
profile of atypical background binders could therefore be
useful in verifying interactor candidates, as we will demon-
strate later on.
Defining Interactors by Comparing Against Other Tagged
Strains—To identify interactors of a specific bait protein in the
presence of the large amount of background binders, we
performed a student’s t test comparing the LFQ intensities of
all proteins identified in replicates of that bait with the LFQ
intensities of all proteins identified in the control (Experimental
Procedures). When the resulting differences between the log2
mean protein intensities between bait and control are plotted
against the negative logarithmized p values in volcano plots,
the unspecific background binders center around zero. The
enriched interactors appear on the right side of the plot,
whereas ideally no proteins should appear on the left side
when comparing to an empty control, as these would represent
proteins depleted by the bait, which is not expected to happen.
The higher the difference between the group means (i.e. the
enrichment) and the p value (i.e. the reproducibility), the more
High Accuracy Label-free Quantitative AE-MS in Yeast
Molecular & Cellular Proteomics 14.1 7
ZSI
tapraid4/zjw-macp/zjw-macp/zjw00115/zjw4939-14a xppws S3 2/12/14 15:57 4/Color Figure(s) F1–5 ARTNO: M114.041012
49
2 Results
the interactors move to the top right corner of the plot, which is
the area of highest confidence for a true interaction.
We started by comparing a specific pull-down to an empty
control strain as it is usually done in AP-MS experiments. First
we used BY4741, the parental strain of the GFP library, as
control; however, cross-reactivity of the anti-GFP antibody
could occur in the complete absence of GFP. Therefore, we
had constructed pHIS3-GFP, a control strain highly similar to
the strains of the GFP library, as it could be grown under the
same selective conditions and expressed moderate amounts
of cytosolic GFP (see above). When we compared the pHIS3-
GFP control strain to its parental strain BY4741, we detected
only one yeast protein to be enriched, which was imidazole-
glycerol-phosphate dehydratase, the protein the HIS3 gene
encodes for (Fig. 3A). This illustrates that GFP does not inter-
act with any yeast protein, and furthermore demonstrates that
our AE-MS workflow is sensitive to an extent that it picks up
genetic differences between strains. This confirms the bene-
fits of using a control strain as similar as possible to the actual
bait strain, and supports our hypothesis that other tagged
strains of the GFP-library could present an excellent control,
as they are genetically identical except for the different tagged
protein. When we tested this idea on the example of the SKI
complex we indeed did not observe any differences in the
identified interactors of the bait SKI2, whether we compared
with pHis3-GFP or a tagged strain, e.g. SMC2-GFP (Fig. 3B
and 3C). As the only side-effect the specific interactors of the
other strain now appeared as de-enriched proteins. (We note
that even this could be put to good use in certain cases, as it
in principle enables detection of the interactors of two differ-
ent bait proteins in only one comparison and without employ-
ing a control.)
A larger control group consisting of many control pull-
downs should help to better identify interactors; and we next
tested whether this holds true for our pull-downs. Comparing
a specific pull-down to eight pHis3-GFP pull-downs, consist-
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FIG. 3. Comparing to unrelated tagged strains. All pull-downs in this figure were measured in quadruplicates. Cut-off lines were those of
ES2 (see Experimental Procedures). Red dots represent members of the SKI complex and blue dots represent members of the condensin
complex. A, Comparison of the control strain pHIS3-GFP against its parental strain BY4741. B, Classic comparison of a tagged strain against
an untagged control strain, in this case SKI2-GFP against pHIS3-GFP. C, SKI2-GFP compared with an unrelated tagged strain, SMC2-GFP.
D, SKI2-GFP compared with 8  pHIS3-GFP in quadruplicate ( 32 control pull-downs). E, SKI2-GFP compared with eight unrelated tagged
strains in quadruplicate (APC1-GFP, CAF1-GFP, CCR4-GFP, PAF1-GFP, PEP5-GFP, SMC1-GFP, SMC2-GFP, and SNF4-GFP  32 control
pull-downs). F, SKI2-GFP compared with its bait specific control group (BSCG) consisting of all other pull-downs in the data set except for the
SKI3 quadruplicate ( 116 control pull-downs).
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ing of four biological replicates each, clearly led to better
separation of interactors from the background cloud than just
comparing to one pHIS3-GFP pull-down (compare Fig. 3D to
Fig. 3B). The larger control group provided a less error-prone
average background intensity of every protein, which in turn
resulted in higher p values of the enriched true interacting
proteins. This is particularly beneficial to separate weaker or
transient interactors, which by their nature tend to only be
mildly enriched, from the background cloud, as long as their
low enrichment is highly reproducible. The more control pull-
downs are included into the control group, the better the
results should become. However, performing a large number
of empty control experiments consumes considerable re-
sources. In a human interactome study in 2007 for example,
the authors conducted 202 control experiments (12). We rea-
soned that if we are able to compare tagged strains to each
other, we would naturally obtain a large control group without
any additional efforts. To test this concept, we first compared
the SKI complex pull-downs to eight unrelated tagged strains.
This resulted in the same or better statistical improvement of
the interactors as we had obtained when using the same
number of control strains (Fig. 3E and 3D). We chose the
tagged strains serving as the control group to be unrelated to
the specific bait of interest, in the sense that their tagged
proteins do not reside in a known complex with this bait. To
obtain the largest possible control group, we selected all
unrelated pull-downs in the data set and termed this the “bait
specific control group” (BSCG). If interacting proteins are
included in the BSCG, they can increase the calculated aver-
age background intensity of interactors and therefore artifi-
cially decrease the t test result. For large control groups;
however, wrong assignment would generally not dramatically
change results, as demonstrated by comparing the SKI2 pull-
downs against all other pull-downs in the data set (supple-
mental Fig. S5). Although we here constructed the BSCG from
prior knowledge, it could also be constructed in an iterative
way. In the case of SKI2, the BSCG included all pull-downs
except the replicates of SKI3, resulting in 116 controls. This
led by far to the best separation, placing the SKI complex into
the far upper right corner of the volcano plot (Fig. 3F). There-
fore, we concluded that other pull-downs can serve as excel-
lent controls and in the following determined interactors by
comparing each specific pull-down to its BSCG.
Combining Enrichment Over Background with Intensity Pro-
file Analysis Leads to High Quality Interaction Data—To clas-
sify a protein as an interactor, we needed to introduce a cutoff
that separates enriched proteins from the unchanged cloud of
background binders centered around zero in the volcano
plots. The position of this cutoff is crucial: A stringent cutoff
leads to a low false positive rate, but may miss weaker or
more transient interactors, whereas a permissive cutoff would
include these, but at the cost of increasing false positives. To
preserve information about weak or transient interactors, we
decided to use a two cutoff strategy, which divides interactor
candidates into mildly and strongly enriched proteins (Fig.
4A). To define the position of the two cutoff lines, we plotted
the distribution of all enrichment factors within one series and
placed two minimum fold change cutoffs at one and two
standard deviations, respectively. Interestingly, in the case of
ES2, the series with biological quadruplicates that had been
measured in one block, the standard deviation was much
lower than for ES1. The cutoff lines were placed once for all
pull-downs within an experimental series with curvature pa-
rameters that best separate the outliers from the cumulative
background cloud (for more details see Experimental Proce-
dures and supplemental Fig. S6A–6H).
We then introduced a new criterion to deal with the false
positives among the mildly enriched interactors close to the
cutoff lines. This criterion makes use of the above mentioned
tendency of intensity profiles of true interactors of a bait
protein to be correlated, because interacting proteins should
be enriched whenever one of the complex members is
tagged. Moreover, slight variations across samples because
of background binding should be followed by all complex
subunits. This concept requires a complete LFQ intensity
matrix, produced by imputing missing values from a suitably
chosen random distribution, to not artificially increase or de-
crease the correlation (Experimental Procedures). To evaluate
the similarity of a given profile to the profile of the bait, we
calculated the Pearson correlation of the two profiles; and this
was repeated for every enriched protein (Fig. 4B). Although
strongly enriched proteins generally show medium to high
correlations, mildly enriched proteins generally show lower
correlations, but with a much higher variation from high to
even negative values (supplemental Fig. S7). This indicates
that true interactors exist among those borderline interac-
tors that can be detected with the help of the correlation
analysis. For the example of the MCM4 pull-down in Fig. 4,
five out of the six complex members were highly enriched,
but one (MCM3) only scored a mild enrichment and mod-
erate p value, but a high correlation (0.56), which led to its
correct identification as an interactor of MCM4. In this ex-
emplary pull-down, the detected true interactors showed an
average correlation of 0.68 to the bait, whereas the detected
unspecific binders showed an average correlation of 0.42. In
ES2, the average correlation of detected unspecific binders
was generally even lower. We determined a series specific
correlation cutoff for ES1 and ES2 by evaluating the corre-
lation of all proteins detected in all pull-downs in a Q-Q-plot,
which visualizes the real distribution of all correlation values
compared with a theoretical normal distribution (supple-
mental Fig. S6I and 6J). The point, where actual and theo-
retical distribution sharply deviated was chosen as the cor-
relation cutoff. Correlation analysis worked particularly well
with our data set, as it contains at least two entry points for
every complex.
We then proceeded to group enriched proteins into inter-
actor confidence classes A–C by their enrichment, p value
High Accuracy Label-free Quantitative AE-MS in Yeast
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and correlation to the bait as summarized in Fig. 4C. Class C
proteins are proteins between the two cutoff lines with low
or medium correlation to the bait and are not regarded as
interactors. Class B proteins are proteins between the cutoff
lines with high correlation or proteins outside the outer
cutoff line with medium correlation, and represent lower
confidence interactors. Finally, class A proteins are proteins
outside the outer cutoff line with high correlation and are
considered high confidence interactors. The result of the
classification is shown for the MCM complex in Fig. 4C, and
the same color scheme is used in all volcano plots throughout
the supplemental Material ES1/ES2. Although we found the
above classification scheme to be very efficient, it should not be
seen as absolute, but rather as a help in interpreting the pull-
downs results.
How the intensity profile analysis can recognize false-pos-
itives is illustrated by the profiles of SFC1 and SDH3 in Fig.
4B. They represent atypical background binders (see above)
fluctuating from low to high intensities across pull-downs.
Because they appeared by chance in all of the replicates of
the specific pull-down they scored both a good enrichment
factor and p value. However, because of the fluctuations in
their profiles, the correlation to the bait intensity profile is
poor, which reclassifies SFC1 as lower confidence interactor
and SDH3 as noninteractor. Without the correlation analysis,
SFC1 would have been considered a high confidence inter-
actor. Conversely, proteins that are only minimally but repro-
ducibly enriched are likely to still be true interactors if they
show good correlation (See MCM3 in Fig. 4B). Using the
data set-dependent cutoff definition, the average complex
coverage per pull-down (calculated as true positives/(true
positives  false negatives), with true complex members de-
rived from UniProt) was 74% for ES1 and even 83% for ES2.
Among the 82 and 79 class A interactors, the false-positive
rates (calculated as false positives/(true positives  false
positives) were only 6 and 0% for ES1 and ES2 respectively.
Among the 32 class B interactors in ES1, the false-positive
rate was 53%; however, 15 out of these 17 false positives
were downgraded from class A and therefore rightfully clas-
sified as lower confidence interactors. Among the 15 class B
interactors in ES2, the false positive rate was 20%. False-
negative rates in class C (calculated as true complex mem-
bers falsely classified as class C/all proteins in class C) were
very low with 3% (4 out of 133) for ES1 and 6% (2 out of 35)
for ES2. For all the aforementioned calculations, the two
large complexes (NPC and proteasome) as well as the com-
plexes were no classification could be performed (APC2,
CDC73, and TEF1) were excluded.
Defining Complexes of Various Sizes, Abundances, and
Cellular Localizations—The bait proteins in our study had
been selected to represent a wide range of cellular abun-
dances (supplemental Fig. S1), localizations (e.g. cytosolic,
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nuclear, and membrane bound), and functions (e.g. cell cycle,
transcription, translation-elongation, and transport). For each
of the pull-downs, the volcano plot containing the results of
our analysis is depicted in supplemental Material ES1 and/or
supplemental Material ES2. All bait proteins and the page
number of the corresponding volcano plot within the supple-
mental Material ES1/ES2 are summarized in a table on the
first page of both files. Given the diversity of these complexes,
they serve to illustrate different aspects of our method.
When we used very low abundant proteins as baits, we
were still able to identify interactors with a surprisingly high
complex coverage, especially considering that our system
uses endogenous expression and relatively little input mate-
rial. For instance the members of the anaphase promoting
complex, which has a key regulatory role in the cell cycle, are
expressed at an estimated average of about 70 copies per cell
in unsynchronized yeast cells (46). Using APC1 (about 30
copies/cell) as the entry point to the APC, our standard pull-
down protocol already identified 11 out of 13 APC members.
The two missing complex members (APC9 and APC11) are
potentially even lower abundant in unsynchronized cells as
they were also not detected in a deep yeast proteome (46).
Similarly, pull-down of the SET1/COMPASS histone methyl-
transferase complex by its SET1 (135 copies/cell) and SWD3
(74 copies/cell) subunits revealed all eight complex members
as clear outliers in the volcano plots.
Conversely, we were also able to detect interactors of very
high abundant proteins. Here the challenge is that these pro-
teins often have very high background intensities – ranging in
our workflow to a log2 intensity of up to about 36 – over which
they can hardly be further enriched. For the elongation factor
CAM1 (49,500 copies/cell, average log2 background intensity
29.9) we identified CAM1 itself and its direct interactor EFB1
with a moderate but clear enrichment but an extremely sig-
nificant p value (p  1025). However, TEF1 (630,000 copies/
cell, average log2 background intensity of 34.8), another elon-
gation factor 1 complex member, did not register as an
interactor as its background intensity is so high that it cannot
be significantly further enriched. Even when we tagged TEF1,
this bait was not an outlier, although all three interactors
CAM1, EFB1, and TEF4 were significantly enriched. We also
targeted another very high abundant complex, the ribosome-
associated complex (RAC) through its components SSZ1
(59,450 copies/cell, average log2 background intensity of
32.2) and ZUO1 (45,188 copies/cell, average log2 background
intensity of 31.4). Although SSZ1 only retrieved itself as out-
lier, when we tagged ZUO, we could indeed detect SSZ1 with
mild enrichment but with a very good p value (p  1022).
Although the above examples serve as positive controls,
illustrating aspects of our affinity enrichment workflow, we
also we detected some interactors that are not part of the
stable, known core complexes. The MCM complex presents
the core of the replicative DNA helicase in yeast and forms a
double hexameric ring around the DNA (48). We identified
TOF1 (Topoisomerase 1-associated factor 1) which is not part
of the core helicase but which has been shown to interact and
regulate it (49). TOF1 is an example of an interactor that was
promoted to likely interactor status (class B), because of its
high correlation with complex members.
The yeast proteasome consists of a 20S core particle com-
posed of 28  and -subunits assembled into four rings, and
a 19S regulatory particle on both sides of the core composed
of 19 proteins. As the proteasome is a highly dynamic holo-
complex, its purification is not trivial (50). Using two 20S
members, PUP1 ( subunit) and PUP2 ( subunit), retrieved
the complete 20S complex and most of the 19S members.
Additionally, we found a number of transient interactors, such
as the proteasome activator BLM10, the proteasome stabiliz-
ing component ECM29, the proteasome chaperone PBA1 and
the uncharacterized protein YCR076C. The latter has already
been reported to interact with proteasome core particle sub-
units (51), an association that we now confirm. Other enriched
proteins found in the PUP1/PUP2 pull-downs that are not
reported to interact with the complex could be proteasome
substrates.
The nuclear pore complex (NPC) represents an example of
a very large complex (about 30 different proteins in multiple
copies) that is embedded in the nuclear membrane (52). Per-
forming pull-downs with two of the subunits (NUP84 and
NUP145), we found many components of the NPC (19 and 16
respectively), which, remarkably, is more than what was iden-
tified for these two baits in a dedicated membrane interac-
tome (53). Additionally, we identified proteins that are not only
components of the NPC but also of the spindle pole body
(SPB), namely CDC31 (54, 55) and NDC1 (56). Consequently,
other components of the SPB including SPC110 and SPC42
were among the outliers. We also identified the inner nuclear
membrane protein HEH2, which has been proposed to be
important for a proper distribution of nuclear pores across the
nuclear envelope (57).
Two further examples are PAF1 (RNA polymerase II-asso-
ciated protein 1), pull-down of which resulted in all five core
complex members as well as RPO21. This protein is a subunit
of the RNA polymerase II. Likewise pull-down of PEP5, a
member of the HOPS complex, retrieved all its members, and
furthermore VPS8, a component of the CORVET complex
sharing four subunits (PEP3,PEP5,VPS16, and VPS33) with
the HOPS complex (58).
Apart from core and transient, proteins can also be mutually
exclusive complex members. As an example, the SNF1 pro-
tein kinase complex is a hetero-trimeric complex consisting of
the alpha subunit SNF1, the gamma subunit SNF4, and one of
three alternative beta subunits SIP1, SIP2, or GAL83 (Fig. 5A)
(59). This complex proved to be a good case to investigate the
effects of mutually exclusive complex members on the inten-
sity profile analysis. We used SNF4 and GAL83 as baits,
hence SIP1 and SIP2 were only identified in the SNF4 pull-
down, as expected (Fig. 5B and 5C). Nevertheless they
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showed a correlation of 0.37 and 0.45, respectively, to the bait
SNF4 (Fig. 5D), which was higher than the correlation cutoff
(0.35 for ES2). This demonstrates the usefulness of correlation
analysis for associating even alternative members with the
core complex. This complex also illustrates the need for sev-
eral entry points per complex to recapitulate more compli-
cated complex arrangements such as alternative cellular sub-
complexes. Using SNF4 as bait, we additionally identified the
protein SAK1, which is an upstream kinase that activates
SNF1 (60).
DISCUSSION
For about two decades, AP-MS techniques have been used
as tools for investigating protein complexes, and they have
been improved greatly during this time. Previously, protein
complexes were extensively purified, to reduce the amount of
copurifying unspecific binders as much as possible. However,
such stringent purification becomes unnecessary as soon as
AP is coupled to high resolution, quantitative MS. Quantifica-
tion can distinguish the true interactors from contaminants.
Therefore, protocols can be less stringent, preserving weaker
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FIG. 5. Correlation analysis and mutually exclusive binding. A, Schematic representation of the three alternate SNF1 protein kinase
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interactions, while resulting in a higher background. In this
work, we have taken this concept to its logical conclusion by
employing low stringent single-step enrichment of protein
complexes followed by label-free quantitative MS analysis in
which we co-purify a very large number of unspecific binders
representing about half of the yeast proteome. Complexes
can still be confidently identified because of their enrichment
in specific bait pull-downs versus all other pull-downs. As we
do not aim to purify but only to enrich, we suggest terming
such methods AE-MS. Our methodology is solely based on
intensity-based label-free quantification, which has advanced
considerably and for pull-downs is now comparable with la-
bel-based quantification approaches like SILAC (20, 33).
Identification of a large number of background binders is
unavoidable with modern MS instrumentation. Perhaps coun-
terintuitively, our results demonstrate that these unspecific
proteins can actually be beneficial, elevating them from a
nuisance to an essential part of the analysis. Apart from their
essential use in normalization, they are indicators of the re-
producibility within a specific workflow and serving as quality
control. As unchanging background binders greatly outnum-
ber changing interactors, pull-downs are highly similar to each
other, which in turn obviates the need for a dedicated control
strain. Finally, we have shown that reproducible detection of
unspecific binders allows further characterization of interactor
candidates by correlating their intensity profiles to the profile
of the bait. Using our pipeline, we identified interactors of a
diverse set of endogenously expressed bait proteins with high
confidence, starting from minimal input amounts of unlabeled
yeast, and requiring modest measuring times despite repli-
cate analysis. In medium or large-scale projects, our workflow
automatically provides a large control group, without actually
performing any control pull-downs. However, as illustrated
with the SKI complex, using only one tagged strain as control
(or an empty stain) already correctly identified all complex
members, demonstrating the feasibility of AE-MS also for
small scale projects.
Although a large improvement, our AE-MS workflow does
not solve all issues in MS-based interaction studies. Mem-
brane complexes always present a challenge because of their
hydrophobic nature. However, our protocol yielded excellent
results for the HOPS vacuolar membrane complex and the
nuclear pore complex without adapting it in any way. For the
SPOTS complex, we only retrieved two out of the six complex
members. Adapting the type of detergent or the detergent
concentration in the lysis buffer may help to better identify
membrane complexes (53). To further verify interactors, we
have introduced intensity profile analysis, which proved to be
very helpful for upgrading weaker interactors and uncovering
false positives. As this method relies on correlation to the bait
profile, it could; however, not be used in three cases where we
did not detect the bait as an outlier (in ES1: APC2 and CDC73;
in ES2: TEF1). In the case of CDC73, the bait was incorrectly
tagged in the strain we used, as we subsequently found by a
control PCR. For APC2 the very low copy number was pre-
sumably the reason, as even in ES2 where we found APC2, it
was only identified with two peptides. Finally, as already men-
tioned, for TEF1 the background intensity was so high that it
did not form a useful profile. However, the intensity profiling
only serves as additional information, and in all these cases
the correct interacting proteins were still identified through
their enrichment. A final potential caveat for the intensity
profile analysis are newly identified proteins interacting with
several baits, which decreases their correlation score. How-
ever, provided their enrichment is high, they would still be
considered (class B) interactors. Examination of the actual
intensity profile of such promiscuous interactors could also
help in judging whether weak correlation to the bait is caused
by strong fluctuation between all samples, making the protein
a false positive, or caused by strong fluctuation between
several replicate groups, making it a potential link between
several complexes.
The two largest yeast interactomes published in 2006 by
Gavin et al. and Krogan et al. both employed TAP-tagging
coupled to nonquantitative MS and among other frequency
filtering of detected proteins to remove unspecific binders (9,
10). This can be problematic in the case of atypical back-
ground binders that appear spontaneously at high intensity in
only some pull-downs. In our AE-MS approach, pull-downs
are performed in replicates, hence such proteins are rarely
scored as interactors. Even if an atypical background binder is
by chance detected in all replicates, the intensity profile anal-
ysis can still uncover it. With very few exceptions, all of the
proteins listed as contaminant in the above studies were also
found in our data set. However, they did not appear as inter-
actors in any of our pull-downs other than where expected.
The data sets of Gavin et al. and Krogan et al. only share
about one quarter of detected interactions (61) and did not
contain 1/3 or 1/2 of the baits that we had tagged here,
respectively. For each of the pull-downs that we could com-
pare between all three studies (APC2, BRE2, CCR4, NUP84,
NUP145, POP2, RTF1, SET1, SKI2, SMC1, SSZ1, and SWD3)
the complex coverage was equal or better using the AE-MS
method. In one case, we only retrieved EFB1 as interactors of
CAM1 whereas Gavin et al. also found TEF1 and TEF2. Al-
though these proteins were also found in a mock TAP-tag
purification and therefore included in the contaminant list, we
reason that more stringent purification could be helpful for
detecting interactors of extremely high expressed proteins
such as CAM1.
Recent interaction proteomics efforts typically at least em-
ploy semiquantitative approaches; however, removal of con-
taminants can still be problematic. There is an ongoing col-
laborative effort to establish a “contaminant repository for
affinity purification,” the “CRAPome,” containing control pull-
downs from various laboratories performed under various
experimental conditions (62). In the case of yeast 17 control
pull-downs are currently available, of which 12 have been
High Accuracy Label-free Quantitative AE-MS in Yeast
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performed using GFP-tagged proteins and nano-magnetic
beads. However, a larger number of controls may be neces-
sary to comprehensively cover all nonspecific binders and
thereby avoid incorrectly classifying a nonspecific binder as
an interactor. Our AE-MS method sidesteps this problem, as
the samples themselves are the controls. The minor but clear
differences between our two experimental series (Fig. 2A)
demonstrate that minor changes in the workflow like using a
different machine of the same type can already alter the
detected low abundant background binders, making the no-
tion of a universal CRAPome problematic.
From the differences between the two experimental series
we also conclude that for the most optimal output, AE-MS
experiments should be executed in a reproducible manner
from sample preparation to MS measurement, which should
ideally be conducted on one machine and in one batch as in
ES2. However, the MaxLFQ normalization algorithm success-
fully corrected for most of the variability in the ES1 series in
general and in the proteasome pull-downs in particular, re-
sulting in excellent results even for ES1.
To perform the AE-MS workflow described here, only three
elements were needed: tagged proteins of interest, a high
resolution LC-MS system, and sophisticated software to
quantify proteins and analyze the data. Here we used the LTQ
Orbitrap classic, which—although not being the latest Or-
bitrap technology—proved to be sufficient for identifying even
very low abundant protein complexes. Such technology is
now widely accessible, as is the MaxQuant software for per-
forming accurate intensity-based label-free quantification and
the Perseus program for statistical analysis of the data. Our
AE-MS protocol is equally suited to investigate a small, me-
dium or large number of samples. For a smaller set of sam-
ples, SILAC labeling could easily be implemented, which
might provide even more accurate ratios in the case of
borderline enrichment. More and more AP-MS workflows al-
ready use single-step protocols and employ high resolution MS,
and therefore rather represent AE-MS methods. The shift in the
conceptual framework from AP-MS to AE-MS and the develop-
ment of sophisticated analysis tools for AE-MS experiments
should contribute to higher quality interaction data, thereby
making studies more comparable, and helping to solve open
challenges in the interactomics field.
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Roland Wedlich-Söldner for providing the strains of the yeast-GFP
clone collection.
* This work was supported by the Bundesministerium für Bildung
und Forschung (grant number FKZ01GS0861, DiGtoP consortium)
and the European Commission’s 7th Framework Program PROS-
PECTS (HEALTH-F4-2008-201648).
□S This article contains supplemental Figs. S1 to S7, Table S1,
Spectra, and Experimental Series S1 and S2.
§ To whom correspondence should be addressed: Department of
Proteomics and Signal Transduction, Max-Planck Institute of Bio-
chemistry, Am Klopferspitz 18, Martinsried (near Munich) D-82152
Germany. Tel.: 49-89-8578 2557; Fax: 49-89-8578 2219; E-mail:
mmann@biochem.mpg.de.
DATA AVAILABILITY: The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium (63).
(http://proteomecentral.proteomexchange.org) via the PRIDE partner
repository (64) with the data set identifier PXD000955.
REFERENCES
1. Gingras, A. C., Gstaiger, M., Raught, B., and Aebersold, R. (2007) Analysis
of protein complexes using mass spectrometry. Nat. Rev. Mol. Cell Biol.
8, 645–654
2. Oeffinger, M. (2012) Two steps forward–one step back: advances in affinity
purification mass spectrometry of macromolecular complexes. Proteom-
ics 12, 1591–1608
3. Gavin, A. C., Maeda, K., and Kuhner, S. (2011) Recent advances in charting
protein–protein interaction: mass spectrometry-based approaches. Curr.
Opin. Biotechnol. 22, 42–49
4. Fields, S., and Song, O. (1989) A novel genetic system to detect
protein–protein interactions. Nature 340, 245–246
5. Rajagopala, S. V., Sikorski, P., Caufield, J. H., Tovchigrechko, A., and Uetz,
P. (2012) Studying protein complexes by the yeast two-hybrid system.
Methods 58, 392–399
6. Parrish, J. R., Gulyas, K. D., and Finley, R. L., Jr. (2006) Yeast two-hybrid
contributions to interactome mapping. Curr. Opin. Biotechnol. 17,
387–393
7. Gavin, A. C., Bosche, M., Krause, R., Grandi, P., Marzioch, M., Bauer, A.,
Schultz, J., Rick, J. M., Michon, A. M., Cruciat, C. M., Remor, M., Hofert,
C., Schelder, M., Brajenovic, M., Ruffner, H., Merino, A., Klein, K., Hudak,
M., Dickson, D., Rudi, T., Gnau, V., Bauch, A., Bastuck, S., Huhse, B.,
Leutwein, C., Heurtier, M. A., Copley, R. R., Edelmann, A., Querfurth, E.,
Rybin, V., Drewes, G., Raida, M., Bouwmeester, T., Bork, P., Seraphin,
B., Kuster, B., Neubauer, G., and Superti-Furga, G. (2002) Functional
organization of the yeast proteome by systematic analysis of protein
complexes. Nature 415, 141–147
8. Ho, Y., Gruhler, A., Heilbut, A., Bader, G. D., Moore, L., Adams, S. L., Millar,
A., Taylor, P., Bennett, K., Boutilier, K., Yang, L., Wolting, C., Donaldson,
I., Schandorff, S., Shewnarane, J., Vo, M., Taggart, J., Goudreault, M.,
Muskat, B., Alfarano, C., Dewar, D., Lin, Z., Michalickova, K., Willems,
A. R., Sassi, H., Nielsen, P. A., Rasmussen, K. J., Andersen, J. R.,
Johansen, L. E., Hansen, L. H., Jespersen, H., Podtelejnikov, A., Nielsen,
E., Crawford, J., Poulsen, V., Sorensen, B. D., Matthiesen, J., Hendrick-
son, R. C., Gleeson, F., Pawson, T., Moran, M. F., Durocher, D., Mann,
M., Hogue, C. W., Figeys, D., and Tyers, M. (2002) Systematic identifi-
cation of protein complexes in Saccharomyces cerevisiae by mass spec-
trometry. Nature 415, 180–183
9. Gavin, A. C., Aloy, P., Grandi, P., Krause, R., Boesche, M., Marzioch, M.,
Rau, C., Jensen, L. J., Bastuck, S., Dumpelfeld, B., Edelmann, A., Heurt-
ier, M. A., Hoffman, V., Hoefert, C., Klein, K., Hudak, M., Michon, A. M.,
Schelder, M., Schirle, M., Remor, M., Rudi, T., Hooper, S., Bauer, A.,
Bouwmeester, T., Casari, G., Drewes, G., Neubauer, G., Rick, J. M.,
Kuster, B., Bork, P., Russell, R. B., and Superti-Furga, G. (2006) Pro-
teome survey reveals modularity of the yeast cell machinery. Nature 440,
631–636
10. Krogan, N. J., Cagney, G., Yu, H., Zhong, G., Guo, X., Ignatchenko, A., Li, J.,
Pu, S., Datta, N., Tikuisis, A. P., Punna, T., Peregrin-Alvarez, J. M., Shales,
M., Zhang, X., Davey, M., Robinson, M. D., Paccanaro, A., Bray, J. E.,
Sheung, A., Beattie, B., Richards, D. P., Canadien, V., Lalev, A., Mena, F.,
Wong, P., Starostine, A., Canete, M. M., Vlasblom, J., Wu, S., Orsi, C.,
Collins, S. R., Chandran, S., Haw, R., Rilstone, J. J., Gandi, K., Thompson,
N. J., Musso, G., St Onge, P., Ghanny, S., Lam, M. H., Butland, G., Altaf-Ul,
A. M., Kanaya, S., Shilatifard, A., O’Shea, E., Weissman, J. S., Ingles, C. J.,
Hughes, T. R., Parkinson, J., Gerstein, M., Wodak, S. J., Emili, A., and
Greenblatt, J. F. (2006) Global landscape of protein complexes in the yeast
Saccharomyces cerevisiae. Nature 440, 637–643
11. Butland, G., Peregrin-Alvarez, J. M., Li, J., Yang, W., Yang, X., Canadien, V.,
Starostine, A., Richards, D., Beattie, B., Krogan, N., Davey, M., Parkin-
son, J., Greenblatt, J., and Emili, A. (2005) Interaction network containing
conserved and essential protein complexes in Escherichia coli. Nature
433, 531–537
High Accuracy Label-free Quantitative AE-MS in Yeast
14 Molecular & Cellular Proteomics 14.1
ZSI
tapraid4/zjw-macp/zjw-macp/zjw00115/zjw4939-14a xppws S3 2/12/14 15:57 4/Color Figure(s) F1–5 ARTNO: M114.041012
56
2.1.1 Publication: AE-MS as a novel concept for investigating protein-protein interactions
12. Ewing, R. M., Chu, P., Elisma, F., Li, H., Taylor, P., Climie, S., McBroom-
Cerajewski, L., Robinson, M. D., O’Connor, L., Li, M., Taylor, R., Dharsee,
M., Ho, Y., Heilbut, A., Moore, L., Zhang, S., Ornatsky, O., Bukhman,
Y. V., Ethier, M., Sheng, Y., Vasilescu, J., Abu-Farha, M., Lambert, J. P.,
Duewel, H. S., Stewart, II, Kuehl, B., Hogue, K., Colwill, K., Gladwish, K.,
Muskat, B., Kinach, R., Adams, S. L., Moran, M. F., Morin, G. B.,
Topaloglou, T., and Figeys, D. (2007) Large-scale mapping of human
protein–protein interactions by mass spectrometry. Mol. Syst. Biol. 3, 89
13. Kuhner, S., van Noort, V., Betts, M. J., Leo-Macias, A., Batisse, C., Rode,
M., Yamada, T., Maier, T., Bader, S., Beltran-Alvarez, P., Castano-Diez,
D., Chen, W. H., Devos, D., Guell, M., Norambuena, T., Racke, I., Rybin,
V., Schmidt, A., Yus, E., Aebersold, R., Herrmann, R., Bottcher, B.,
Frangakis, A. S., Russell, R. B., Serrano, L., Bork, P., and Gavin, A. C.
(2009) Proteome organization in a genome-reduced bacterium. Science
326, 1235–1240
14. Guruharsha, K. G., Rual, J. F., Zhai, B., Mintseris, J., Vaidya, P., Vaidya, N.,
Beekman, C., Wong, C., Rhee, D. Y., Cenaj, O., McKillip, E., Shah, S.,
Stapleton, M., Wan, K. H., Yu, C., Parsa, B., Carlson, J. W., Chen, X.,
Kapadia, B., VijayRaghavan, K., Gygi, S. P., Celniker, S. E., Obar, R. A.,
and Artavanis-Tsakonas, S. (2011) A protein complex network of Dro-
sophila melanogaster. Cell 147, 690–703
15. Malovannaya, A., Lanz, R. B., Jung, S. Y., Bulynko, Y., Le, N. T., Chan,
D. W., Ding, C., Shi, Y., Yucer, N., Krenciute, G., Kim, B. J., Li, C., Chen,
R., Li, W., Wang, Y., O’Malley, B. W., and Qin, J. (2011) Analysis of the
human endogenous coregulator complexome. Cell 145, 787–799
16. Makarov, A. (2000) Electrostatic axially harmonic orbital trapping: a high-
performance technique of mass analysis. Anal. Chem. 72, 1156–1162
17. Gibson, T. J., Seiler, M., and Veitia, R. A. (2013) The transience of transient
overexpression. Nat. Methods 10, 715–721
18. Glatter, T., Wepf, A., Aebersold, R., and Gstaiger, M. (2009) An integrated
workflow for charting the human interaction proteome: insights into the
PP2A system. Mol. Syst. Biol. 5, 237
19. Poser, I., Sarov, M., Hutchins, J. R., Heriche, J. K., Toyoda, Y., Pozniak-
ovsky, A., Weigl, D., Nitzsche, A., Hegemann, B., Bird, A. W., Pelletier, L.,
Kittler, R., Hua, S., Naumann, R., Augsburg, M., Sykora, M. M.,
Hofemeister, H., Zhang, Y., Nasmyth, K., White, K. P., Dietzel, S., Mech-
tler, K., Durbin, R., Stewart, A. F., Peters, J. M., Buchholz, F., and Hyman,
A. A. (2008) BAC TransgeneOmics: a high-throughput method for explo-
ration of protein function in mammals. Nat. Methods 5, 409–415
20. Hubner, N. C., Bird, A. W., Cox, J., Splettstoesser, B., Bandilla, P., Poser,
I., Hyman, A., and Mann, M. (2010) Quantitative proteomics combined
with BAC TransgeneOmics reveals in vivo protein interactions. J. Cell
Biol. 189, 739–754
21. Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., and Seraphin, B.
(1999) A generic protein purification method for protein complex char-
acterization and proteome exploration. Nat. Biotechnol. 17, 1030–1032
22. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H.,
Pandey, A., and Mann, M. (2002) Stable isotope labeling by amino acids
in cell culture, SILAC, as a simple and accurate approach to expression
proteomics. Mol. Cell. Proteomics 1, 376–386
23. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold,
R. (1999) Quantitative analysis of complex protein mixtures using iso-
tope-coded affinity tags. Nat. Biotechnol. 17, 994–999
24. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K.,
Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha, S.,
Juhasz, P., Martin, S., Bartlet-Jones, M., He, F., Jacobson, A., and
Pappin, D. J. (2004) Multiplexed protein quantitation in Saccharomyces
cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell.
Proteomics 3, 1154–1169
25. Thompson, A., Schafer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G.,
Neumann, T., Johnstone, R., Mohammed, A. K., and Hamon, C. (2003)
Tandem mass tags: a novel quantification strategy for comparative anal-
ysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895–1904
26. Blagoev, B., Kratchmarova, I., Ong, S. E., Nielsen, M., Foster, L. J., and
Mann, M. (2003) A proteomics strategy to elucidate functional
protein–protein interactions applied to EGF signaling. Nat. Biotechnol.
21, 315–318
27. Ranish, J. A., Yi, E. C., Leslie, D. M., Purvine, S. O., Goodlett, D. R., Eng, J.,
and Aebersold, R. (2003) The study of macromolecular complexes by
quantitative proteomics. Nat. Genet. 33, 349–355
28. Paul, F. E., Hosp, F., and Selbach, M. (2011) Analyzing protein–protein
interactions by quantitative mass spectrometry. Methods 54, 387–395
29. Liu, H., Sadygov, R. G., and Yates, J. R., 3rd (2004) A model for random
sampling and estimation of relative protein abundance in shotgun pro-
teomics. Anal. Chem. 76, 4193–4201
30. Bondarenko, P. V., Chelius, D., and Shaler, T. A. (2002) Identification and
relative quantitation of protein mixtures by enzymatic digestion followed
by capillary reversed-phase liquid chromatography-tandem mass spec-
trometry. Anal. Chem. 74, 4741–4749
31. Nahnsen, S., Bielow, C., Reinert, K., and Kohlbacher, O. (2013) Tools for
label-free peptide quantification. Mol. Cell Proteomics 12, 549–556
32. Luber, C. A., Cox, J., Lauterbach, H., Fancke, B., Selbach, M., Tschopp, J.,
Akira, S., Wiegand, M., Hochrein, H., O’Keeffe, M., and Mann, M. (2010)
Quantitative proteomics reveals subset-specific viral recognition in den-
dritic cells. Immunity 32, 279–289
33. Eberl, H. C., Spruijt, C. G., Kelstrup, C. D., Vermeulen, M., and Mann, M.
(2013) A map of general and specialized chromatin readers in mouse
tissues generated by label-free interaction proteomics. Mol. Cell 49,
368–378
34. Choi, H., Glatter, T., Gstaiger, M., and Nesvizhskii, A. I. (2012) SAINT-MS1:
protein–protein interaction scoring using label-free intensity data in af-
finity purification-mass spectrometry experiments. J. Proteome Res. 11,
2619–2624
35. Poulsen, J. W., Madsen, C. T., Young, C., Poulsen, F. M., and Nielsen, M. L.
(2013) Using guanidine-hydrochloride for fast and efficient protein diges-
tion and single-step affinity-purification mass spectrometry. J. Proteome
Res. 12, 1020–1030
36. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide
protein quantification. Nat. Biotechnol. 26, 1367–1372
37. Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., and Mann, M.
(2014) Accurate proteome-wide label-free quantification by delayed nor-
malization and maximal peptide ratio extraction, termed MaxLFQ. Mol.
Cell. Proteomics 13, 2513–2526
38. Nagaraj, N., Kulak, N. A., Cox, J., Neuhauser, N., Mayr, K., Hoerning, O.,
Vorm, O., and Mann, M. (2012) System-wide perturbation analysis with
nearly complete coverage of the yeast proteome by single-shot ultra
HPLC runs on a bench top Orbitrap. Mol. Cell. Proteomics 11, M111
013722
39. Huh, W. K., Falvo, J. V., Gerke, L. C., Carroll, A. S., Howson, R. W.,
Weissman, J. S., and O’Shea, E. K. (2003) Global analysis of protein
localization in budding yeast. Nature 425, 686–691
40. Hubner, N. C., and Mann, M. (2011) Extracting gene function from
protein–protein interactions using Quantitative BAC InteraCtomics
(QUBIC). Methods 53, 453–459
41. Rappsilber, J., Mann, M., and Ishihama, Y. (2007) Protocol for micro-
purification, enrichment, prefractionation, and storage of peptides for
proteomics using StageTips. Nat. Protoc. 2, 1896–1906
42. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and
Mann, M. (2011) Andromeda: a peptide search engine integrated into the
MaxQuant environment. J. Proteome Res. 10, 1794–1805
43. Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012) Compar-
ative proteomic analysis of eleven common cell lines reveals ubiquitous
but varying expression of most proteins. Mol. Cell. Proteomics 11, M111
014050
44. Trinkle-Mulcahy, L., Boulon, S., Lam, Y. W., Urcia, R., Boisvert, F. M.,
Vandermoere, F., Morrice, N. A., Swift, S., Rothbauer, U., Leonhardt, H.,
and Lamond, A. (2008) Identifying specific protein interaction partners
using quantitative mass spectrometry and bead proteomes. J. Cell Biol.
183, 223–239
45. Rees, J. S., Lowe, N., Armean, I. M., Roote, J., Johnson, G., Drummond, E.,
Spriggs, H., Ryder, E., Russell, S., St Johnston, D., and Lilley, K. S. (2011)
In vivo analysis of proteomes and interactomes using Parallel Affinity
Capture (iPAC) coupled to mass spectrometry. Mol. Cell. Proteomics 10,
M110 002386
46. Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N., and Mann, M. (2014)
Minimal, encapsulated proteomic-sample processing applied to copy-
number estimation in eukaryotic cells. Nat. Methods 11, 319–324
47. Cox, J., and Mann, M. (2012) 1D and 2D annotation enrichment: a statistical
method integrating quantitative proteomics with complementary high-
throughput data. BMC Bioinformatics 13, S12
48. Remus, D., Beuron, F., Tolun, G., Griffith, J. D., Morris, E. P., and Diffley,
High Accuracy Label-free Quantitative AE-MS in Yeast
Molecular & Cellular Proteomics 14.1 15
tapraid4/zjw-macp/zjw-macp/zjw00115/zjw4939-14a xppws S3 2/12/14 15:57 4/Color Figure(s) F1–5 ARTNO: M114.041012
57
2 Results
J. F. (2009) Concerted loading of Mcm2–7 double hexamers around DNA
during DNA replication origin licensing. Cell 139, 719–730
49. Nedelcheva, M. N., Roguev, A., Dolapchiev, L. B., Shevchenko, A., Taskov,
H. B., Shevchenko, A., Stewart, A. F., and Stoynov, S. S. (2005) Uncou-
pling of unwinding from DNA synthesis implies regulation of MCM heli-
case by Tof1/Mrc1/Csm3 checkpoint complex. J. Mol. Biol. 347,
509–521
50. Forster, F., Unverdorben, P., Sledz, P., and Baumeister, W. (2013) Unveiling
the long-held secrets of the 26S proteasome. Structure 21, 1551–1562
51. Hatanaka, A., Chen, B., Sun, J. Q., Mano, Y., Funakoshi, M., Kobayashi, H.,
Ju, Y., Mizutani, T., Shinmyozu, K., Nakayama, J., Miyamoto, K., Uchida,
H., and Oki, M. (2011) Fub1p, a novel protein isolated by boundary screen-
ing, binds the proteasome complex. Genes Genet. Syst. 86, 305–314
52. Fernandez-Martinez, J., and Rout, M. P. (2012) A jumbo problem: mapping
the structure and functions of the nuclear pore complex. Curr. Opin. Cell
Biol. 24, 92–99
53. Babu, M., Vlasblom, J., Pu, S., Guo, X., Graham, C., Bean, B. D., Burston,
H. E., Vizeacoumar, F. J., Snider, J., Phanse, S., Fong, V., Tam, Y. Y.,
Davey, M., Hnatshak, O., Bajaj, N., Chandran, S., Punna, T., Christopolous,
C., Wong, V., Yu, A., Zhong, G., Li, J., Stagljar, I., Conibear, E., Wodak,
S. J., Emili, A., and Greenblatt, J. F. (2012) Interaction landscape of
membrane–protein complexes in Saccharomyces cerevisiae. Nature 489,
585–589
54. Spang, A., Courtney, I., Fackler, U., Matzner, M., and Schiebel, E. (1993)
The calcium-binding protein cell division cycle 31 of Saccharomyces
cerevisiae is a component of the half bridge of the spindle pole body.
J. Cell Biol. 123, 405–416
55. Rout, M. P., Aitchison, J. D., Suprapto, A., Hjertaas, K., Zhao, Y., and Chait,
B. T. (2000) The yeast nuclear pore complex: composition, architecture,
and transport mechanism. J. Cell Biol. 148, 635–651
56. Chial, H. J., Rout, M. P., Giddings, T. H., and Winey, M. (1998) Saccharo-
myces cerevisiae Ndc1p is a shared component of nuclear pore com-
plexes and spindle pole bodies. J. Cell Biol. 143, 1789–1800
57. Yewdell, W. T., Colombi, P., Makhnevych, T., and Lusk, C. P. (2011)
Lumenal interactions in nuclear pore complex assembly and stability.
Mol. Biol. Cell 22, 1375–1388
58. Balderhaar, H. J., and Ungermann, C. (2013) CORVET and HOPS tethering
complexes - coordinators of endosome and lysosome fusion. J. Cell Sci.
126, 1307–1316
59. Nath, N., McCartney, R. R., and Schmidt, M. C. (2002) Purification and
characterization of Snf1 kinase complexes containing a defined Beta
subunit composition. J. Biol. Chem. 277, 50403–50408
60. Hedbacker, K., and Carlson, M. (2008) SNF1/AMPK pathways in yeast.
Front. Biosci. 13, 2408–2420
61. Kiemer, L., Costa, S., Ueffing, M., and Cesareni, G. (2007) WI-PHI: a
weighted yeast interactome enriched for direct physical interactions.
Proteomics 7, 932–943
62. Mellacheruvu, D., Wright, Z., Couzens, A. L., Lambert, J. P., St-Denis, N. A.,
Li, T., Miteva, Y. V., Hauri, S., Sardiu, M. E., Low, T. Y., Halim, V. A.,
Bagshaw, R. D., Hubner, N. C., Al-Hakim, A., Bouchard, A., Faubert, D.,
Fermin, D., Dunham, W. H., Goudreault, M., Lin, Z. Y., Badillo, B. G.,
Pawson, T., Durocher, D., Coulombe, B., Aebersold, R., Superti-Furga,
G., Colinge, J., Heck, A. J., Choi, H., Gstaiger, M., Mohammed, S.,
Cristea, I. M., Bennett, K. L., Washburn, M. P., Raught, B., Ewing, R. M.,
Gingras, A. C., and Nesvizhskii, A. I. (2013) The CRAPome: a contami-
nant repository for affinity purification-mass spectrometry data. Nat.
Methods 10, 730–736
63. Vizcaino, J. A., Deutsch, E. W., Wang, R., Csordas, A., Reisinger, F., Rios,
D., Dianes, J. A., Sun, Z., Farrah, T., Bandeira, N., Binz, P. A., Xenarios,
I., Eisenacher, M., Mayer, G., Gatto, L., Campos, A., Chalkley, R. J.,
Kraus, H. J., Albar, J. P., Martinez-Bartolome, S., Apweiler, R., Omenn,
G. S., Martens, L., Jones, A. R., and Hermjakob, H. (2014) Proteome-
Xchange provides globally coordinated proteomics data submission and
dissemination. Nat. Biotechnol. 32, 223–226
64. Vizcaino, J. A., Cote, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster,
J. M., Griss, J., Alpi, E., Birim, M., Contell, J., O’Kelly, G., Schoenegger,
A., Ovelleiro, D., Perez-Riverol, Y., Reisinger, F., Rios, D., Wang, R., and
Hermjakob, H. (2013) The PRoteomics IDEntifications (PRIDE) database
and associated tools: status in 2013. Nucleic Acids Res. 41,
D1063–D1069
High Accuracy Label-free Quantitative AE-MS in Yeast
16 Molecular & Cellular Proteomics 14.1
tapraid4/zjw-macp/zjw-macp/zjw00115/zjw4939-14a xppws S3 2/12/14 15:57 4/Color Figure(s) F1–5 ARTNO: M114.041012
58
2.1.2 A high-throughput pipeline to measure 96 yeast pulldowns in one day
Hosp F., Scheltema R.A., Eberl H.C., Kulak N.A., Keilhauer, E. C., Mayr, K. & Mann,
M.
A double-barrel LC-MS/MS system to quantify 96 interactomes per day
Molecular and Cellular Proteomics 2015 Apr 17 [epub ahead of print]
Since the new yeast AE-MS method had proven very successful, we next wished to fur-
ther develop it into a high-throughput pipeline. Having spent quite some time already
on a purely technological project, I decided not to take the lead in this but rather a sup-
portive role. Hence, the project was first started by Dr. Christian Eberl, a PostDoc in the
group. The initial idea was to transfer all sample preparation steps to a 96-well format
to be able to process many more pulldowns in parallel. With my help, Chris started to
adapt the yeast pulldowns to a 96-well format using filter plates. However he soon left
the group, and the project was taken over by a new PostDoc, Dr. Fabian Hosp. After
I introduced him to the yeast pulldown pipeline, he successfully optimized the yeast
culture by transferring it to 96-well plates, enabling the growth of 96 GFP-strains in par-
allel. The challenge here is the maximum culture volume of only 2 ml, however, already
in the initial yeast pulldown pipeline I had used relatively low input amounts. Yeast
lysis could unfortunately not efficiently be performed in the 96-well plates, hence was
performed as optimized by me before by beadbeating. For the pulldowns, we switched
from the established robotic platform to 96-well plates coated with anti-GFP antibodies
and manual pipetting, due to the low input amounts. After a high-throughput sample
preparation pipeline was established, the MS measurement time with gradient lengths
of over two hours became the major bottleneck in regard of throughput. The gradient
length had to be reduced, which proved to be feasible because of the low complexity pull-
down samples and the high performance of the Q Exactive HF. To even further increase
sample throughput, Dr. Richard Scheltema, another PostDoc in the group, implemen-
ted a double-barrel system driving two chromatography columns in parallel. Whenever
a gradient was running on one column, the second column could already be loaded
with the next sample which drastically shortened machine idling time between runs. Fi-
nally, we adapted the data analysis pipeline to the low complexity pulldowns. Due to the
double-barrel system, the new high-throughput pipeline now allows to measure up to 96
pulldowns in about one day. We applied the method to investigate the yeast chromatin
59
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remodeling landscape, and obtained high complex coverage for the 21 targeted com-
plexes using our high-throughput format. The described method provides the means
for future dynamic interactome analyses, but should also be universally applicable to
various kinds of low complexity proteomes.
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2.1.2 Publication:A high-throughput pipeline to measure 96 yeast pulldowns in one day
A Double-Barrel Liquid Chromatography-
Tandem Mass Spectrometry (LC-MS/MS)
System to Quantify 96 Interactomes per Day*□S
Fabian Hosp‡, Richard A. Scheltema‡, H. Christian Eberl‡¶, Nils A. Kulak‡,
Eva C. Keilhauer‡, Korbinian Mayr‡, and Matthias Mann‡§
The field of proteomics has evolved hand-in-hand with
technological advances in LC-MS/MS systems, now ena-
bling the analysis of very deep proteomes in a reasonable
time. However, most applications do not deal with full cell
or tissue proteomes but rather with restricted subpro-
teomes relevant for the research context at hand or re-
sulting from extensive fractionation. At the same time,
investigation of many conditions or perturbations puts a
strain on measurement capacity. Here, we develop a high-
throughput workflow capable of dealing with large num-
bers of low or medium complexity samples and specifi-
cally aim at the analysis of 96-well plates in a single day
(15 min per sample). We combine parallel sample proc-
essing with a modified liquid chromatography platform
driving two analytical columns in tandem, which are cou-
pled to a quadrupole Orbitrap mass spectrometer (Q Ex-
active HF). The modified LC platform eliminates idle time
between measurements, and the high sequencing speed
of the Q Exactive HF reduces required measurement time.
We apply the pipeline to the yeast chromatin remodeling
landscape and demonstrate quantification of 96 pull-
downs of chromatin complexes in about 1 day. This is
achieved with only 500 g input material, enabling yeast
cultivation in a 96-well format. Our system retrieved
known complex-members and the high throughput al-
lowed probing with many bait proteins. Even alternative
complex compositions were detectable in these very
short gradients. Thus, sample throughput, sensitivity and
LC/MS-MS duty cycle are improved severalfold compared
with established workflows. The pipeline can be extended
to different types of interaction studies and to other me-
dium complexity proteomes. Molecular & Cellular Pro-
teomics 14: 10.1074/mcp.O115.049460, 2030–2041, 2015.
Shotgun proteomics is concerned with the identification
and quantification of proteins (1–3). Prior to analysis, the
proteins are digested into peptides, resulting in highly com-
plex mixtures. To deal with this complexity, the peptides are
separated by liquid chromatography followed by online anal-
ysis with mass spectrometry (MS), today facilitating the char-
acterization of almost complete cell line proteomes in a short
time (3–5). In addition to the characterization of entire pro-
teomes, there is also a great demand for analyzing low or
medium complexity samples. Given the trend toward a sys-
tems biology view, relatively larges sets of samples often have
to be measured. One such category of lower complexity
protein mixtures occurs in the determination of physical inter-
action partners of a protein of interest, which requires the
identification and quantification of the proteins “pulled-down”
or immunoprecipitated via a bait protein. Protein interactions
are essential for almost all biological processes and orches-
trate a cell’s behavior by regulating enzymes, forming macro-
molecular assemblies and functionalizing multiprotein com-
plexes that are capable of more complex behavior than the
sum of their parts. The human genome has almost 20,000
protein encoding genes, and it has been estimated that 80%
of the proteins engage in complex interactions and that
130,000 to 650,000 protein interactions can take place in a
human cell (6, 7). These numbers demonstrate a clear need
for systematic and high-throughput mapping of protein–
protein interactions (PPIs) to understand these complexes.
The introduction of generic methods to detect PPIs, such as
the yeast two-hybrid screen (Y2H) (8) or affinity purification
combined with mass spectrometry (AP-MS)1 (9), have revolu-
tionized the protein interactomics field. AP-MS in particular
has emerged as an important tool to catalogue interactions
with the aim of better understanding basic biochemical mech-
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anisms in many different organisms (10–17). It can be per-
formed under near-physiological conditions and is capable of
identifying functional protein complexes (18). In addition, the
combination of affinity purification with quantitative mass
spectrometry has greatly improved the discrimination of true
interactors from unspecific background binders, a long-
standing challenge in the AP-MS field (19–21). Nowadays,
quantitative AP-MS is employed to address many different
biological questions, such as detection of dynamic changes in
PPIs upon perturbation (22–25) or the impact of posttransla-
tional signaling on PPIs (26, 27). Recent developments even
make it possible to provide abundances and stoichiometry
information of the bait and prey proteins under study, com-
bined with quantitative data from very deep cellular pro-
teomes. Furthermore, sample preparation in AP-MS can now
be performed in high-throughput formats capable of produc-
ing hundreds of samples per day. With such throughput in
sample generation, the LC-MS/MS part of the AP-MS pipeline
has become a major bottleneck for large studies, limiting
throughput to a small fraction of the available samples. In
principle, this limitation could be circumvented by multiplex-
ing analysis via isotope-labeling strategies (28, 29) or by dras-
tically reducing the measurement time per sample (30–32).
The former strategy requires exquisite control of the process-
ing steps and has not been widely implemented yet. The latter
strategy depends on mass spectrometers with sufficiently
high sequencing speed to deal with the pull-down in a very
short time. Since its introduction about 10 years ago (33), the
Orbitrap mass spectrometer has featured ever-faster se-
quencing capabilities, with the Q Exactive HF now reaching a
peptide sequencing speed of up to 17 Hz (34). This should
now make it feasible to substantially lower the amount of time
spent per measurement.
Although very short LC-MS/MS runs can in principle be
used for high-throughput analyses, they usually lead to a drop
in LC-MS duty cycle. This is because each sample needs
initial washing, loading, and equilibration steps, independent
of gradient time, which takes a substantial percentage for
most LC setups - typically at least 15–20 min. To achieve a
more efficient LC-MS duty cycle, while maintaining high sen-
sitivity, a second analytical column can be introduced. This
enables the parallelization of several steps related to sample
loading and to the LC operating steps, including valve switch-
ing. Such dual analytical column or “double-barrel: setups
have been described for various applications and platforms
(30, 35–39).
Starting from the reported performance and throughput of
workflows that are standard today (16, 21, 40–42), we asked
if it would be possible to obtain a severalfold increase in both
sample throughput and sensitivity, as well as a considerable
reduction in overall wet lab costs and working time. Specifi-
cally, our goal was to quantify 96 medium complexity samples
in a single day. Such a number of samples can be processed
with a 96-well plate, which currently is the format of choice for
highly parallelized sample preparation workflows, often with a
high degree of automation. We investigated which advances
were needed in sample preparation, liquid chromatography,
and mass spectrometry. Based on our findings, we developed
a parallelized platform for high-throughput sample prepara-
tion and LC-MS/MS analysis, which we applied to pull-down
samples from the yeast chromatin remodeling landscape. The
extent of retrieval of known complex members served as a
quality control of the developed pipeline.
EXPERIMENTAL PROCEDURES
Preparation of Yeast Lysates—GFP-tagged yeast strains from the
Saccharomyces cerevisiae GFP Clone Collection (43), the parental
strain BY4741 and the control strain pHis3-GFP (21) were cultured in
YPD liquid medium in 96-deep well plates (Sarstedt, Nümbrecht,
Germany) at standard conditions. We used 32 distinct yeast strains in
biological triplicates, resulting in 96 experimental samples. Yeast cells
were grown until they reached an Optical Density600 nm of around 1,
followed by harvesting culture volumes equaling 2 ODs per well.
Yeast cell pellets were dissolved in 300 l lysis buffer (150 mM NaCl,
50 mM Tris-HCl (pH 8.0), 1 mM MgCl2, 5% glycerol, 1% IGEPAL
CA-630 (Sigma-Aldrich, Schnelldorf, Germany), complete protease
inhibitors (Roche, Mannheim, Germany), 1% benzonase (Merck,
Darmstadt, Germany)), transferred into FastPrep tubes (MP Biomedi-
cals, Eschwege, Germany) containing 1 mm silica spheres (lysing
matrix C, MP Biomedicals), and lysed in a FastPrep24 instrument (MP
Biomedicals) for 6  1 min at maximum speed. Lysates were cleared
by centrifugation at 16,100  g for 10 min at 4 °C.
Affinity Purification—Each well of a GFP-multiTrap plate (Chro-
moTek, Martinsried, Germany) was washed three times with 200 l
buffer 1 (150 mM NaCl, 50 mM Tris-HCl, pH 8.0) and then incubated
with the cleared yeast cell lysate (500 g total protein extract) with
gentle shaking at 100 rpm for 60 min at 4 °C. Next, each well was
washed twice with 200 l buffer 2 (150 mM NaCl, 50 mM Tris-HCl (pH
8.0), 0.25% IGEPAL CA-630) and four times with 200 l buffer 1
before incubation with 25 l elution buffer (2 M urea, 20 mM Tris-HCl
(pH 8.0), 1 mM DTT, 100 ng sequence-grade modified trypsin (Pro-
mega, Madison, WI, USA) at room temperature for 90 min. Subse-
quently, the resulting peptides were alkylated with 25 l alkylation
buffer (2 M urea, 20 mM Tris HCl (pH 8.0), 5 mM iodoacetamide) and
finally washed once with 50 l urea buffer (2 M urea, 20 mM Tris HCl,
pH 8.0) for 10 min, respectively. The supernatants from the elution,
alkylation and washing step were collected after each step and com-
bined in a clean 96-well plate. This plate was incubated overnight at
room temperature to ensure a complete digest. The next morning, the
digest was stopped by addition of 10 l 10% TFA per well. The
acidified peptides were purified on StageTips (44) containing two
layers of Poly(styrenedivinylbenzene)-Reversed-Phase Sulfonate
(Empore 2241, 3 M, Neuss, Germany) material to desalt and purify the
peptides. Samples were eluted from the StageTips with 60 l elution
buffer (80% acetonitrile, 1% ammonium hydroxide) and evaporated in
a SpeedVac concentrator for 30 min. The remaining peptide solution
volume was adjusted to 4 l with buffer A* (2% ACN, 0.1% formic
acid).
LC-MS/MS Analysis—Online chromatography was performed with
a modified Thermo EASY-nLC 1000 UHPLC system (Thermo Fisher
Scientific, Bremen, Germany) coupled online to the Q Exactive HF
instrument with a nano-electrospray ion source (Thermo Fisher Sci-
entific). Two analytical columns (15 cm long, 75 m inner diameter)
were packed in-house with ReproSil-Pur C18 AQ 1.9 m reversed
phase resin (Dr. Maisch GmbH, Ammerbuch, Germany) in buffer A
(0.5% formic acid) and matched with regard to back-pressure to
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ensure intercolumn reproducibility. During online analysis, the analyt-
ical columns were placed in a modified column heater (Sonation
GmbH, Biberach, Germany) regulated to a temperature of 55 °C.
Modifications to both systems are described in RESULTS. Peptides
were loaded onto the analytical columns with buffer A at a back
pressure of 650 bar (generally resulting in a flow rate of 500 nL/min)
and separated with two distinct linear gradients of 8–30% buffer B
(80% ACN and 0.5% formic acid) at a flow rate of 450 nL/min
controlled by IntelliFlow technology over 10 min and 22 min, respec-
tively (generally at a back pressure of around 500 bar). Online quality
control was performed with SprayQc (45), which was extended with
an additional plugin to support a high-voltage switch controlling the
spray voltage for the analytical columns (RESULTS). MS data were
acquired with a Q Exactive Plus (27 min gradients) and a Q Exactive
HF (14 min gradients) instrument, as the latter has been found to be
up to twice as fast (34) and thus capable of dealing with the fast
chromatography of the 14 min gradient. The instruments were pro-
grammed with a data-dependent top 5 and top 10 method, respec-
tively, dynamically choosing the most abundant not yet sequenced
precursor ions from the survey scans (300–1,650 Th). Instruments
were controlled using Tune 2.5 and Xcalibur 3.0.63. At a maximum ion
inject time of 45 ms for both instruments, the cycle time was 800
ms, sufficient for generating a median of 16 data points (14 min) or 25
data points (27 min) over the observed elution peaks (RESULTS).
Further settings were chosen according to their previously deter-
mined optimal values (34). Sequencing was done with higher-energy
collisional dissociation fragmentation with a target value of 1e5 ions
determined with predictive automatic gain control, for which the
isolation of precursors was performed with a window of 1.4 Th.
Survey scans were acquired at a resolution of 70,000 and 60,000,
respectively, at m/z 200 and the resolution for HCD spectra was set to
17,500 and 15,000, respectively, at m/z 200. Normalized collision
energy was set to 27 and the “underfill ratio,” specifying the minimum
percentage of the target ion value likely to be reached at maximum fill
time was defined as 10% (27 min) and 40% (14 min). The elevated
sequencing threshold ensured that, with the reduced complexity of
samples, the fragmentation scans are of higher quality. Furthermore,
the S-lens radio frequency level was set to 60, which gave optimal
transmission of the m/z region occupied by the peptides from our
digest (34). We excluded precursor ions with unassigned, single, or
five and higher charge states from fragmentation selection.
Data Analysis—All data were analyzed with the MaxQuant pro-
teomics data analysis workflow version 1.4.3.14 (46). The false dis-
covery rate (FDR) cut off was set to 1% for protein and peptide
spectrum matches. Peptides were required to have a minimum length
of seven amino acids and a maximum mass of 4,600 Da. MaxQuant
was used to score fragmentation scans for identification based on a
search with an initial allowed mass deviation of the precursor ion of a
maximum of 4.5 ppm after time-dependent mass calibration. The
allowed fragment mass deviation was 20 ppm. Fragmentation spectra
were identified using the UniprotKB S. cerevisiae database (based on
2014–07 release; 6,643 entries) combined with 262 common con-
taminants by the integrated Andromeda search engine (47). Enzyme
specificity was set as C-terminal to arginine and lysine, also allowing
cleavage before proline, and a maximum of two missed cleavages.
Carbamidomethylation of cysteine was set as fixed modification and
N-terminal protein acetylation and methionine oxidation as variable
modifications. Both “match between runs,” with a maximum time
difference of 30 s, and label-free quantification (LFQ) with standard
settings, were enabled (48). Additional metadata stored in the RAW
files (e.g. ion inject time, noise level, etc.) were extracted using MS-
FileReader (Thermo Scientific) with in-house-developed tools.
Further data analysis with the goal of assigning the interactors was
performed with the R scripting and statistical environment (49) using
ggplot (50) for data visualization. Briefly, LFQ intensity values were
base10 logarithmized, resulting in a normal distribution. Missing val-
ues were imputed by randomly selecting from a normal distribution
centered on the lower edge of the intensity values (for this normal
distribution the shift was set to 1.8 standard deviations from the mean
and the width to 0.3 standard deviations; see histograms describing
placement in Figs. S8 and S9). Proteins were excluded in subsequent
steps for baits with less than two valid values in the triplicate for the
bait (mostly presented as significantly depleted proteins due to the
imputed character of the intensity values). The fold enrichment was
calculated as the mean ratio between the bait measurements and
the proteome measurements of the parental strain (conforming to the
mean used in the consequent t test). For the fold enrichment, the
standard error of the mean was additionally determined. Permutation-
based FDR-controlled t test p values were calculated for each protein
between the bait triplicate and the parental strain triplicate (employing
250 permutations). The p value was adjusted using a scaling factor s0
with a value of 1 prior to FDR control, which magnifies the importance
of the difference of the mean (51). Furthermore, the correlation of
each protein’s LFQ intensity profile (consisting of all the measured
intensity values for that protein) to the LFQ intensity profile of the bait
was calculated (21), and the resulting correlation p values were ad-
justed to 1% FDR using the Benjamini and Hochberg procedure.
Interactor classes were assigned based on the following rules: (A) only
1% FDR t test significance, (A) both 1% FDR t test significance,
and 1% FDR correlation significance, (B) both 5% FDR t test
significance and 1% FDR correlation significance and (B) only 5%
FDR t test significance. Known interactors from the Saccharomyces
Genome Database (www.yeastgenome.org) mainly fell in classes A,
A, and B. Therefore, we conducted follow-up analyses solely on
these classes. For each significant outlier, we also introduced a single
significance value, based on the s0 scaling introduced in the t test,
which combines the enrichment value and the t test statistic. This is
calculated as the distance in log-space from the origin. The higher this
value, the better the data quality and experimental success of that
particular interactor. Stoichiometry information was determined in
two ways. The first, termed interaction stoichiometry, is the ratio
between the calculated intensity-based absolute quantification values
(determining the copy numbers from the acquired mass spectrometry
data) of the interactors to the bait (52). The second, termed abun-
dance stoichiometry, is the ratio between the normal cellular copy
numbers of the interactors to the bait.
RESULTS
Reducing the LC-MS/MS Analysis Time—First, we aimed to
establish optimal conditions for reducing the LC gradient
length. Both the flow rate and gradient starting percentage
require adaptations to ensure that the signal of each peptide
does not degrade and to maximize the spread of peptides
over the gradient. To achieve this, we tested the effect of flow
rate (ranging from 200 to 500 nl/min) and gradient length (from
15 to 120 min) on the chromatographic peak-width with a
standard HeLa digest on the Q Exactive HF (34). By far, the
largest effect on peak width was shortening the gradient
length as this provided a reduction of 75% on the width,
while the flow rate reduced it only by 4% (Fig. 1A). With
regard to overall proteome depth, we were able to identify
about 740 proteins with a standard HeLa digest using the
shortest gradient length of 15 min with the Q Exactive HF (Fig.
1B). Hence, the complexity of protein samples should not
exceed such a number when high sample throughput is en-
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visioned. We also determined protein identifications for lower
sequencing speed (Fig. 1B). Notably, even platforms with
lower sequencing speed like the Orbitrap XL identified about
1,000 proteins with a 120 min gradient, suggesting that al-
ready this machine generation had the potential to identify all
proteins of a lower complexity sample given sufficiently long
gradients.
Higher flow rates could have a detrimental effect on the
signal-to-noise due to the higher dilution of peptides in the
buffer, which we investigated by extracting the signal-to-
noise values for a set of 750 isotope patterns identified in all
the runs and spread out over the full retention time range. For
the longest gradient length of 120 min, we observe a slight
decrease in signal-to-noise for the higher flow rates, whereas
unexpectedly higher flow rates partially improve the signal-to-
noise for the shortest gradient. For the intermediate gradient
lengths, the flow rate does not appreciably affect the signal-
to-noise ratio. Between the two shortest gradients of 30 and
15 min, we observe a drop in signal-to-noise, which we at-
tribute to imprecision of the buffer delivery by the LC (Fig. 1C).
Given that it takes time for the buffer mixture to arrive from
the mixing T connection to the tip of the analytical column,
and therefore for the peptides to elute, the shorter gradients
suffer in terms of gradient occupancy (percentage of the
gradient occupied by peptides) when using lower flow rates.
This is mostly improved by forcing the peptides to elute
earlier with higher flow rates. For the shortest gradient
lengths, we were able to move the start of peptide elution
from 60% in the gradient (at 9 min) to 40% in the gradient (at
6 min), improving the spread of the peptides over the com-
plete gradient and providing better chromatographic reso-
lution. For the 30 min gradient, the first elution was moved
from 10 min (35% of the gradient time) to 7 min (25%)
(Fig. 1D).
Based on these findings, we determined the optimal gradi-
ent time to be 27 min with a flow rate of 450 nl/min, which kept
the backpressure of the LC pumps at an acceptable level of
around 500 bar. This, however, still results in 2 days of mea-
surements for 96 samples. The 12 min gradient at the same
flow rate necessary for exactly 24 h of measurement for the
same number of samples is expected to have reduced chro-
matographic performance compared with the 27 min gradi-
ent. This period is also too short to transfer the peptides onto
the analytical column in parallel. We therefore increased the
gradient time to 14 min and activated the loading pump during
the intersample preparation time, which reliably loaded all the
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FIG. 1. Chromatography optimization for very short gradients. (A) Peak-width as a function of gradient length and flow rate. Effect size
is the calculation of the reduction compared with the largest change in peak-width. (B) Extrapolation of protein identifications as a function of
gradient length and scan speed of various MS platforms (Q Exactive HF and plus, Orbitrap Elite, and Velos, LTQ Orbitrap XL, respectively). (C)
Effect of flow rate on the signal-to-noise for a set of 750 unique isotope patterns identified in all measurements and spread out over the entire
gradient. (D) Elution time shift induced by higher flow rates, normalized to the gradient length.
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peptides onto the analytical column. Additionally, we in-
creased the starting acetonitrile percentage of the gradient
from 2% to 8% (EXPERIMENTAL PROCEDURES) to start the
peptide elution at an earlier point of the gradient. Collectively,
this resulted in a time frame for peptide elution of 8 min and 18
min, representing 60 and 75%, respectively, of the total mea-
surement time for the 14 and 27 min gradients. At these
conditions, the median peak-width (base-to-base) was 6 s (14
min) and 11 s (27 min), respectively.
Double-Barrel Chromatography on the EASY-nLC—Next,
we set out to develop a double-barrel chromatography sys-
tem in order to reduce the idling time of the mass spectrom-
eter during loading of the peptides to the LC column. Unfor-
tunately, no such setup has been described for the Thermo
EASY-nLC 1000 UHPLC systems (Thermo Fisher Scientific)
that we employ and that are widely used with the Orbitrap-
family of mass spectrometers. To address this, we modified
the liquid pathway of the EASY-nLC 1000 UHPLC system
(Figs. 2A-2D). In brief, we placed the sample loop directly
between the pump S and valve S, allowing the system to
utilize pump S as both the sample pickup as well as the
sample-loading pump (in the original setup, pump A is used
as sample-loading pump). The valve S is connected to valve
W (in the original setup this valve is connected to a waste line
used for rapid evacuation of the buffers from the lines), which
connects to the buffer A and B mixing-T connection and the
two analytical columns through standard sample lines. This
setup allows loading of one sample onto one of the analytical
columns while the other is eluted.
To make use of this new liquid pathway and to drive two
analytical columns in parallel, we also modified the “business
logic” controlling the UHPLC system. The normally sequential
steps in the analysis process (Fig. 2E) were altered to work in
parallel with each other (Fig. 2F). As soon as the preparation
for the currently active analytical column has finished, the
initiation phase and the valve W has switched to elute the
loaded peptides, the inactive analytical column is prepared in
parallel for the next sample. This is done in three consecutive
steps: First, the sample loop is washed, then the new sample
is loaded into the sample loop, and finally the sample is
loaded from the sample loop onto the analytical column. With
the above described arrangement of the pumps and valves,
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these operations can be performed independently for each
of the two analytical columns. The intermeasurement time for
the double-barrel system was clocked at a maximum of 160 s
(Figs. 2E and 2F), which cannot be further reduced on this
particular system due to the necessity of refilling the syringe-
based pumps and bringing them back up to pressure (Sup-
plemental Fig. S1).
Finally, we modified our standard analytical column heater
(33) to accommodate the two analytical columns. The two
columns are now pointing sideways toward the mass spec-
trometer inlet at a fixed angle of 45 degrees at a distance of
roughly 2 mm from each other at the tip ends (equaling the
width of the heated capillary mounted on Orbitrap platforms;
Fig. 2G). As we utilize a fixed setup for the analytical columns,
we cannot supply the spray voltage in parallel (Fig. 2H). To
shift the voltage between the analytical columns, we addition-
ally developed a high-voltage switch capable of supplying
electricity to a single analytical column, controllable through a
universal serial bus connection (Supplemental Fig. S2). A
plugin module that we developed for the SprayQc environ-
ment (45) monitors the current position of the valve W and
switches the spray voltage to the eluting analytical column
according to a user-definable setting.
A Parallel Workflow for Analyzing 96 Pull-Down Samples
within a Single Day—A high-throughput platform should be
able to prepare samples in a parallelized format and subse-
quently measure all of them within a very short time period.
Here, we developed an analysis pipeline for pull-down sam-
ples that is capable of achieving this goal on pull-down sam-
ples (Fig. 3). To facilitate a streamlined workflow necessary for
achieving high-throughput processing of pull-down samples,
we used GFP-tagged yeast strains originating from the yeast
GFP clone collection (43). Further improvements were gained
by combining both the cultivation of the yeast and the pull-
downs in a 96-well format. Each well yields 50 million yeast
cells, equal to 500 g of protein lysate, which turned out to be
sufficient for the pull-down experiments.
Mass Spectrometry Platform Performance on Pull-Down
Samples—Using the transcriptional adapter protein ADA2 as
a bait, we compared the performance of the Q Exactive HF to
that of the LTQ-Orbitrap XL, an instrument introduced about 9
years ago with a sequencing speed of 2 Hz that is frequently
used for pull-down analyses. Notably, both instruments were
able to identify all known members of the reconstituted ADA2
complex within the commonly used measurement time of 2 h
(Supplemental Fig. S3A). This suggests that protein interac-
tion data acquired with older Orbitrap generations over the
last 10 years would generally gain little by remeasurement as
long as extended LC-MS/MS gradients have been used.
However, we note that the protein sequence coverage and,
consequently, enrichment of the preys (calculated by dividing
the MaxLFQ intensity of the interactors by the median of all
MaxLFQ intensities) was somewhat improved with the Q Ex-
active HF, making the setup slightly more sensitive in detect-
ing interactors (Supplemental Fig. S3B). Clearly, these gradi-
ent times are not making effective use of the superior
sequencing speed of the Q Exactive HF. By lowering the
measurement time to as low as 15 min, the identification
performance of the older platform started to suffer while that
of the Q Exactive HF still allowed capturing all the expected
interactors (Supplemental Fig. S3A). The major difference be-
tween the systems was in the sequence coverage per protein,
which for the Q Exactive HF remains constant up to 30 min
and slightly degrades at 15 min, while it degrades dramatically
for the Orbitrap XL (Supplemental Fig. S3C). The decreased
sequence coverage negatively impacts the ability to accu-
rately quantify proteins as label-free quantification improves
with the number of peptides associated to a given protein
(48). This is reflected in the measured enrichment ratios,
which for the Orbitrap XL made the bait interactors nearly
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FIG. 3. Workflow of the high-throughput LC-MS/MS protein interaction analysis pipeline. Both culturing of yeast cells and affinity
purification are performed in 96-well plate format, thus parallelizing sample preparation and minimizing handling errors. LC-MS/MS analysis
of 96 pull-down samples in 1 day is achieved through a double-barrel chromatography setup and the increased sequencing speed of the Q
Exactive HF mass spectrometer.
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indistinguishable from the background, while for the Q Exac-
tive HF it remained superior even at 30 min when comparing
to 2 h (Supplemental Fig. S3B). Overall, as expected, the Q
Exactive HF outperformed the Orbitrap XL for all measure-
ment times tested in terms of prey enrichment, sequence
coverage, and isotopic features (Supplemental Fig. S3B-
S3D). While we observed a decrease in obtained sequence
information in the 15 min Q Exactive HF methods, these very
short runs still yielded sufficiently high sequence coverage to
identify the members of the complex under investigation. In
conclusion, these results show that mass spectrometers with
relatively low sequencing speed can perform equivalently at
long gradients for protein interaction studies, whereas very
high sequencing speeds are required for high-throughput
identification.
Reproducibility of the Data Acquisition System—To inves-
tigate the reproducibility of protein quantification between
different measurements, we acquired PPI data for the yeast
chromatin remodelers RSC8, SPT7, and SWI3 with our work-
flow. Visual inspection of the chromatograms for the RSC8
pull-down, measured in triplicates, already shows a high de-
gree of technical reproducibility for the double barrel system
with back pressure matched analytical columns (Fig. 4A). In
modern PPI experiments, the number of background binders
can be in the thousands as opposed to only a few true
interactors. We take advantage of these unspecific binders to
estimate reproducibility by calculating the correlation be-
tween each pair of the measurements where only the gener-
ally small number of true interactors degrade the correlation
(21). Most of the detected unspecific binders were indeed
reproducibly quantified in all three samples. There was one
exception with a slightly reduced Pearson correlation coeffi-
cient for the RSC8 pull-down (Fig. 4B), for which we con-
cluded based on the large number of imputed values that the
enrichment was not completely successful. A small outlier
population observed for each bait protein indeed represented
the expected interaction partners (Fig. 4C and Supplemental
Fig. S4). Collectively, these results indicate that our double-
barrel setup can be operated with very low MS idling time
between two independent measurements and achieves high
reproducibility at the same time.
PPI Data Quality from Very Short Gradients—To identify
preys of a given bait protein, we classified all interactors into
four distinct classes essentially as described (21) and im-
proved on that concept by making it completely data driven
(EXPERIMENTAL PROCEDURES). Distinction of specific from
unspecific binders was achieved by a permutation-based
false-discovery rate approach operating on a t test and en-
richment with two distinct stringencies (EXPERIMENTAL
PROCEDURES; Supplemental Fig. S5A). Proteins passing the
stringent cutoff represent highly enriched interactors, whereas
proteins only passing the less stringent cutoff are character-
ized as mildly enriched interactors. All other proteins were
considered to be unspecific binders. In addition, we used
Benjamini–Hochberg-corrected intensity profile correlation of
potential interactors compared with the bait protein to mini-
mize false-positive identifications of mildly enriched interac-
tors (EXPERIMENTAL PROCEDURES; Supplemental Figs.
S5E and S5F) (21). With these criteria, interactors were
grouped into confidence classes A, A, B, and B (Supple-
mental Figs. S4C and S4G). Absolute quantification data from
whole yeast proteome experiments (53) allowed us to also
estimate interaction and abundance stoichiometries for every
protein complex under investigation (Supplemental Fig. S5D).
To assess the quality control of both the LC-MS/MS mea-
surements and the subsequent interactor classification given
our large throughput, we employed three distinct layers. The
first layer consists of the real-time validation provided by
SprayQc (45). Besides the logic for the voltage switch, this
software implements automatic warnings via E-mail to the
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operator for a large number of components involved in the
measurement and reports meta-data for these components
(EXPERIMENTAL PROCEDURES). The second layer consists
of verification of the sample preparation and LC-MS/MS
measurement success by the number of identified proteins
per measurement. Given the preponderance of background
proteins, this value should be roughly equal for all pull-downs.
The histograms displaying the imputed values provide a sim-
ple visual guide in the form of the peaks for the imputed
proteins (EXPERIMENTAL PROCEDURES). The third layer is
the data-driven determination of what constitutes a success-
ful pull-down experiment. For this, we used the information
from the volcano plots, specifically the significance value as
described (EXPERIMENTAL PROCEDURES). For all the pull-
downs, we combine this value for all the baits to determine a
valid range for the baits. Anything falling outside this range is
flagged as potentially unreliable.
A Snapshot of the S. cerevisiae Chromatin Remodeling
Landscape—The data obtained from our very short LC-
MS/MS measurements operated with double barrel chroma-
tography demonstrated that AP-MS screens of sufficient
quality can be performed in a high-throughput format (Fig. 4).
To investigate our workflow on a set of protein complexes
involved in a particular biological pathway, we selected 30
distinct bait proteins that are part of the yeast chromatin
remodeling landscape. In addition, we also used a GFP-
expressing control and the haploid parental strain (EXPERI-
MENTAL PROCEDURES). Our bait selection spans three or-
ders of expression abundance over the whole yeast proteome
(Fig. 5A) and includes several baits with very low abundance
(100 copies per cell). We found that the protein input
amount of 500 g, which is much lower than that traditionally
used, was sufficient to identify the bait proteins and to retrieve
known interactors, even for lowest expressed bait proteins
(Supplementary Material_14min and Supplementary Material_
27min). Additionally, where possible, we selected multiple
baits per protein complex in an attempt to characterize the
complex as thoroughly as possible. This collection covers 21
distinct protein complexes subdivided into four enzyme class-
es: histone acetyltranferase, chromatin remodeling, histone
methyltransferase, and histone deacetylase complexes. For
the 32 distinct yeast strains, we performed pull-down exper-
iments in biological triplicates, resulting in 96 samples. Each
of these pull-down samples was measured with both the 14
and the 27 min LC-MS/MS methods, respectively. Together,
the interactomes of 96 pull-down samples were measured in
either 47.5 h (27 min method) or 26.7 h (14 min method) of
start-to-end complete measurement time, including all over-
head. As expected, we found that the sequence coverage of
bait proteins and specific interactors was reduced for almost
every protein in the 14 compared with the 27 min method (Fig.
5B). Nevertheless, the sequence information acquired in the
14 min runs was still sufficient to identify enriched baits and
their corresponding preys. We did not experience problems
with regard to the bioinformatic enrichment value based on
the LFQ intensities, as had been the case for the short gradi-
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ents on the older platforms (see Supplemental Figs. S6
and S7, Supplementary Material_14min and Supplementary
Material_27min).
To provide an overview of our identified PPIs, we created a
topology network of all interactors assigned to one of the
defined prey classifications. While the overall interactor class
ranking was slightly reduced, we found only small variations in
the final complex coverage even though the LC-MS/MS gra-
dient was nearly halved when comparing the 14 to the 27 min
method (Fig. 6). Out of 21 protein complexes analyzed, both
run times performed equally well in nine cases, whereas the
27 min outperforms the 14 min in ten cases. Conversely, the
14 min runs were better in two cases. The 27 min method
allowed a high retrieval of known interactors even for several
very low abundant baits with less than 100 copies per cells.
While the 14 min method identified less preys of baits with
very low abundance, its superior speed allowed throughput of
the same sample set in almost half the time.
Remarkably, we could even validate the presence of two
different RSC nucleosome-remodeling complexes. The RSC
complex is present in two distinct isoforms with distinct roles
in the DNA damage response, as defined by the presence of
either RSC1 or RSC2 (54, 55). While performing pull-downs on
either RSC4 or RSC8, we identified both RSC1 and RSC2 as
interactors, demonstrating that RSC4 and RSC8 are part of
both RSC complex isoforms (Supplementary Material_
27min). In contrast, pulling down RSC2 only resulted in RSC2
but not RSC1 as complex members. These results demon-
strate that our workflow is capable of identifying distinct com-
plex compositions in a rapid manner.
Discussion and Outlook—In this study, we have described
advances for analyzing up to 96 proteomes with lower com-
plexity in about 1 day of LC-MS/MS data acquisition, includ-
ing all overhead. Our interaction workflow employs parallel-
ized sample generation in a 96-well format together with a
modified LC setup and mass spectrometers with very high
sequencing speed. With this combination, we demonstrated a
severalfold increase in sample processing throughput and
sensitivity, as well as in the LC-MS duty cycle.
Including the preceding yeast cultivation and sample prep-
aration steps, processing of 96 pull-down experiments can be
achieved within 48 h. However, several 96 samples could be
handled in parallel, allowing nesting upstream sample prepa-
ration and downstream LC-MS/MS analysis. This in principle
would allow a sustained workflow with a capacity of 96 dis-
tinct samples per day. The data presented here were acquired
following manual sample preparation. However, the majority
of sample preparation steps in our workflow only require liquid
handling and are thus easily automated using robotic sample
preparation systems.
LC-MS/MS data acquisition within 14 min per sample
pushes both the LC and MS systems to their current limits.
Consequently, the 14 min runs yielded reduced chromato-
graphic quality compared with the 27 min runs. Although this
was still sufficient to yield almost the same complex coverage,
the 14 min runs did result in lower sequence coverage for both
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bait and prey proteins (Fig 5B). This adversely affects analy-
ses and more importantly reduces the enrichment values,
making it harder to pinpoint interactors (Fig 2B). Potential
optimization could be obtained in an improved experimental
design. In this study, we focused on the reproducibility of the
complete workflow and chose to perform all steps and mea-
surements in a consecutive series of steps. However, random-
izing the measurements, while ensuring that all the replicates
of one particular pull-down are always run on the same col-
umn, should further improve higher data quality and statistical
significance for the interaction determination.
The implementation of double-barrel systems opens up
interesting possibilities. On the technological side, it enables
automatic detection of a break down in one of the columns
due to clogging and reacting to this by using the other col-
umn, instead of stopping further analysis. To detect this sit-
uation, the software tracks the amount of pressure during the
gradient and the flow rate achieved during loading. When the
pressure during the gradient or the flow rate during loading
exceed critical parameters the system automatically stops
operations on this particular column. Further operation is then
continued as a single-barrel system. This simple mechanism
has the potential to drastically extend the effective up-time
and enable almost 24/7 operation of the mass spectrometer.
A second technological possibility is the automatic determi-
nation of the optimal time for sample loading. The flow rate
achieved during loading of the previous sample on the par-
ticular analytical column can be used to estimate the required
loading time for the current sample. The software then auto-
matically determines the delay required before loading the
sample, for instance with a 10 min overhead to ensure that
the sample is completely loaded irrespective of fluctuations in
the flow rate. This is particularly important for double-barrel-
based LC setups as during long gradients it is conceivable
that it would be detrimental for the sample to be loaded at the
start of the gradient of the other analytical column and then
remain at the elevated temperature conditions of the analyti-
cal column heater. Third, the described setup could be further
extended by using two completely independent UHPLC sys-
tems. Even though such a concept is not straightforward to
implement on our current system due to software-related
issues, the extra redundancy of hardware components would
enable troubleshooting of an erroneous UHPLC while the
other system maintains measuring. In this way, genuine 24/7
operation of LC-MS/MS data acquisition would be feasible.
Recently, we have reported a high-performance affinity en-
richment-mass spectrometry method (21) that uses accurate
quantitation of background and unspecific binders for re-
trieval of true protein complexes. We propose to combine
both strategies to allow both the confident retrieval of binding
partners and a high throughput. This should be a powerful
strategy, especially when a high sequence coverage is not
essential (56). Moreover, our results also show that AP-MS
can be performed with protein input amounts as low as 500
g per pull-down and probably much lower in the future,
which is considerably less than previously described (21, 42).
This increase in sensitivity strongly promotes parallelization
and thus throughput efforts. Currently, our pipeline permits a
maximum throughput of 96 samples in about 1 day. Employ-
ment of other quantification strategies with higher multiplex-
ing, such as TMT labeling for instance, would drastically in-
crease throughput even further.
While we have demonstrated the workflow for protein–
protein interactions, our pipeline is generic and can be ex-
tended to any kind of protein-based interaction studies in
which there is an effective immobilization of the bait material
as affinity matrix. We envision other baits such as peptides,
DNA, RNA, lipids, or small molecules will greatly facilitate
large-scale screening and elucidate drug targets, changes in
protein complex formation upon perturbation, and the inter-
twined relationship between proteins and DNA or RNA.
Finally, the advances described here for the LC-MS/MS
part of the workflow can also be extended to the analysis of
whole proteomes. For example, biochemical fractionation of
whole cell lysates is a routine procedure in mass-spectrom-
etry-based proteomics as it enables much deeper character-
ization (57, 58). The concomitant increase in LC-MS/MS
measurement time caused by the larger number of fractions
could be mitigated by using our optimized LC-MS/MS setup.
Here, we demonstrated that our very short gradients of 15 min
are still able to identify about 700 proteins in a standard HeLa
digest (Fig. 1B). If such a complexity is not exceeded, high-
throughput analysis can be performed even for fractionated
whole proteomes of cell lines, small model organisms, or
clinical samples. Finally, given the exponential progress in
proteomics related technology, it should only be a matter of
time until entire proteomes can be measured in minutes.
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In a very fruitful collaboration project with Sebastian Pünzeler from the group of Dr.
Sandra Hake, we set out to identify interaction partners of human histone H2A vari-
ants. For many of the canonical core histone proteins including H2A, certain low abun-
dant variants exist. These variants show specific expression and chromatin localization,
modify the properties of the nucleosomes they are incorporated in, and affect transcrip-
tion. However, often little is known on how their distinct localization and function is
achieved. We hypothesized that the H2A variants attract different interactions partners
than the canonical histones.
Sebastian Pünzeler was specifically interested in three variants of histone H2A, called
H2A.Z.1, H2A.Z.2.1 and H2A.Z.2.2. He had already established cell lines expressing GFP-
tagged versions of canonical H2A and the three variants. To investigate the properties
of the variants in their ‘natural context’, he prepared nuclear extracts from these tagged
cells and digested the chromatin into mononucleosomes using micrococcal nuclease.
Together, we then implemented our MS-compatible immunoprecipitation protocol in
the laboratory of Dr. Sandra Hake, to enrich whole mononucleosomes containing either
canonical H2A or the three variants, and to identify their interaction partners by label-
free quantitative mass spectrometry.
We first performed such pulldowns in HeLa cells, where we could identify many of the
known general H2A interactors, but also intriguing new candidates specific for the vari-
ants. One particular interesting candidate is now further validated and investigated by
Sebastian Pünzeler (manuscript in preparation).
Contributing to a project of Dr. Chiara Vardabasso from the group of Prof. Emily
Bernstein, Sebastian Pünzeler and I then also performed pulldowns of H2A variants
in melanoma cells, which is the work presented in the following. The aim of Dr. Chiara
Vardabasso’s project was to elucidate the role of the variants H2A.Z.1 and H2A.Z.2 in the
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context of metastatic melanoma. Next to many other interesting findings in this publi-
cation, our interaction analysis identified several melanoma-specific H2A.Z interactors.
The most interesting of these interactors was Brd2, a protein known to interact with the
transcription factor E2F1, which in turn controls the expression of a number of genes
involved in cell cycle regulation. Our discovery of Brd2 as a specific H2A.Z interactor
in melanoma cells was validated using complementary approaches. Although Brd2 was
identified as an interactor of both H2A.Z.1 and H2A.Z.2 in our pulldown experiments,
only H2A.Z.2 knockdown reduced Brd2 levels in melanoma cells. Therefore, Brd2 was
proposed as crucial component of an H2A.Z.2-Brd2-E2F1 axis driving melanoma pro-
gression, and as a potential key target for melanoma therapy.
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SUMMARY
Histone variants are emerging as key regulatory mol-
ecules in cancer. We report a unique role for the
H2A.Z isoform H2A.Z.2 as a driver of malignant mel-
anoma. H2A.Z.2 is highly expressed in metastatic
melanoma, correlates with decreased patient sur-
vival, and is required for cellular proliferation. Our in-
tegrated genomic analyses reveal that H2A.Z.2 con-
trols the transcriptional output of E2F target genes
inmelanoma cells. These genes are highly expressed
and display a distinct signature of H2A.Z occupancy.
We identify BRD2 as an H2A.Z-interacting protein,
levels of which are also elevated in melanoma.
We further demonstrate that H2A.Z.2-regulated
genes are bound by BRD2 and E2F1 in an H2A.Z.2-
dependent manner. Importantly, H2A.Z.2 deficiency
sensitizes melanoma cells to chemotherapy and tar-
geted therapies. Collectively, our findings implicate
H2A.Z.2 as a mediator of cell proliferation and drug
sensitivity in malignant melanoma, holding transla-
tional potential for novel therapeutic strategies.
INTRODUCTION
Malignant melanoma is the most lethal form of skin cancer, has
an increasing incidence, and remains largely incurable. Whereas
advances in immune and targeted therapies have made tremen-
dous progress recently (Chapman et al., 2011; Kaufman et al.,
2013), they are effective only in distinct subsets of patients or
result in the emergence of drug resistance (Lito et al., 2013).
Thus, investigation of alternative approaches is essential.
Recent studies have shed light on the importance of
epigenetic regulation in melanoma biology. Key roles for BRD4
(Segura et al., 2013), histone methyltransferases SETDB1 (Ceol
et al., 2011) and EZH2 (Zingg et al., 2015), and the histone variant
macroH2A (Kapoor et al., 2010) have been reported. Relevant to
the present study, histone variants and their chaperones are
emerging as key regulatory molecules in cancer (Vardabasso
et al., 2013).
H2A.Z is a highly conserved H2A variant, with only 60% iden-
tity to canonical H2A, and is expressed and incorporated into
chromatin throughout the cell cycle (Bönisch and Hake, 2012).
Although somewhat confounded by species-specific functions
and context-dependencies, the role of H2A.Z in transcriptional
regulation is well established (Svotelis et al., 2009). H2A.Z is
enriched at gene promoters, as well as other regulatory regions,
generally exerting a positive role on transcription (Hu et al., 2013;
Obri et al., 2014).
Two distinct H2A.Z isoforms, H2A.Z.1 and H2A.Z.2, have
been identified in the vertebrate genome as products of two
non-allelic genes, H2AFZ and H2AFV, respectively (Dry-
hurst et al., 2009; Horikoshi et al., 2013; Matsuda et al., 2010).
While differing by only three amino acids at the protein level,
H2A.Z.1 and H2A.Z.2 are encoded by distinct nucleotide
sequences. Isoform-specific functions remain unclear, and
H2A.Z.1 mouse knockout studies suggest that the two genes
are non-redundant (Faast et al., 2001). In the context of tumori-
genesis, H2A.Z is overexpressed in breast, prostate, and
bladder cancers, where, in some cases, it regulates proliferation
(reviewed in Vardabasso et al., 2013). However, these studies
either focused solely on H2A.Z.1, or did not clearly distinguish
between isoforms.
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Here we report a distinct role for H2A.Z.2 in melanoma.
H2A.Z.2 is highly expressed in melanoma and drives pro-
liferation by promoting expression of E2F target genes. These
cell cycle regulatory genes are highly expressed and acquire
a unique signature of H2A.Z occupancy—high promoter
enrichment and gene body depletion. We further identified
the BET (bromodomain and extraterminal domain) protein
BRD2 as an H2A.Z interacting protein, whose levels are also
elevated in melanoma specimens. Depletion of H2A.Z.2 results
in reduced histone acetylation, BRD2 and E2F1 levels, and
impairs recruitment of BRD2 and E2F1 to its target genes.
Moreover, H2A.Z.2 deficiency cooperates with BET or MEK
inhibition to induce melanoma cell death. Hence, our studies
suggest that targeting H2A.Z deposition may be effective ther-
apeutically in combination with existing or emerging therapies
for melanoma.
RESULTS
H2A.Z Isoforms Are Overexpressed in Melanoma
By probing a panel of primary and metastatic melanoma cell
lines, we detected increased levels of H2A.Z protein in metasta-
tic cells (Figure 1A). Immunoblotting of histones extracted from
benign nevi and melanoma specimens revealed increased
H2A.Z in melanoma tissues (Figure 1B). We also investigated
H2A.Z levels in human primary melanocytes induced to senesce
via serial passaging (replicative senescence) and BRAFV600E
(oncogene-induced senescence) (Duarte et al., 2014). We
observed diminished H2A.Z upon both modes of senescence
(Figure S1A). Together, these data link global levels of H2A.Z
to cellular proliferation.
To assess whether H2A.Z expression is regulated tran-
scriptionally, as well as to examine the individual H2A.Z
isoforms (which is not possible with currently available anti-
bodies), we performed quantitative RT-PCR (qRT-PCR) using
isoform-specific primers. H2A.Z isoforms are decreased in
human melanocytes induced to senescence (Figure S1A).
Conversely, in a panel of benign nevi and melanoma speci-
mens, we observed increased H2A.Z.1 and H2A.Z.2 mRNA
in melanoma (Figure 1C). H2A.Z.1 and H2A.Z.2 mRNA levels
were also increased in cell lines derived from metastatic
versus primary melanoma (Figure S1B). Analysis of published
transcriptional data is consistent with these findings (Talantov
et al., 2005; Riker et al., 2008; Xu et al., 2008) (Figure S1C).
Finally, in a cohort of patients followed clinically for 3 years
after excision of metastatic lesions (Bogunovic et al., 2009),
patients with high H2A.Z.1 and H2A.Z.2 showed significantly
lower survival (Figure 1D). Collectively, these findings suggest
that H2A.Z isoforms have a functional role in melanoma
progression.
We next performed quantitative copy number analysis of
H2A.Z.1 and H2A.Z.2 in nevi and metastases by qPCR and de-
tected copy gains for both (Figure 1E). The Cancer GenomeAtlas
(TCGA) reports increased copy number in 13% and 52%of cuta-
neous melanomas for H2A.Z.1 and H2A.Z.2, respectively, which
correlates with increased mRNA levels (Figure S1D). Fluores-
cence in situ hybridization (FISH) of melanoma cell lines corrob-
orated these findings (Figure S1E).
H2A.Z.2 Depletion Induces G1/S Arrest in Melanoma
Cells
Next, we investigated the functional consequences of
depleting H2A.Z.1 and H2A.Z.2 in melanoma cell lines. Using
sequence-specific shRNAs for H2A.Z isoforms, we estab-
lished stable SK-mel147 (NRASQ61R), WM266-4 (BRAFV600D),
and 501mel (BRAFV600E) cell lines targeting either H2A.Z.1 or
H2A.Z.2. Knockdown was monitored by qRT-PCR and/or
immunoblot (Figures S2A–S2C). As H2A.Z.1 is the predomi-
nant isoform in melanoma (via RNA sequencing, below), its
knockdown can be appreciated at the protein level, whereas
H2A.Z.2 knockdown is obscured by H2A.Z.1 (Figures S2A
and S2B).
We observed that loss of H2A.Z.2, but not H2A.Z.1, reduced
proliferation in all cell lines (Figures 2A, 2B; Figure S2D). To
confirm these variant-specific effects, we generated cells sta-
bly expressing H2A.Z.1 or an shRNA-resistant H2A.Z.2 that
were infected with sh_Z.2 and a control (sh_scr). Only those
cells expressing an shRNA-resistant H2A.Z.2 were able to
overcome the proliferation defect induced by sh_Z.2 (Fig-
ure 2C). Interestingly, HeLa cells depleted of H2A.Z isoforms
did not show proliferation defects (Figure S2E). Thus, H2A.Z
isoforms exert distinct and non-redundant functions in mela-
noma cells.
H2A.Z.2 knockdown induced a G1/S cell cycle arrest
(Figures 2D, 2E, S2F, and S2G), accompanied by hypophos-
phorylation of Rb and decreased levels of cyclins E and A
(Figure 2F). This phenotype was not consistent with cellular
senescence because the expression of cyclin-dependent
kinase (CDK) inhibitors (Figure S2H) and b-galactosidase
activity (data not shown) were not increased. Moreover, we
observed minimal cell death (Figure S2I). Next, SK-mel147
cells were arrested at early S phase via double thymidine block
and subsequently released. Both control and H2A.Z.1 knock-
down cells progressed through S and G2/M phases, and at
10 hr, 30% of the cells re-entered G1. However, H2A.Z.2-
depleted cells remained largely arrested for the entire duration
of the assay (Figure 2G). These findings suggest that H2A.Z.2
loss causes delayed entry into S phase. These data are
strikingly similar to htz1 (H2A.Z) mutant budding yeast, which
shows delayed DNA replication and cell cycle progression
(Dhillon et al., 2006).
H2A.Z.2 Regulates E2F Target Genes
To further understand the observed proliferation defect, we char-
acterized the transcriptional profile of H2A.Z.2-deficient cells.
We used Affymetrix microarrays for SK-mel147 and WM266-4
cells depleted of either H2A.Z.1 or H2A.Z.2 (Figure 3A; Table
S1). Interestingly, the majority of genes were downregulated
(Figures 3A and 3B), with only 35 overlapping genes between
H2A.Z.1 andH2A.Z.2 knockdown in SK-mel147 cells (Figure 3B).
Similar expression data were observed for WM266-4 cells (Fig-
ures S3A and S3B; Table S1).
Consistent with the observed phenotype, functional annota-
tion revealed that H2A.Z.2-regulated genes are enriched for
cell cycle regulators (Figures 3C, 3D and S3C). This is in contrast
to H2A.Z.1-regulated genes, which are enriched for immunolog-
ical pathways (Figure S3D). This is in line with the lack of cell
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Figure 1. H2A.Z.1 and H2A.Z.2 Are Overexpressed in Melanoma
(A) Chromatin extracted from primary and metastatic cell lines probed with H2A.Z antibody; H3 used for loading. Signals quantified by densitometry. See also
Figure S1B for mRNA expression.
(B) H2A.Z immunoblot of acid extracted histones from fresh-frozen human benign nevi andmelanoma specimens; H3 used for loading. Signals quantified as in (A).
(C) Expression analysis by qRT-PCR of H2A.Z.1 and H2A.Z.2 in benign nevi (n = 20) and melanoma (n = 38). Values normalized to GAPDH; mean ± SEM.
Mann-Whitney test (two-tailed).
(D) Survival of melanoma patients with high and low (above or below the median, respectively) mRNA levels ofH2A.Z.1 and H2A.Z.2. Gene expression data of 44
metastatic melanoma tissues (Bogunovic et al., 2009) were used to define high and low expressor groups (boxplots, Mann-Whitney test) and to generate
Kaplan-Meier curves (log-rank test).
(E) Analysis ofH2A.Z.1 andH2A.Z.2 gene copy number by qPCR of a subset of benign nevi andmelanoma in (C), relative to primarymelanocytes. Data aremean ±
SEM; unpaired Student’s test (two-tailed).
See also Figures S1D and S1E.
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cycle defects observed upon H2A.Z.1 knockdown and impli-
cates a distinct role for H2A.Z.1 in melanoma.
Gene set enrichment analysis (GSEA) and transcription
factor (TF) analysis further demonstrated that the H2A.Z.2-regu-
lated genes are associated with transcriptional hallmarks of
advanced melanoma and are targets of the E2F family,
including E2F1 and E2F4 (Figures 3E, 3F, and S3E). Further-
more, qRT-PCR analysis revealed that E2F target gene
expression correlates with H2A.Z.2 levels in human melanoma
(Figure 3G). Given that E2F1 and E2F4 promote melanoma pro-
gression and metastasis (Alla et al., 2010; Ma et al., 2008), these
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Figure 2. H2A.Z.2 Depletion Induces G1/S
Arrest in Melanoma Cells
(A) Proliferation curves of SK-mel147 and WM266-4
cells expressing control and isoform-specific
shRNAs as shown. Data are mean ± SEM (n R 3);
two-way ANOVA. See also Figure S2D.
(B) Colony formation assays of SK-mel147 and
WM266-4 cells expressing shRNAs as in (A).
(C) Proliferation assay of SK-mel147 cells express-
ing H2A.Z.1, shRNA-resistant H2A.Z.2, or empty
vector control. Each line was infected with H2A.Z.2
shRNA (sh_37) and with sh_scr. Data are mean ±
SEM (n = 2); two-way ANOVA.
(D) BrdU staining of SK-mel147 cells expressing
shRNAs as in (A). Profiles from one representative
experiment are displayed. BrdU-positive S phase
cells are shown as mean values ± SD (n R 3) (right);
unpaired Student’s test (two-tailed). See also Fig-
ure S2G.
(E) Percentage of SK-mel147 in G1, S, or G2/M
phases, as revealed by PI incorporation. Values are
mean ± SD (n R 3); unpaired Student’s test (two-
tailed). Asterisks as follows, in all figures: *p < 0.05,
**p < 0.01, ***p < 0.001. See also Figure S2F.
(F) Whole-cell extracts from shRNA-expressing SK-
mel147 cells were immunoblotted for unmodified
and phosphorylated Rb and cyclins. B-actin used as
loading control.
(G) shRNA-expressing SK-mel147 cells were syn-
chronized at early S phase by a double thymidine
block and cell synchrony monitored by flow cy-
tometry of PI stained cells at 5-hr intervals. Flow
cytometry profiles from a representative experiment
are shown.
results implicate concerted H2A.Z.2-E2F
function in melanoma progression.
H2A.Z.2-Regulated Genes Show a
Unique Signature of H2A.Z
Occupancy
We next performed native chromatin
immunoprecipitation followed by high-
throughput sequencing (ChIP-seq) of
H2A.Z to determine its genomic occupancy
in melanoma cells (Figure 4). ChIP-seq of
SK-mel147 cells stably expressingN-termi-
nally eGFP-tagged H2A.Z.1 or H2A.Z.2
(along with eGFP-H2A as a control) was
also carried out (Figure S4A), and exhibited highly overlapping
genome-wide occupancy patterns with endogenous H2A.Z (Fig-
uresS4BandS4C) aswell aswith eachother (Figure S4D). There-
fore, we used endogenous H2A.Z ChIP-seq for further analyses.
Among H2A.Z-bound sites, 14% lie within promoters and
29% in gene bodies (Figure 4A). By integrating RNA seq-
uencing and ChIP analyses from SK-mel147 cells, we found
that H2A.Z promoter levels positively correlate with expression
(Figure 4B), as previously reported (Barski et al., 2007; Hu
et al., 2013). Intriguingly, gene body occupancy shows a
striking negative correlation with gene expression (Figure 4B).
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Figure 3. H2A.Z.2 Regulates Cell Cycle-Promoting Genes
(A) Gene expression profiles of SK-mel147 cells upon H2A.Z.1 and H2A.Z.2 knockdown (day 8 post-infection). Two biological replicates (with Pearson
correlation), and genes displaying a significant (lfdr < 0.2) change in each replicate are shown.
(B) Venn diagrams exhibiting the numbers of genes that are significantly up- and downregulated upon H2A.Z.1 and H2A.Z.2 knockdown in SK-mel147 cells. See
also Figures S3A and S3B.
(C) Functional annotation (biological process) of genes downregulated upon H2A.Z.2 knockdown in SK-mel147 cells. Enriched groups are ranked by the most
significant p value.
(D) Functional annotation (molecular pathways) of genes as described in (C). Selected genes belonging to each pathway are shown; p value indicated.
(E) GSEA plots of genes altered upon H2A.Z.2 knockdown in SK-mel147 display negative correlation gene signatures as shown. FDR = 0.0; NES (normalized
enrichment score) as indicated.
(F) TF regulation analysis of genes as described in (C). Enriched groups are ranked by the most significant p value. Analyses for (C), (D), and (F) were performed
with MetaCore. See also Figures S3C–S3E.
(G) Heatmap generated by qRT-PCR values of the indicated genes in a subset of melanoma specimens (P1-P10) from Figure 1C. P1-P5 = high H2A.Z.2 and
P6-P10 = lowH2A.Z.2 expression levels (above and below themedian, respectively). Expression levels of each gene are shown as fold change (FC) relative to one
patient (not shown).
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Figure 4. A Unique Signature of H2A.Z Occupancy at H2A.Z.2-Regulated Genes
(A) Pie chart displaying the percentages of H2A.Z peaks occupying promoters, gene bodies and distal regions. Promoters: 3 kb < TSS < +1 kb; gene bodies:
from +1 kb > TSS to TES; all other regions defined as distal. TSS, transcription start site; TES, transcription end site.
(B) Correlation of H2A.Z signals at the promoter or gene body with mRNA expression levels. Genes were divided by expression level into high (top 25%), medium
(middle 50%), and low (bottom 25%) from RNA sequencing data. Fold enrichment profiles (sliding 100 bp window) and boxplots were calculated around the TSS
(3 kb, +3 kb) and over the gene body (TSS to TES) for each group; Mann-Whitney test (two-tailed).
(legend continued on next page)
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Finally, in line with previous reports (Barski et al., 2007; Hu
et al., 2013; Obri et al., 2014), our results show that half
of the H2A.Z-bound sites lie within intergenic regions
(Figure 4A).
Next, we integrated H2A.Z ChIP-seq with H2A.Z.2 downre-
gulated genes. Taking into account both promoter and gene
body occupancy, we defined four classes of genes: H2A.Z-
bound and H2A.Z.2 downregulated (Class I), H2A.Z-bound
but not H2A.Z.2 downregulated (Class II), H2A.Z.2 downre-
gulated but not H2A.Z-bound (Class III), and neither down-
regulated nor bound (Class IV) (Figure 4C; Table S2). Gene
ontology analyses revealed that Class I is enriched for cell cycle
genes, while Class II is enriched for metabolic processes
(Figure S4E). Accordingly, ChIP Enrichment Analysis (ChEA2)
(Kou et al., 2013) uncovered distinct TF binding profiles for
each Class, with only Class I showing enrichment for E2Fs (Fig-
ure 4D). By examining H2A.Z distribution, we found that Class I
genes were significantly enriched at the promoter and depleted
within the gene body (Figures 4E and 4F). Conversely, many
Class II genes lie within broader H2A.Z domains (Figure 4F).
Expression of Class I genes is significantly higher than Class
II genes in melanoma (Figure 4G), consistent with our findings
in Figure 4B.
H2A.Z ChIP-seq in normal human melanocytes revealed that
the Class I signature is not detectable because H2A.Z is not
depleted in the gene body (Figure 4H). Consistent with this, Class
I genes are expressed at significant lower levels in melanocytes
than melanoma cells, whereas expression of all other classes
remains largely unchanged (Figure 4G).
Collectively, our analyses revealed that H2A.Z.2 regu-
lated/H2A.Z bound genes (Class I) have unique features in
melanoma cells. They are E2F targets, highly expressed, and
enriched for H2A.Z at the promoter and depleted in the gene
body. These features do not apply to H2A.Z.1-downregulated
genes (Figures S4F and S4G; Table S3), suggesting a unique
chromatin signature at genes that regulate melanoma cell
proliferation.
BRD2 Interacts with H2A.Z-Containing Nucleosomes
and Is Overexpressed in Melanoma
To further decipher H2A.Z function, we investigated the factors
that interact with H2A.Z-containing nucleosomes in melanoma
cells. To this aim, we used unbiased label-free quantitative
mass spectrometry (MS) (Eberl et al., 2013). Chromatin isolated
from SK-mel147 cells stably expressing eGFP, eGFP-H2A,
eGFP-H2A.Z.1, or eGFP-H2A.Z.2 was digested to mononu-
cleosomes (Figure S5A), immunoprecipitated (Figure S5B),
and analyzed with liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). We found significant enrichment of
45 H2A.Z interactors as compared to H2A-containing nucleo-
somes (Figures 5A and S5C). The majority of these proteins
were found in both H2A.Z variant IPs, including members
of the H2A.Z histone chaperone complex, SRCAP (Billon and
Côté, 2013).
We identified BRD2 to be enriched in H2A.Z.1- and
H2A.Z.2-containing nucleosomes (Figures 5A and 5B). BET
proteins (BRD2, BRD3, BRD4, and BRDT) bind to acetylated
lysine residues in histones (LeRoy et al., 2008, 2012) and
function as scaffolds to recruit chromatin modifying enzymes
and TFs, thereby coupling histone acetylation to transcrip-
tion (reviewed in Belkina and Denis, 2012). Whereas BRD2
and BRD4 are both overexpressed in melanoma (Segura
et al., 2013), only BRD2 specifically interacts with H2A.Z-con-
taining nucleosomes (Figure 5A and data not shown). We next
tested whether hyperacetylation of histones would enhance
the interaction between BRD2 and H2A.Z isoforms in mela-
noma cells. Treatment with the HDAC inhibitor trichostatin A
(TSA) resulted in increased histone H4 and H2A.Z acetylation
and increased BRD2 chromatin association (Figure 5C).
Furthermore, the BRD2-H2A.Z interaction was enhanced (Fig-
ure 5C). By probing primary and metastatic melanoma cell
lines (as in Figure 1A), we observed hyperacetylation of H4
and H2A.Z, and high levels of BRD2 in metastatic cells (Fig-
ure 5D). Collectively, these results are consistent with the
fact that BRD2 is recruited to chromatin by a combination of
acetylated H4 (H4ac) and H2A.Z (Draker et al., 2012).
Through immunohistochemistry (IHC) of BRD2 in a cohort of
patient samples including benign nevi, thick primary melanoma,
and metastatic melanoma, we detected a significant increase of
BRD2 in primary and metastatic melanoma specimens as
compared to dermal melanocytes of nevi (Figure 5E). Next, we
investigated BRD2 knockdown in multiple melanoma cell lines
and observed proliferation defects via G1/S arrest (Figures 5F,
5G, and S5D–S5F). BRD2 knockdown altered gene expression
of selected E2F targets (Figures 5H and S5G). Collectively,
BRD2 knockdown recapitulated the phenotype observed upon
H2A.Z.2 loss, suggesting that H2A.Z.2 and BRD2 work together
to promote Class I transcription.
(C) Venn diagrams displaying H2A.Z.2 downregulated genes and H2A.Z bound genes by ChIP-seq in SK-mel147. Class I (downregulated in H2A.Z.2 knockdown
and bound by H2A.Z, red); Class II (bound by H2A.Z but unaffected by H2A.Z.2 knockdown, light blue); Class III (downregulated by H2A.Z.2 knockdown but not
bound by H2A.Z, purple); Class IV (11,003 genes that are not downregulated by H2A.Z.2 knockdown and not bound, gray).
(D) ChIP enrichment analysis tool (ChEA2) analysis of Class I, Class II, and Class III genes (as defined and color coded in A). The ChEA2 database contains
ChIP-seq data of 200 transcription factors from 221 publications for a total of 458,471 TF-target interactions (Kou et al., 2013). Transcription factors are ranked by
ChEA combined score.
(E) H2A.Z occupancy at the promoter and gene body of the four classes of genes defined in (C), in SK-mel147 cells. Profiles and boxplots represent fold
enrichment over input. Mann-Whitney test (two-tailed).
(F) Captures of the UCSC genome browser (GRCh37/hg19) showing the ChIP-seq profiles for H2A.Z for genes belonging to each of the classes defined in (C).
RefSeq annotated genes are displayed on top.
(G) Boxplot representing expression levels (FPKM) for each gene class as in (C), in primary melanocytes and in SK-mel147. Mann-Whitney test (two-tailed).
Two-way ANOVA.
(H) H2A.Z occupancy at the promoter and gene body of the four classes of genes defined in (C) in primary melanocytes.
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Figure 5. BRD2 Interacts with H2A.Z-Containing Nucleosomes and Is Overexpressed in Melanoma
(A) Volcano plots of label-free interactions of eGFP-H2A.Z.1- or eGFP-H2A.Z.2-containing nucleosomes. Significantly enriched proteins over eGFP-H2A
containing nucleosomes are shown in the upper right box (gray shading). Members of the H2A.Z-specific chaperone/remodeling complex SRCAP are highlighted
in blue, H2A.Z in green, BRD2 and BRD4 as red and orange dots, respectively. See also Figures S5A–S5C.
(legend continued on next page)
82 Molecular Cell 59, 75–88, July 2, 2015 ª2015 Elsevier Inc.
83
2 Results
An H2A.Z.2-BRD2-E2F1 Axis in Melanoma
To test this hypothesis, we performed ChIP-seq of BRD2 in
SK-mel147 cells, and found a similar genomic distribution as
H2A.Z (Figures 4A and S6A). We next determined the extent
of co-localization of BRD2 and H2A.Z genome-wide and found
that BRD2 peaks overlap with H2A.Z largely at promoters
(Figure 6A). Promoters of Classes I and II genes are bound
by BRD2 (Figures 6B and S6B), consistent with the fact that
BRD2 interacts with both H2A.Z isoforms. However, H2A.Z
and BRD2 have the highest enrichment at Class I genes (Fig-
ures 4E and 6C).
Because our in silico analyses predicted that Class I genes
are E2F targets (Figure 4D), and BRD2 interacts with E2F1
to mediate its recruitment to chromatin (Denis et al., 2006;
Sinha et al., 2005), we next queried whether Class I genes
are bound by E2F1. ChIP-seq of E2F1 in SK-mel147 cells
showed this was indeed the case (Figures 6B, 6C, and S6B).
Taken together, these data suggest that H2A.Z.2 works coop-
eratively with BRD2 and E2F1 (Figure 6D) to promote high
levels of transcription at Class I genes in melanoma. Next, we
probed a panel of benign nevi and melanoma tissues for
H2A.Z, BRD2, E2F1, and H4ac, and found evidence of the
H2A.Z-BRD2-E2F axis in melanoma specimens (Figure 6E).
This reinforces the relevance of our findings for melanoma
disease.
H2A.Z.2 Depletion Impairs BRD2 and E2F1 Function
The findings above prompted us to investigate BRD2 and E2F1
levels upon H2A.Z silencing. We observed marked reduction
of BRD2 and E2F1 levels upon H2A.Z.2, but not H2A.Z.1,
knockdown across melanoma cell lines (Figures 6F and S6C).
BET family members are not transcriptionally regulated by
H2A.Z.2 (Figure S6D), suggesting that H2A.Z.2 stabilizes these
factors. This was paralleled by a dramatic loss of H4 and H3
acetylation (Figures 6F, S6C, and S6E). These data suggest
that BRD2 and E2F1 chromatin recruitment to Class I genes,
mediated by histone acetylation, is impaired in H2A.Z.2-deficient
cells. Thus, we performed ChIP-qPCR for BRD2 and E2F1 in
either control or H2A.Z isoform-depleted cells, and found that
BRD2 and E2F1 recruitment to Class I promoters is dependent
on H2A.Z.2 (Figure 6G). Overall, H2A.Z.2 deficiency results in
dramatic alterations of chromatin structure, thereby clearly dis-
tinguishing it from H2A.Z.1. Overall, our ChIP studies demon-
strate that H2A.Z.2, BRD2, and E2F1 work cooperatively to
promote high levels of transcription at cell cycle-promoting
genes in melanoma.
H2A.Z.2 Deficiency Sensitizes Melanoma Cells to
Therapy
Because we observed loss of histone acetylation upon H2A.Z.2
knockdown, we queried whether H2A.Z.2 depletion might
potentiate the effects of BET inhibitors (BETi). BETi prevent the
acetyl-lysine binding of bromodomains with high affinity and
are effective agents in a number of tumors (Dawson et al.,
2012; Segura et al., 2013). We first assessed the sensitivity of
melanoma cells to JQ1 (Filippakopoulos et al., 2010) (Figure 7A)
and found a dose-dependent growth inhibitory effect in the
majority of cell lines tested (Figures S7A–S7C). Cells treated
with JQ1 for 4 days accumulated in G2/M (Figure S7B), with
minor induction of apoptosis (data not shown).
Next, we investigated whether H2A.Z.2 knockdown coop-
erates with JQ1 to enhance the antiproliferative effect of mela-
noma cells. Whereas JQ1 treatment or H2A.Z.2 knockdown
alone induced growth arrest (Figures S7B and 2D–2G), the
combination resulted in cell death in both BRAF and NRAS
mutant lines (Figures 7B and S7D). Functional annotation of
the SK-mel147 transcriptome upon JQ1 treatment (Table S4) re-
vealed enrichment in developmental processes, distinguishing
it from cell cycle annotation associated with H2A.Z.2 silencing
(see Figures 3C and S7E). Consistent with this synergy, we
observed that the transcriptional profiles of H2A.Z.2 knockdown
and BETi show minimal overlap (Figure 7C; Table S4), suggest-
ing that whereas H2A.Z.2-regulated genes are BRD2 and
E2F1 targets, the mode of action of JQ1 is largely distinct
from H2A.Z.2. Although H2A.Z and BRD2 are enriched on pro-
moters of JQ1 regulated genes (however, significantly less so
than on H2A.Z.2-regulated genes), E2F1 binding is absent (Fig-
ure 7D). JQ1 regulated genes are instead targets of distinct TFs
(Figure S7F).
H2A.Z.2 loss not only enhances sensitivity of melanoma cells
to BETi, but also to chemotherapy and targeted therapies
(MEKi) used clinically for melanoma (Figure 7E). Collectively,
these data suggest that H2A.Z.2 is a critical mediator of mela-
noma drug sensitivity and regulating its deposition may serve
as an important target for novel therapeutic strategies.
DISCUSSION
H2A.Z.2 Is a Driver of Malignant Melanoma
While histone variants and their chaperones have emerged as
critical players in cancer biology (Vardabasso et al., 2013), our
mechanistic understanding remains limited. Here, we report a
unique role for H2A.Z.2 in driving melanoma cell proliferation
(B) Immunoblots for BRD2 and GFP upon immunoprecipitation of mononucleosomes generated from SK-mel147 cells expressing eGFP, eGFP-H2A, -H2A.Z.1,
or -H2A.Z.2.
(C) SK-mel147 cells as in (B) were treated with DMSO or TSA (200 nM for 2 hr), and chromatin was probed for BRD2, H4ac, and H2A.Zac (top). Histones used for
loading. Bottom: Immunoblots for BRD2 and GFP upon immunoprecipitation are shown.
(D) Chromatin extracted from primary and metastatic cell lines probed with BRD2, H2A.Zac, and H4ac antibodies; H3 used for loading. See also Figure 1A.
(E) IHC for BRD2 in representative intradermal nevi, thick primary, and metastatic melanoma tissue. Images at 203 magnification; insets at 403 magnification.
Scale bar represents 100 mm. Scores derived by multiplying the number of positively stained cells (1–4) by intensity of stain (1–3); Mann-Whitney (two-tailed).
(F) Colony formation and proliferation assays of SK-mel147 cells expressing control or BRD2 shRNAs as shown. Data are mean ± SEM (nR 2); two-way ANOVA.
(G) Percentage of SK-mel147 cells in G1, S, or G2 phases, as shown by PI incorporation. Values are mean ± SD (n R 3); unpaired Student’s test (two-tailed).
(H) Expression of a handful of Class I genes was analyzed by qRT-PCR upon BRD2 knockdown. Expression is shown normalized to GAPDH and relative to
scrambled shRNA. Mean ± SD is shown (n R 3).
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Figure 6. An H2A.Z.2-BRD2-E2F1 Axis in Melanoma
(A) Histograms of the ratio between BRD2 peaks bound by H2A.Z and BRD2 peaks not bound by H2A.Z at promoters, gene bodies, and distal regions as defined
in Figure 4A.
(B) Heatmaps of promoters (3 kb, +3 kb) of Class I and Class II genes based on H2A.Z, BRD2, and E2F1 fold enrichment over input, and ranked by expression
level. Expression is indicated as log2 RNA-seq signal. See also Figure S6B.
(C) BRD2 and E2F1 occupancy at the promoter Class I and Class II genes in SK-mel147 cells. Profiles and boxplots represent fold enrichment over input.
Mann-Whitney test (two-tailed).
(D) UCSC genome browser (GRCh37/hg19) capture of 30 kb region of human chromosome 15 depicting a Class I gene. Read counts (normalized fold
enrichment of ChIP over input DNA) for BRD2, E2F1, and H2A.Z and FPKM for RNA-seq are shown. RefSeq annotated genes are displayed above.
(E) Whole-cell extracts from fresh-frozen benign nevi andmetastatic specimens probed with BRD2, E2F1, H2A.Z, and H4ac antibodies; GAPDH used for loading.
(F) Whole-cell extracts from control and isoform-depleted SK-mel147 andWM266-4 cells were immunoblotted for BRD2, E2F1, H3ac, and H4ac. GAPDH served
as loading control. See also Figures S6C and S6E.
(G) ChIP-qPCR for BRD2 (left) and E2F1 (right) at Class I genes in SK-mel147 expressing control or isoform-specific shRNAs as indicated. Fold enrichment ChIP/
input is plotted relative to scrambled shRNA. One representative experiment shown; values are mean ± SD (n R 2).
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Figure 7. H2A.Z.2 Deficiency Sensitizes Melanoma Cells to Chemotherapy and Targeted Therapies
(A) Chromatin and whole-cell extracts from SK-mel147 cells exposed to DMSO or 0.5–2 mM of JQ1 for 2 days were immunoblotted for BRD2, BRD4, Myc, and
H4ac. Amido black staining of histones for loading.
(B) SK-mel147 cells were infected with shRNAs as shown and subsequently treated with JQ1 as indicated for 4 days. Percentage of Annexin V positive cells
shown. Values are mean ± SD (n R 3); unpaired Student’s test (two-tailed).
(C) Venn diagram of genes downregulated in SK-mel147 upon H2A.Z.2 knockdown (red) or JQ1 treatment (1 mM for 6 hr; cutoff of FC R 2), (orange).
(D) H2A.Z, BRD2, and E2F1 occupancy at the promoter of H2A.Z.2 downregulated (red) or JQ1 downregulated genes (orange). Profiles and boxplots represent
fold enrichment over input. Mann-Whitney test (two-tailed).
(E) SK-mel147 cells were infected as in (B) and treated with doxorubicin as indicated (Dox, left) and MEK inhibitor PD325901 (MEKi, right). Percentage of sub-G1
cells upon 2 days of treatment shown. Values are mean ± SD (n R 3); unpaired Student’s test (two-tailed).
(F) Amodel for the H2A.Z.2-dependent regulation of cell cycle gene transcription in melanoma. Depletion of H2A.Z.2 results in reduced histone acetylation, BRD2
and E2F1 levels, impairs recruitment of BRD2 and E2F1 to its target genes, and inducesG1/S arrest. Combining depletion of H2A.Z.2 losswith targeted therapy or
chemotherapy leads to cell death.
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and drug sensitivity. Our study suggests a melanoma-specific
role for H2A.Z.2 in promoting proliferation, and it will be of inter-
est to learn if H2A.Z.2 plays a similar role in other tumors. Impor-
tantly, we do not exclude a role for H2A.Z.1 in melanoma
because it is also upregulated and correlates with shorter patient
survival.
Because H2A.Z isoforms have distinct roles in melanoma, we
hypothesized they may have unique interaction partners and
genomic occupancy. Our studies indicate that H2A.Z.1 and
H2A.Z.2 share genomic occupancy patterns and interact with
similar histone chaperone complexes. However, it is clear that
H2A.Z.2 is critical for promoting cell cycle progression in mela-
noma, and acts distinctly from H2A.Z.1. Our data strongly sug-
gest that a unique property of H2A.Z.2 is to promote and/or
maintain BRD2, E2F1, and histone acetylation levels. While the
exact mechanism remains unclear, H2A.Z.2 likely acts together
with histone acetylation to recruit co-activators and TFs, such
as BRD2 and E2F1, respectively, to promote expression of cell
cycle regulators (see below).
A Unique Signature of H2A.Z Occupancy at E2F Target
Genes
Our analyses revealed that H2A.Z.2 promotes the expression of
E2F target genes. In melanoma cells, these genes are character-
ized by a unique signature of H2A.Z occupancy—highly enriched
at the TSS and depleted within the gene body—and this pattern
associates with high gene expression levels. Our findings are in
line with previous observations in plants and yeast (Coleman-
Derr and Zilberman, 2012; Sadeghi et al., 2011; Zilberman
et al., 2008); for example, H2A.Z is excluded from the bodies
of actively transcribed genes in Arabidopsis (Coleman-Derr
and Zilberman, 2012; Zilberman et al., 2008). Intriguingly, the
DREAM complex was recently reported to promote H2A.Z
gene body incorporation to repress cell cycle progression
genes inC. elegans (Latorre et al., 2015). Together, these studies
suggest that H2A.Z is differentially distributed across promoters
and gene bodies at distinct subsets of genes to regulate their
expression levels.
An H2A.Z.2-BRD2-E2F1 Axis in Melanoma
Our study has identified BRD2 as an H2A.Z-interacting protein in
malignant melanoma. Work by Denis and colleagues initially
demonstrated that BRD2 has oncogenic potential: BRD2 trans-
forms mouse fibroblasts in the context of oncogenic Ras (Denis
et al., 2000), and Em-BRD2 transgenic mice develop B cell lym-
phoma and leukemia (Greenwald et al., 2004). In fact, BRD2
has a crucial role in cell cycle control, and by interaction with
E2F1, it regulates the expression of cyclins and other cell cycle
regulatory genes (Denis et al., 2000, 2006; Sinha et al., 2005).
Our loss-of-function approach revealed that the chromatin as-
sociation and total levels of BRD2, E2F1, and histone acetylation
are H2A.Z.2 dependent. This is in line with the fact that BRD2’s
preference for H2A.Z-containing nucleosomes is mediated by
a combination of hyperacetylated H4, and features on H2A.Z
itself (Draker et al., 2012), and that histone acetyltransferase
(HAT) activity is contained within BRD2 nuclear complexes (Si-
nha et al., 2005). Furthermore, we find evidence of an H2A.Z-
BRD2-E2F axis in melanoma tissues. Accordingly, our ChIP
analyses show that BRD2 and E2F1 are enriched at promoters
of Class I genes and that H2A.Z.2 is required for recruitment of
these factors to these E2F targets. Interestingly, Draker et al.
found that recruitment of BRD2 to androgen receptor (AR)-regu-
lated genes in prostate cancer cells is dependent on H2A.Z.1.
Thus, BRD2may associate with distinct TFs and H2A.Z isoforms
to achieve oncogenic gene transcription in different tumor types.
Collectively, we envision that H2A.Z.2 recruits BRD2 and
E2Fs, along with HAT activity, to E2F target genes in melanoma
cells. This in turn results in increased expression of cell cycle
genes, and ultimately promotes proliferation (Figure 7F). Our
findings implicate the H2A.Z.2-BRD2-E2F1 axis as a driver of
melanoma progression. Of these molecules, BRD2 represents
a key target for therapy.
Novel Epigenetic Therapeutic Strategies to Treat
Melanoma
Metastatic melanoma is notoriously refractory to conventional
cancer therapies and remains largely resistant to current tar-
geted therapies (Lito et al., 2013). Here we show that in combina-
tionwith BET inhibition, H2A.Z.2 depletion is effective in inducing
cell death. Because a tool to disrupt H2A.Z deposition is
currently lacking, it is plausible that combining BETi with a potent
inhibitor of HAT activity will potentiate melanoma cell death (Fig-
ure 7F). This combination may not only evict BET proteins from
chromatin, but cause additional destabilization of BET proteins
and their associated TFs due to loss of acetylation (Figure 7F).
It will be of interest to create BRD-specific inhibitors, if achiev-
able, because our study suggests that BRDs function distinctly
in disease. Finally, our findings implicate H2A.Z.2 as a mediator
of cell proliferation and drug sensitivity in malignant melanoma.
Because histone modification and deposition are reversible
processes, our study holds therapeutic potential for this highly
intractable neoplasm.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Infections
Primary (WM115, WM1789, WM39), metastatic (SK-mel147, WM266-4,
501mel, A375, SK-mel2, SK-mel28, SK-mel239, SK-mel5, M14, WM165-1)
melanoma cell lines, HeLa cells, and human melanocytes were cultured as
described in the Supplemental Experimental Procedures. Lentiviral vectors
and shRNAs used for the generation of stable cell lines are described in the
Supplemental Experimental Procedures. Infections were performed according
to standard procedures (Kapoor et al., 2010).
Chromatin Fractionation, Acid Extraction of Histones, and
Immunoblotting
Chromatin fractionation and acid extraction of histones were performed as
described (Kapoor et al., 2010) and in the Supplemental Experimental Proce-
dures. Antibodies used in this study are listed in the Supplemental Experi-
mental Procedures.
Clinical Specimens
Approval to collect melanoma specimens was granted by Mount Sinai Bio-
repository Cooperative and the New York University Interdisciplinary Mela-
noma Cooperative Group (project number HSD08-00565 and IRB number
10362, respectively). Approval to collect benign nevi was granted by ISMMS
(Icahn School of Medicine at Mount Sinai) Division of Dermatopathology
(project number 08-0964).
86 Molecular Cell 59, 75–88, July 2, 2015 ª2015 Elsevier Inc.
87
2 Results
RNA Extraction, qRT-PCR, and Microarray Hybridization
For RNA extraction, qRT-PCR, and primers, see the Supplemental Experi-
mental Procedures. RNA amplification, labeling, and hybridization to Human
Gene 1.0 ST Arrays (Affymetrix) were performed as described previously (Wie-
demann et al., 2010), and data processed in R/bioconductor (http://www.
bioconductor.org). For data analysis, see the Supplemental Experimental
Procedures.
Cell Proliferation, Colony Formation, and Flow Cytometry
For proliferation curves, cells were counted up to 7 days and normalized to cell
counts at day 1. Colony formation assay was performed by seeding cells at low
density and allowing growth for 2 weeks. Cells were washed with phosphate
buffered saline, fixed in 10% methanol/acetic acid solution, and stained with
1% crystal violet. Flow cytometry experiments were performed as described
in the Supplemental Experimental Procedures.
Native and Crosslinked ChIP and Next-Generation Sequencing
Chromatin from SK-mel147 cells was digested with micrococcal nuclease
(MNase) and used for ChIP with H2A.Z (Abcam ab4174) and GFP Trap Beads
(Chromotek), essentially as described (Hasson et al., 2013). SK-mel147 cells
stably expressing control or isoform-specific shRNAs were crosslinked for
10 min with 1% formaldehyde and immunoprecipitated with BRD2 and
E2F1 antibodies (Bethyl Laboratories A302-583A and Santa Cruz sc-193,
respectively) as described in the Supplemental Experimental Procedures.
Sequencing libraries were generated and barcoded for multiplexing as
described (Hasson et al., 2013) and libraries were submitted for 100-bp,
single-end Illumina sequencing on a HiSeq 2500. For data processing and
analysis, see the Supplemental Experimental Procedures.
RNA Sequencing
Total RNA samples were isolated from human melanocytes and enantiomer-
or JQ1-treated SK-mel147 using miRNeasy mini kit (QIAGEN) following man-
ufacturer’s protocol. Sequencing libraries were prepared and data analysis
performed as described in the Supplemental Experimental Procedures.
Mononucleosome Immunoprecipitation
Mononucleosomes were generated according to (Sansoni et al., 2014) and
described in the Supplemental Experimental Procedures.
LC-MS/MS Analysis and MS Data Analysis
See the Supplemental Experimental Procedures for details.
Statistical Methodologies
Statistical tests were applied as indicated in figure legends. Asterisks are as
follows: *p < 0.05; **p < 0.01; ***p < 0.001. Boxplots represent Tukey boxplots
with outliers omitted.
ACCESSION NUMBERS
The accession number for all microarray, RNA-seq, and ChIP-seq data sets
reported in this paper is NCBI GEO: GSE59060.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.molcel.2015.05.009.
AUTHOR CONTRIBUTIONS
C.V. andE.B. conceived this studywith guidance fromS.B.H.C.V. performedall
qPCR and shRNA studies and generated eGFP melanoma cell lines. C.V. and
T.P. performed immunoblots and cell cycle analyses. S.B.H. and T. Straub per-
formed and analyzed microarrays, respectively. C.V., D.H., and S.P. performed
ChIP-seq experiments, and data analyses were led by C.V., A.G.-M., D.V.-G.,
D.H., and T. Straub. S.P. performed IPs for MS, and E.C.K. performed MS
with the support of M.M. S.P. analyzed MS results under the guidance of
E.C.K.C.V. andT. Strubperformeddrug treatments, andS.P.,C.V., andT. Strub
performed BRD2 immunoblots. J.D. performed BRD2 IHC, and J.L.Y. and R.S.
scored tissues. C.-Y.C. assistedwith network analyses, and A.V. provided copy
numberanalysis support.M.F.S., B.F.-C., andE.H.providedassistancewithpa-
tient data and with BETi experiments. B.F.-C. prepared samples for RNA-seq,
and D.H. analyzed RNA-seq data. C.V., A.G.-M., D.V.-G., D.H., S.P., E.C.K.,
S.B.H., and E.B. designed experiments and interpreted results. C.V., E.B., and
S.B.H. wrote the manuscript with contributions from all other coauthors.
ACKNOWLEDGMENTS
The authors are grateful for assistance and reagents provided by Luis Duarte,
Avnish Kapoor, Nicholas Mills, Clemens Bönisch, Pauline Rimmele, Danielle
Martinez, and the laboratories of Robert Fisher, Stuart Aaronson, Ramon
Parsons, and Jay Bradner. We thank Cristina Montagna and Jidong Shan at
Molecular Cytogenetic Core at Albert Einstein College of Medicine; Genomics
Core Facility atMount Sinai; Avi Ma’ayan for statistical support; Robert Phelps,
Madelaine Haddican, Shelbi Jim On, and Giselle Singer for assistance with
benign nevi collection; and Mark Lebwohl for his support. Funding was
supported by a Melanoma Research Development Award (Mount Sinai) to
C.V.; DOD BCRP Postdoctoral fellowship (W81XWH-11-1-0018) and NYSCF
Druckenmiller Fellowship to A.G.-M.; graduate fellowship from CONACyT
(239663) to D.V.-G.; International Max Planck Research School for Life Sci-
ence (IMPRS-LS) to S.P.; Bundesministerium für Bildung und Forschung
(FKZ01GS0861, DiGtoP consortium) to M.M.; DOD Collaborative Awards
CA093471 (W81XWH-10-1-080), 1R01CA155234, and 1R01CA163891 to
E.H.; Deutsche Forschungsgemeinschaft through the Collaborative Research
Center SFB 1064 (project A10 to S.B.H. and project Z04 to T.S.); HA 5437/4-1
and the Center for Integrated Protein Science Munich (CIPSM) to S.B.H.;
Worldwide Cancer Research, Hirschl/Weill-CaulierResearch Award; and
NCI/NIH R01CA154683 to E.B. We dedicate this study in memory of Estela
Medrano.
Received: October 30, 2014
Revised: March 24, 2015
Accepted: April 30, 2015
Published: June 4, 2015
REFERENCES
Alla, V., Engelmann, D., Niemetz, A., Pahnke, J., Schmidt, A., Kunz, M.,
Emmrich, S., Steder, M., Koczan, D., and Pützer, B.M. (2010). E2F1 in mela-
noma progression and metastasis. J. Natl. Cancer Inst. 102, 127–133.
Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G.,
Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methyl-
ations in the human genome. Cell 129, 823–837.
Belkina, A.C., and Denis, G.V. (2012). BET domain co-regulators in obesity,
inflammation and cancer. Nat. Rev. Cancer 12, 465–477.
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2.2 Investigating unknown and unusual posttranslational modifications by mass
spectrometry-based proteomics
Specific addition and removal of posttranslational modifications is an important cellular
mechanism to modulate protein structure, localization and function. For instance, in or-
der to become activated, many proteins are dependent on the addition of a specific PTM
at a specific site. In the first publication in the area of PTMs, I set out to identify a previ-
ously unknown activating PTM. Modifications of unknown composition can naturally
not be detected by conventional database searching, hence in this project I applied the
unbiased dependent peptide search approach. With this, I discovered the modification
that activates elongation factor P in a specific branch of bacteria.
In contrast to the specific enzyme-mediated processes mentioned above, unspecific (non-
enzymatic) addition of modifications to proteins can have detrimental effects. Unsur-
prisingly, such modifications are often associated with diseases. The second PTM pro-
ject had a clinical focus: I developed a mass spectrometry-based method for investiga-
ting protein glycation, an unspecific PTM relevant in diabetes. Since in this case the
modification mass was known, I could use a conventional database search approach. I
successfully evaluated the HCD fragmentation behavior of glycated peptides on model
proteins, and finally applied the method for detecting protein glycation directly in blood
plasma.
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2.2.1 Identification of the previously unknown modification that activates elongation
factor P
Lassak, J., Keilhauer, E. C., Fürst, M., Wuichet, K., Gödeke, J., Starosta, A.L., Chen, J.,
Søgaard-Andersen, L.,Rohr, D., Wilson, D.N., Häussler, S. Mann, M. & Jung, K.
Arginine-rhamnosylation as new strategy to activate translation elongation factor P
Nature Chemical Biology 2015 Apr; 11(4); 266-270
This highly interesting collaboration project was initiated by Dr. Jürgen Lassak, then a
senior PostDoc in the group of Prof. Kirsten Jung. The subject of this study was elon-
gation factor P (EF-P), a protein required to resolve ribosome stalling caused by certain
polyproline motifs. To be functional, EF-P needs to be posttranslationally activated. In
eukaryotes and certain bacteria like Escherichia coli (E.coli), the corresponding activa-
tion systems are completely understood, and the corresponding modification is known
to occur on a particular lysine. However, for other types of bacteria, both the activa-
ting enzyme and associated PTM remained elusive. Dr. Jürgen Lassak identified one
particularly interesting branch of bacteria with unknown EF-P activation mechanism,
characterized by an arginine at the position homologous to the modified lysine in eu-
karyotes and E. coli. He also bioinformatically identified a protein of unknown function
strictly co-occuring with this arginine-type EF-P branch. In further experiments, he de-
termined this protein to be the modifying enzyme necessary for EF-P activation in this
group of bacteria. The question what kind of modification this enzyme transfers to EF-P
to activate it remained unsolved.
At this point he approached me, and I tried to tackle this problem by MS-based pro-
teomics. To that end, I analyzed EF-P produced both in the presence and the absence
of the modifying enzyme by LC-MS/MS. Since I had no potential modification mass to
use for standard database searching, I applied the dependent peptide search approach.
This search mode outputs complex and long lists of potential modifications, hence dis-
covering the needle in the haystack, i.e. the true modification, proved to be challenging.
However, using expert knowledge and spectra exploration I determined a promising
candidate: attachment of rhamnose, a 6-deoxy-hexose sugar, to the specific arginine
residue of EF-P. Subsequently, we further confirmed this modification by reconstitut-
ing the modification reaction in vitro and analyzing the resulting modified peptides by
MS. Together with other biochemical validation experiments performed by Dr. Jürgen
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2 Results
Lassak and coworkers, we unequivocally showed that EF-P in the chosen model system
Schewanella oneidensis is activated by arginine-rhamnosylation.
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Ribosomes translate an mRNA sequence into a polypeptide chain. During this process, specific X-PP-X tripeptide sequence motifs can induce ribosome stalling1–6. Eukaryotic/archaeal 
initiation factor 5A (e/aIF5A) and its bacterial ortholog, EF-P, alle-
viate the stalled ribosomes by binding and stimulating peptide bond 
formation3,4,7–10. With its three β-barrel domains, the L-shaped EF-P 
is structurally reminiscent of transfer RNA (tRNA)11 and binds to the 
ribosome between the sites of peptidyl-tRNA binding (P-site) and 
tRNA exiting (E-site)12. A positively charged residue at the tip of the 
loop region in domain I of EF-P protrudes toward the peptidyl-trans-
ferase center and can reach into it when elongated by modification12. 
Accordingly, the conserved lysine in e/aIF5A is extended to hypu-
sine by deoxyhypusine synthase and deoxyhypusine hydroxy-
lase13–15. Analogously, in bacteria such as E. coli, the protruding 
lysine (K34) of EF-P is (R)-β-lysinylated and hydroxylated by the 
concerted action of EF-P lysyl-transferase (EpmA), lysine amino-
mutase (EpmB) and EF-P hydroxylase (EpmC; Fig. 1a)16–20. Here 
we report the identification of an EF-P subfamily activated by a 
chemically different modification. Using Shewanella oneidensis as a 
model organism, we found rhamnosylation of a conserved arginine. 
We also identified the corresponding glycosyltransferase, EarP. This 
modification is not only crucial for bacterial fitness but also for 
pathogenicity in P. aeruginosa, and thus it might be equally impor-
tant in other clinically relevant species such as Neisseria gonorrhoea 
or Bordetella pertussis.
RESULTS
Identification of the EarP-arginine type EF-P subfamily
Whereas the hypusinylation pathway is highly conserved in 
archaea and eukaryotes, EpmA (also known as YjeA, PoxA, 
GenX) and EpmB (YjeK) are only found in about 26% of all 
bacteria20 (Supplementary Results, Supplementary Figs. 1–5 
and Supplementary Data Set 1). The third modification enzyme, 
EpmC (YfcM), co-occurs with EpmA and EpmB but is restricted 
almost exclusively to γ-proteobacterial genomes (Supplementary 
Figs. 4,5 and Supplementary Data Set 1) corroborating its minor 
role in EF-P function3,6–8,21. We hypothesized that the genes encod-
ing EF-P and the associated modification system have coevolved. In 
a phylogenetic analysis of EF-P sequences, we identified a distinct 
subfamily, encoded in genomes lacking EpmABC orthologs, that 
has a strictly conserved arginine (R32) in the position equivalent to 
K34 in E. coli (Fig. 1b,c, Supplementary Fig. 4 and Supplementary 
Data Set 1). The members of this subfamily represent about 9% of 
all EF-Ps, but the distribution deviates from the currently accepted 
species phylogeny. As the newly identified EF-P branch encom-
passes all β-proteobacteria, we hypothesize this subdivision as 
the phylogenetic origin, with subsequent horizontal transfer into 
several γ-proteobacterial orders (including Pseudomonadales, 
Aeromonadales and Alteromonadales) as well as some Fusobacteria, 
Planctomycetes and Spirochetes (Supplementary Data Set 1). We 
took advantage of the anomalous EF-P phylogeny by searching for 
putative EF-P modification enzymes associated with this subfam-
ily via gene neighborhood and co-occurrence using STRING22. This 
led us to identify a protein with a conserved domain of unknown 
function (DUF 2331), which we designated as EarP. Its distribu-
tion strictly coincides with the newly identified EF-P subfamily 
(Supplementary Fig. 5). Moreover, the corresponding gene, earP, 
always lies within a four-gene distance to efp; in 94% of cases, both 
genes are directly adjacent (Supplementary Fig. 6a).
EF-P and EarP are functionally linked
To investigate whether EF-P and EarP are functionally linked, 
we used the ubiquitous, facultative anaerobic, alteromonadal 
γ-proteobacterium S. oneidensis. Bacteria of the genus Shewanella 
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arginine-rhamnosylation as new strategy to 
activate translation elongation factor p
Jürgen Lassak1,2*, eva Keilhauer3, Maximilian fürst1,2, Kristin Wuichet4, Julia Gödeke5,  
agata L starosta1,6, Jhong-Min Chen7, Lotte søgaard-andersen4, Jürgen rohr7, daniel n Wilson1,6, 
susanne Häussler5,8, Matthias Mann3 & Kirsten Jung1,2*
Ribosome stalling at polyproline stretches is common and fundamental. In bacteria, translation elongation factor P (EF-P) res-
cues such stalled ribosomes, but only when it is post-translationally activated. In Escherichia coli, activation of EF-P is achieved 
by (R)-b-lysinylation and hydroxylation of a conserved lysine. Here we have unveiled a markedly different modification strategy 
in which a conserved arginine of EF-P is rhamnosylated by a glycosyltransferase (EarP) using dTDP-L-rhamnose as a substrate. 
This is to our knowledge the first report of N-linked protein glycosylation on arginine in bacteria and the first example in which a 
glycosylated side chain of a translation elongation factor is essential for function. Arginine-rhamnosylation of EF-P also occurs 
in clinically relevant bacteria such as Pseudomonas aeruginosa. We demonstrate that the modification is needed to develop 
pathogenicity, making EarP and dTDP-L-rhamnose–biosynthesizing enzymes ideal targets for antibiotic development. 
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are commonly used in microbial fuel cells and have high potential 
in bioremediation because of their ability to use a wide range of ter-
minal electron acceptors, including heavy metals23,24.
In a first step, we generated markerless in-frame deletions of 
S. oneidensis efp (locus tag SO_2328) and earP (locus tag SO_2329) 
and phenotypically characterized the resulting mutant strains, 
ΔefpS.o. and ΔearPS.o., respectively. Bacteria lacking efp, such as E. coli 
or Agrobacterium tumefaciens, have diminished growth rates16,25. In 
line with these results, deleting either efpS.o. or earPS.o. increased the 
doubling time from 40 min to 110 min and 70 min, respectively, 
which was reversed by providing the corresponding gene copy in 
trans (Fig. 2a and Supplementary Fig. 6a). In parallel, we analyzed 
the growth of the ΔefpS.o. strain, which encodes an EF-P variant 
where the strictly conserved R32 (Fig. 1c) was substituted by either 
lysine (R32K) or alanine (R32A). Both strains phenocopied ΔefpS.o., 
demonstrating the importance of this conserved arginine for EF-PS.o. 
function (Fig. 2a and Supplementary Fig. 6a). We also investigated 
whether the synthesis of polyproline-containing proteins is affected 
in the absence of efpS.o. and earPS.o.. Therefore, we used the reporter 
plasmid p3LC-TL30-3P, which encodes a LacZ variant that is pre-
ceded by a stretch of three proline residues (Fig. 2b)3,7. As expected, 
the β-galactosidase activities of the ΔefpS.o. or ΔearPS.o. strains 
were both reduced by about tenfold, providing clear experimental 
evidence that EarP is required for EF-P activity.
EarP is sufficient to activate EF-P
To test whether EarPS.o. is sufficient for activation of EF-PS.o., we 
examined the phenotypes of an E. coli efp deletion (ΔefpE.c.) heter-
ologously producing EF-PS.o. and EarPS.o.. As a readout, we used a 
chromosomal PcadBA-dependent lacZ reporter in which activation of 
PcadBA strictly depends on the pH-responsive transcriptional activa-
tor CadC26. Translation of CadC is impaired in cells lacking active 
EF-P because of the presence of a polyproline motif (Supplementary 
Fig. 6b)7. As expected, the E. coli ΔefpE.c. PcadBA::lacZ strain was char-
acterized by low-level β-galactosidase activity, and wild-type–like 
lacZ expression was restored in the presence of a plasmid express-
ing EF-PE.c.. Whereas β-galactosidase activity remained low when 
EF-PS.o. or EarPS.o. were expressed alone, simultaneous production 
of both proteins complemented for the lack of EF-PE.c.. The dimin-
ished growth rate of the ΔefpE.c. mutant18 was consistently eliminated 
when EF-PS.o. and EarPS.o. were produced together, regardless of the 
presence of the E. coli EF-P modification enzymes EpmA or EpmB 
(Supplementary Fig. 6c). Next, we asked whether EpmABC and 
EarP had adapted to specifically activate their corresponding EF-Ps. 
Therefore EF-PE.c. K34 and EF-PS.o. R32 substitution variants were 
produced in ΔefpE.c., and PcadBA activation, growth rate or both were 
investigated in the resultant strains (Supplementary Fig. 6b,c). 
Neither EF-PS.o.R32K with EpmABC nor the EF-PE.c.K34R with EarP 
could reverse the mutant phenotype, thus further corroborating our 
hypothesis for the coevolution of EF-P with its associated modifica-
tion system.
EarP modifies EF-P at Arg32
Having demonstrated that EarPS.o. is necessary and sufficient for 
specific activation of EF-PS.o., we addressed whether EarPS.o. post-
translationally modifies the conserved R32 of EF-PS.o.. To that 
end, we overproduced His6-tagged EF-PS.o. in two S. oneidensis  
strains, ΔefpS.o. and ΔefpS.o./ΔearPS.o.. Purified EF-PS.o. from these 
two strains was proteolytically digested, and the resulting peptides 
were analyzed by high-resolution LC/MS/MS using an unbiased 
‘dependent peptide’ search27. We detected eight high-confidence 
R32-containing peptides that were 146.058 Da heavier than their 
unmodified counterparts (Fig. 3 and Supplementary Fig. 7). This 
mass shift only occurred on R32-containing peptides of EF-PS.o. 
and never when EF-PS.o. was produced in cells lacking EarP 
(Supplementary Fig. 8). The fragmentation pattern of the modi-
fied peptides strongly suggested the modification site to be on R32 
(Fig. 3). To further confirm this, we performed a standard vari-
able modification search with a potential arginine mass shift of 
146.058 Da, corresponding to a molecular composition of C6H10O4 
(146.0579 Da). This second analysis identified the modification to 
exist exclusively on R32 of EF-P, confirming both the molecular 
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Figure 1 | bioinformatic identification of the EarP-arginine type EF-P 
subfamily. (a) (R)-β-lysinylation and hydroxylation of eF-p in E. coli. 
(b,c) A 31-amino-acid (aa)-long sequence logo of eF-p encompassing a 
part of domain i, including the loop region. Arrows point to the positively 
charged residue at the tip of the loop region. numbering depicts aa in the 
polypeptide chain. (b) Weblogo generated from eF-p of bacteria encoding 
epmA and epmb. (c) Weblogo generated from eF-p of bacteria derived 
from the newly identified branch that co-occurs with earp.
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Figure 2 | Phenotypic analysis of S. oneidensis mR-1 earP and efp 
deletion mutants. (a) Growth of S. oneidensis MR-1 strains. left, wild-type 
strains in comparison to ΔefpS.o. and ΔearPS.o. deletion strains and after 
complementation in trans (+efpS.o., +earPS.o.). Right, the ΔefpS.o. deletion strain 
and after complementation with plasmids encoding His6 versions of eF-pS.o. 
(+R32) or the corresponding substitution variants eF-pS.o.R32A (+R32A) and 
eF-pS.o.R32K (+R32K), respectively. the presented growth curves are average 
data from three independent data sets, with statistical error below 10%. 
(b) β-galactosidase (β-gal) activity assay of S. oneidensis MR-1 ΔefpS.o., 
ΔearPS.o. encoding a constitutively produced lacZ-hybrid without (black 
bars) or with (gray bars) a polyproline motif (3× pro). β-galactosidase 
activity is given in percent and is normalized to the wild-type values. the 
relative activities are average data from three independent data sets, with 
statistical error below 10%.
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composition and the location of the modification (Supplementary 
Fig. 9). Notably, no peptides with this modification could be found 
when two arginine substitution EF-P variants were analyzed (His6- 
EF-PS.o.R32K and His6-EF-PS.o.R32A; Supplementary Fig. 10). This obser-
vation explains the efp-null mutant phenotype of strains encoding 
His6-EF-PS.o.R32K or His6-EF-PS.o.R32A substitution variants (Fig. 2a and 
Supplementary Fig. 6) as a consequence of the absence of EF-PS.o. 
R32 modification by EarPS.o..
EarP is a rhamnosyltransferase
We reasoned that a modification on R32 with a molecular compo-
sition of C6H10O4 might be the result of N-glycosylation with an 
activated deoxyhexose sugar (C6H12O5 – H2O = C6H10O4). E. coli 
synthesizes two nucleotide diphosphate deoxyhexoses: GDP-L-
fucose and dTDP-L-rhamnose (Fig. 4a)28. The biosynthesis genes 
encoding the latter (represented by rmlD) are strictly conserved in 
bacteria encoding EarP but are less frequently found in bacteria 
with EpmABC (Supplementary Fig. 5). To test whether dTDP-L-
rhamnose or GDP-L-fucose might act as a substrate for EarPS.o., we 
interrupted the corresponding synthesis pathways. GDP-L-fucose 
and dTDP-L-rhamnose are synthesized from fructose-6-phosphate 
and glucose-1-phosphate, respectively, with each biosynthetic 
pathway encompassing four specific enzymes (Fig. 4a). To pre-
vent formation of GDP-L-fucose, we deleted fcl, which arrested 
synthesis at the GDP-4-keto-6-deoxy-D-mannose step, whereas 
dTDP-L-rhamnose formation was blocked at the intermediate dTDP-
4-keto-6-deoxy-L-mannose step by deletion of rmlD (Fig. 4a). The 
deletions were generated in an E. coli PcadBA::lacZ 
strain lacking efp. The β-galactosidase activities 
of both resultant strains deficient either in GDP-
L-fucose (ΔefpE.c./ΔfclE.c.) or in dTDP-L-rhamnose 
(ΔefpE.c./ΔrmlDE.c.) were comparable to wild-type 
activity when a copy of efpE.c. was provided in 
trans (Fig. 4b). Similarly, the ΔefpE.c./ΔfclE.c. strain 
could be complemented with EF-PS.o./EarPS.o., 
indicating that GDP-L-fucose is not a substrate 
for EarP. In stark contrast, the coproduction of 
EF-PS.o./EarPS.o. in the context of ΔefpE.c./ΔrmlDE.c. 
cells phenocopied the ΔefpE.c. strain, suggest-
ing that dTDP-L-rhamnose is the substrate 
needed for EarPS.o. to activate EF-PS.o. To further 
corroborate this result, we deleted rmlC (locus 
tag SO_3160) in S. oneidensis and analyzed trans-
lation of a polyproline-containing LacZ reporter 
hybrid in the resultant dTDP-L-rhamnose– 
deficient strain ΔrmlCS.o. (Fig. 4c)3,7. As observed 
for ΔefpS.o. or ΔearPS.o., β-galactosidase activity 
was low in the ΔrmlCS.o. strain harboring the 
p3LC-TL30-3P reporter. Consistent with our 
previous results, in vivo activation of EF-PS.o. 
strictly depends on the biosynthesis of dTDP-
L-rhamnose, leading us to conclude that dTDP-
L-rhamnose acts as the substrate for EF-PS.o. 
modification and that it was recruited for this 
role upon the development of the EarP–EF-P 
phylogenetic relationship (Supplementary 
Figs. 4,5 and Supplementary Data Set 1).
To directly demonstrate that EarPS.o. can gly-
cosylate EF-PS.o. using dTDP-L-rhamnose as a 
substrate, we performed in vitro glycosylation 
reactions with purified components. LC/MS/MS 
analysis, performed as described above, 
revealed the presence of R32 rhamnosylation 
of wild-type EF-PS.o. if and only if all three compo-
nents were provided (Supplementary Fig. 11). 
Collectively, our data demonstrate unambigu-
ously both in vivo and in vitro that EarP is an EF-P arginine rhamno-
syltransferase essential for post-translational activation.
EF-P stimulates peptide bond formation indirectly
Rhamnosyl-arginine differs substantially from (R)-β-lysinyl-
hydroxylysine and hypusine of EF-PE.c. and a/eIF5A, respectively, 
raising the question of how this unusual extension protrudes into 
the peptidyl-transferase center of the ribosome (Fig. 5a–d). To 
investigate this, we generated molecular models for the different 
modifications of EF-P orthologs based on the crystal structure of 
unmodified Thermus thermophilus EF-P bound to the 70S ribo-
some12. These models suggest that the (R)-β-lysinylation found 
on EF-PE.c. could reach within 2 Å of the proline attached to the 
P-site tRNA (Fig. 5b), whereas the hypusine and rhamnose-argi-
nine modifications are shorter and cannot reach the P-site proline 
(Fig. 5c,d). Therefore, EF-P bearing either hypusine or rhamnose-
arginine modifications is not likely to stimulate peptide-bond 
formation by directly influencing the conformation of the poly-
peptide chain but rather does so indirectly by interacting with and 
stabilizing the CCA-end of the P-site peptidyl-Pro-tRNA.
EarP and EF-P are essential for P. aeruginosa pathogenicity
Distinct bacterial strategies to functionalize EF-P may provide a 
basis for development of customized antibiotics. Deleting EF-P or 
its modifying enzymes has been shown to reduce bacterial fitness16,25 
and lead to a loss of pathogenicity in Salmonella enterica and 
A. tumefaciens. To test whether rhamnosylated EF-P is also required 
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to develop pathogenicity in the P. aeruginosa strain PAO1, we inves-
tigated transposon mutants of efpP.a. (locus tag PA2851) and earPP.a. 
(locus tag PA2852) in an infection assay using the human cell line 
A549-Gluc (Fig. 5e). Whereas wild-type P. aeruginosa decreased 
the number of living cells by about 80%, infection with ΔefpP.a. or 
ΔearPP.a. mutants had no effect on cell viability. Pathogenicity of 
P. aeruginosa PAO1 is dependent on a large number of cell-associated 
and extracellular virulence factors, such as rhamnolipids and 
pyocyanin, that are important for colonization and invasion 
during infection29. Bioinformatic analysis on the P. aeruginosa  
proteome revealed that the synthesis of those virulence factors 
involves polyproline-containing proteins, suggesting a dependence 
on EF-P for their translation (Supplementary Table 4). Consistently, 
efpP.a. or earPP.a. disruption mutants showed a substantial decrease 
in the production of rhamnolipids and pyocyanin, and production 
was restored by introducing EarPS.o. and EF-PS.o. but not the substitu-
tion mutants EF-PS.o.R32A and EF-PS.o.R32K (Supplementary Fig. 12). 
Therefore, both EF-PP.a. and the corresponding rhamnosyltrans-
ferase EarPP.a. contribute to pathogenicity in P. aeruginosa.
DIScUSSIoN
Protein glycosylation is a commonly used strategy to alter 
structural and functional properties of a protein. However, until 
recently, N-linked glycosylation was almost exclusively associated 
with asparagine. The only known additions of a sugar to arginine 
were restricted to two reported examples on eukaryotic proteins. 
Arginine glycosylation was discovered first in search of a protein 
primer for starch synthesis in 1995 (ref. 30). Here, the authors 
identified sweet corn amylogenin to be self-β-glucosylated. Second, 
in 2013, two independent research groups showed that NleB, 
an enteropathogenic E. coli type III secretion system effector, 
antagonizes death receptor signaling by modifying conserved argi-
nines in human death receptor domains with N-acetylglucosamine 
(GlcNAc)31,32. With S. oneidensis and P. aeruginosa EF-P, we now 
report what is to our knowledge the first arginine-glycosylated bac-
terial protein, thus demonstrating that this type of post-translational 
modification is not restricted to eukaryotic proteins but is 
common to other domains of life. 
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replicates ± s.d. (c) β-galactosidase activity assay of S. oneidensis MR-1 
ΔrmlCS.o. encoding a constitutively produced lacZ hybrid without (black 
bars) or with (gray bars) a polyproline motif (3× pro). β-galactosidase 
activity is given in percent and is normalized to the wild-type values.  
the relative activities are average data from three independent data sets, 
with statistical error below 10%.
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Bioinformatics software. Hidden Markov model (HMM) analyses were carried 
out using the HMMER3 software package33. Multiple sequence alignments were 
constructed using the l-ins-i algorithm of the MAFFT version 6.864b software 
package34. BLASTP searches were performed using the BLAST+ software pack-
age version 2.2.26 (ref. 35). All phylogenetic trees were constructed using FastTree 
with default settings36. Sequences logos were created using the Weblogo server37.
Genome set and domain architecture. 1,611 completely sequenced prokary-
ote genomes from a previously defined set available from 4 April 2012 were 
collected38. We used a set of 1,004 genomes with reduced redundancy based 
on the 16S comparison for all sequence analyses. The Pfam26 HMM library39 
was used to define domain architecture of all sequences with default gathering 
thresholds. In the event of domain overlaps, the highest-scoring domain model 
was chosen for the final architecture.
EarP, EF-P, RmlD and EpmC were identified by collecting sequences that 
contain the DUF2331, EF-P, RmlD_sub_bind and DUF462 domains, respec-
tively. EpmA consists of a class II tRNA synthetase domain (tRNA-synt_2), 
which is found in a variety of proteins. All 2,684 sequences containing the 
tRNA-synt_2 domain were collected and aligned. The core region correspond-
ing to the tRNA-synt_2 domain was extracted from the multiple sequence 
alignment and used to build a phylogenetic tree. Domain architecture and 
gene neighborhood analyses identified a conserved clade of 239 sequences in 
the tree that were determined to be EpmA homologs because of their genomic 
context association with EF-P homologs (Supplementary Fig. 1). EpmB is 
composed of a Radical SAM domain (Radical_SAM), which is found in over 
15,000 proteins in our sequence set, making a phylogenetics-based approach to 
EpmB identification challenging. EpmB is often encoded near efp or epmA. We 
collected all of the sequences with Radical_SAM domains that were encoded 
within a distance of four genes to efp or epmA homologs (181 sequences) and 
aligned them. A tree constructed from the alignment revealed two distinct 
clades, one with many short branches presumed to be true EpmB sequences 
and another composed of many long branching sequences, which suggest 
divergence. Furthermore, some sequences in the divergent clade are from 
genomes represented in the EpmB-associated clade, supporting that they are 
not true EpmB orthologs (Supplementary Fig. 2). These 36 sequences of the 
divergent clade were removed from the set, and the remaining sequences were 
used as queries in BLASTP searches against our representative sequence set. 
All sequences with an e-value of 0.0001 or less were collected (515 sequences) 
and aligned. A phylogenetic tree was built from the core region of the multiple 
sequence alignment corresponding to the Radical_SAM domain. Conserved 
clades that were associated with EF-P or EpmA on the basis of genome context 
and phylogenetic distribution were identified (Supplementary Fig. 3). The 236 
sequences that are members of these clades were defined as EpmB homologs, and 
this is consistent with the 239 EpmA homologs we identified that are presum-
ably part of the same pathway. All EarP, EF-P, RmlD, EpmC, EpmA and EpmB 
homologs in the representative genome set can be found in Supplementary Data 
Set 1. We further identified all of the EarP homologs in the full 1,611 genome 
set on the basis of the presence of the DUF2331 domain (Supplementary Data 
Set 2). We identified all of the EarP-associated EF-Ps in this set using a HMM 
built from an alignment of the EarP-associated EF-Ps identified in the EF-P 
phylogenetic analyses. All sequences with a score greater than or equal to that 
of the lowest-scoring member of the representative set of EarP-associated EF-Ps 
were identified as homologs (Supplementary Data Set 2).
Phylogenetic analysis of EF-P homologs. A phylogenetic tree was built from 
the core region of a multiple sequence alignment of EF-P homologs. Conserved 
clades associated with EarP, EpmA or EpmB on the basis of genome context 
and phylogenetic distribution data were identified (Supplementary Fig. 4). 
Sequences from these clades were collected, with the exception of those from 
an EpmA/EpmB-associated subfamily that includes members of the EF-P–like 
family (the YeiP subfamily), which lack the conserved lysine. The collected 
sequences were aligned, and the core region of the alignment was used to 
construct a phylogenetic tree (Supplementary Fig. 5).
Oligonucleotides, plasmids and bacterial strain construction. Primers, plas-
mids and strains used in this study are listed in Supplementary Tables 1–3. Of 
note, transposon mutant P. aeruginosa PAO1 ID 30853 from the Washington 
Genome Center40 with a transposon insertion in open reading frame (ORF) 
PA4684 was used as a wild-type control41. Strains BW-Δefp/epmA::npt, 
BW-Δefp/epmB::cat, MG-CR-efp-fcl and MG-CR-efp-rmlD were constructed 
by using pRED/ET recombination technology together with rpsL counter-
selection42 in accordance to the technical protocol of the Quick and Easy 
E. coli Gene Deletion Kit of Gene Bridges (http://www.genebridges.com/). 
Strains ΔefpS.o., ΔearPS.o., ΔefpS.o./ΔearPS.o. and ΔrmlCS.o. were constructed as 
essentially described in ref. 43, leaving terminal sections of the target gene.
Molecular biology methods. Enzymes and kits were used according to the manu-
facturer’s directions. Genomic DNA was purified according to standard protocols. 
DNA fragments were purified from agarose gels using a high-yield PCR cleanup 
and gel extraction kit (Sued-Laborbedarf). Restriction endonucleases were pur-
chased from New England Biolabs. Sequence amplifications by PCR were per-
formed by using the Phusion high-fidelity DNA polymerase from Finnzymes or 
the Taq DNA polymerase from New England Biolabs, respectively. All efp mutants 
were constructed by one- or two-step PCR using mismatched primer pairs44.
Growth conditions. E. coli, P. aeruginosa PAO1 and S. oneidensis MR-1 were 
routinely grown at 37 °C (for E. coli and P. aeruginosa) and 30 °C (S. oneidensis), 
unless indicated otherwise. According to the NaCl modification of Miller, lysogeny 
broth (LB)45 was used as complex medium. When indicated, LB was buffered with 
100 mM sodium-phosphate to pH 5.8. Microaerobic conditions were achieved by 
growing cells in closed Eppendorf cups with minimal agitation. Antibiotics were 
used when necessary with the following concentrations: 100 μg/ml ampicillin 
sodium salt, 50 μg/ml kanamycin sulfate, 34 μg/ml chloramphenicol, 50 μg/ml 
streptomycin sulfate or 15 μg/ml tetracycline hydrochloride. For blue-white selec-
tion, LB agar plates were additionally supplemented with 80 μM 5-bromo-4- 
chloro-3-indolyl β-D-galactopyranoside (X-Gal; Sigma Aldrich) and 1 mM isopro-
pyl β-D-1-thiogalactopyranoside (IPTG; Sigma Aldrich).
β-Galactosidase activity assay. Cells expressing lacZ under control of the cadC 
or cadBA promoters were grown in buffered LB medium to mid-exponential 
growth phase or overnight and harvested by centrifugation. β-Galactosidase 
activities were determined for at least three independent experiments and are 
given in Miller units (MU). The significance of the results was determined by 
applying the two-sided Student’s t-test, and results were considered signifi-
cantly different if P < 0.05.
Overproduction and purification of recombinant proteins. C-terminal 
His6-tagged EF-PS.o. as well as the corresponding R32A and R32K substitution 
variants were overproduced either in S. oneidensis MR-1 wild-type, ΔefpS.o. and 
ΔefpS.o./ΔearPS.o. mutant strains or in E. coli LMG194 and grown in LB over-
night at 16 °C after the addition of 0.2% (w/v) L-arabinose to exponentially 
grow cells. Similarly, C-terminal His6-tagged EarPS.o. was produced in E. coli 
LMG194. Cells were lysed and purified using Ni-NTA (Qiagen) and 250 mM 
imidazole. For further MS analysis and in vitro rhamnosylation, proteins 
were dialyzed against reaction buffer (50 mM HEPES, pH 7.8, 100 mM NaCl, 
50 mM KCl, 10 mM MgCl2, 2.5 mM β-mercaptoethanol, 2.0% (v/v) glycerol).
Protein digestion and sample preparation for MS. Purified EF-P was predi-
gested with LysC for 3 h in 8 M urea, 50 mM Tris-HCl, pH 7.5, 1 mM DTT and 
5 mM chloroacetamide (CAA). Then, samples were diluted 1:4 with 50 mM 
Tris HCl, pH 7.5, to decrease the urea concentration to 2 M and digested over-
night with trypsin. Peptide mixtures were purified on C18 StageTips46.
LC/MS/MS analysis. Peptides were eluted from the C18 StageTips according to 
the standard protocol. They were analyzed by reversed-phase LC on an EASY-
nLC 1000 system (Thermo Fisher Scientific) directly coupled to a quadrupole 
Orbitrap mass spectrometer (Q Exactive, Thermo Fisher Scientific). HPLC 
columns with a length of 50 cm and an inner diameter of 75 μm were packed 
in-house with ReproSil-Pur 120 C18-AQ 1.9-μm particles (Dr. Maisch GmbH). 
Peptide mixtures were separated using gradients of either 60 min or 140 min 
(total run time plus washout) and a two-buffer system: buffer A++ (0.1% for-
mic acid) and buffer B++ (80% acetonitrile in 0.1% formic acid). The flow rate 
was set to 250 nl/min, and the column was heated to 50 °C using a column oven 
(Sonation GmbH). Peptides eluting from the column were directly sprayed into 
the mass spectrometer; spray voltage was set to 2.3–2.4 kV, and the capillary 
temperature was set to 250 °C. The mass spectrometer was operated in a data-
dependent mode with switching between a survey scan and fragmentation 
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scans of the top five most abundant peaks. In the 60-min method, full scans 
were acquired at a resolution of 140,000 with an AGC target of three E06 ions 
and a maximum injection time of 20 ms. Precursors were selected with an iso-
lation window of 3 Th, and MS2 scans were acquired at a resolution of 17,500 
with an AGC target of one E05 ion and a maximum injection time of 120 ms. 
In the 140-min method, full scans were acquired at a resolution of 70,000 with 
an AGC target of three E06 ions and a maximum injection time of 20 ms. 
Precursors were selected with an isolation window of 2 Th, and MS2 scans 
were acquired at a resolution of 35,000 with an AGC target of one E05 ion and 
a maximum injection time of 120 ms. In both cases, peptides were fragmented 
by higher-energy collisional dissociation (HCD) with a normalized collision 
energy of 25. To minimize resequencing of peptides, dynamic exclusion was 
enabled within a time window of 20 s.
MS data analysis. MS raw files were processed using MaxQuant27 version 
1.5.0.0. MS/MS spectra were searched using the Andromeda search engine47 
against FASTA files obtained from Uniprot adapted to the corresponding sam-
ple. For EF-P samples from homologous production in S. oneidensis, raw data 
were searched against the S. oneidensis reference proteome downloaded from 
Uniprot on 20 January 2014 and a FASTA file containing the sequence of His6-
tagged EF-PS.o.. Depending on the experiment, we added additional FASTA files 
containing the sequence of His6-tagged EF-PS.o.R32A or EF-PS.o.R32K. Cysteine car-
bamidomethylation was set as a fixed modification; N-terminal acetylation and 
methionine oxidation were set as variable modifications. Trypsin was chosen as 
the specific enzyme, with a maximum of two missed cleavages allowed. Peptide 
and protein identifications were filtered at a 1% false discovery rate (FDR). 
The initial mass tolerance was set to 4.5 p.p.m. for the precursor masses and to 
20 p.p.m. for the fragment masses. All of the other parameters were left at stand-
ard settings. For dependent peptide analysis (essentially as described in ref. 47), 
the corresponding feature was enabled. For the variable modification searches, 
L-rhamnose –H2O (C6H10O4 = 146.058 Da) was first defined as a variable modifi-
cation with specificity for arginine in the Andromeda con figuration and was sub-
sequently added to the other variable modifications in the MaxQuant search.
Bioinformatic analysis of the MaxQuant processed data was performed using 
the Perseus software (version 1.4.2.35, available in the MaxQuant environ-
ment). In brief, for dependent peptide analysis, the ‘all.peptides.txt’ table was 
loaded and filtered for DP decoy ≠ ‘+’, ‘DP Protein’ = EF-P, ‘DP Base sequence’ 
containing ‘SGR’, ‘DP Mass Difference’ > 0 and ‘DP Score’ > 80. Remaining hits 
were further validated in a manual fashion. Spectra were visualized using the 
Viewer program (version 1.5.0.0, integrated into MaxQuant) and annotated 
using the Expert System48. For rhamnosylation analysis, the ‘Rhamsites.txt’ 
table was loaded, and the site table was expanded, logarithmized and then 
filtered for ‘Protein’ = EF-P, ‘Localization Probability’ = 1 and ‘Score’ > 80.
Enzymatic total synthesis of TDP-L-rhamnose. The synthesis was carried 
out in two steps. First, TDP-4-keto-6-deoxy-D-glucose was prepared from 
glucose-1-phosphate using two purified E. coli enzymes (RmlA and RmlB) 
and TTP. TTP was generated in situ from TMP with a mix of TMP kinase 
and acetate kinase. TDP-4-keto-6-deoxy-D-glucose is a key intermediate of 
many 6-deoxyhexoses and can be stored at −80 °C. E. coli BL21(DE3) (EMD 4 
Biosciences) was used for the conversion of TDP-4-keto-6-deoxy-D-glucose to 
TDP-L-rhamnose. This E. coli strain contains naturally TDP-4-ketorhamnose 
3,5-epimerase (RmlC) and TDP-4-keto-rhamnose reductase (RmlD). Crude 
cell lysates of E. coli BL21 (DE3) were added to a solution of TDP-4-keto-6-
deoxy-D-glucose in phosphate buffer (50 mM, pH 7.5), MgCl2 (4 mM) and 
NADH (5 mM). The reaction continued for 3 h at 37 °C. The production of 
TDP-L-rhamnose was monitored by HPLC49,50.
The resulting solution containing TDP-L-rhamnose was desalted by size-
exclusion chromatography (BioGel P2 column) and further purified by HPLC 
(Waters 600 system consisting of a controller, a Waters 996 photodiode array 
detector and a Delta 600 pump; a Dionex CarboPac PA1, 4 × 250 mm column 
was used for 60-min runs at a flow rate of 1.0 ml/min, and UV monitoring 
absorbance was set at 254 nm). The gradient used was as follows: solvent A, 
water; solvent B, 0.5 mM ammonium acetate solution. Solvent B was increased 
from 5% to 20% (0 min to 15 min), from 20% to 60% (15 min to 35 min), and 
then from 60% to 100% (35 min to 45 min); it was kept at 100% for 5 min 
before it was decreased back to 5% within 2 min, and it was kept at 5% for the 
last 8 min49,51. Under these conditions, TDP-L-rhamnose elutes at 34.04 min.
In vitro glycosylation. A total of 10 μM of His6-EF-PS.o. or substitution variants 
and 10 μM His6-EarPS.o. were incubated in reaction buffer (50 mM HEPES, pH 
7.8, 100 mM NaCl, 50 mM KCl, 10 mM MgCl2, 2.5 mM β-mercaptoethanol, 
2.0% (v/v) glycerol) with 100 μM of dTDP-L-rhamnose for 60 min at 30 °C.
Cytotoxicity assay. The cytotoxicity of the P. aeruginosa strains was assayed 
as described earlier52. Briefly, eukaryotic A549-Gluc cells were cultured 
in completed Dulbecco’s modified Eagle’s medium at 37 °C with 5% CO2. 
A549-Gluc cells were generated from A549 by lentiviral gene transfer as 
described previously53,54. Cytotoxicity of the P. aeruginosa strains was assessed 
by infecting A549-Gluc cells, which secrete Gaussia luciferase, as a measure 
of cell integrity. A549-Gluc cells were seeded in 96-well plates at a density 
of 2.5–5 × 104 cells per well and grown until ~90% confluence. After wash-
ing, cells were inoculated with 6-h-old P. aeruginosa LB cultures adjusted to a 
multiplicity of infection (MOI) of 200 and centrifuged to increase cell-cell con-
tact. 100 μl cell culture super natants were collected after 3 h of incubation, and 
Gaussia luciferase activity was measured for 0.1 s using an LB 960 Centro XS3 
plate luminometer (Berthold Technologies) after the addition of 60 μl of 10 μM 
coelenterazine (PJK GmbH). Luciferase activities were determined for at least 
three independent experiments. The significance of the results was determined 
by applying the two-sided Student’s t-test, and results were considered signi-
ficantly different if P < 0.05.
Assay for pyocyanin production. Pyocyanin was extracted from P. aeruginosa 
supernatant and measured according to ref. 55. 5 ml of 24-h-old cultures were 
extracted with 1 volume of chloroform and then re-extracted into 0.2 N HCl 
to give a pink solution. The aqueous layer was transferred to a fresh tube, and 
absorbance was measured at 520 nm. Pyocyanin produced per milliliter of 
culture supernatant was calculated as described elsewhere55.
Quantification of rhamnolipid production. Overnight cultures of 
P. aeruginosa were freshly diluted to an OD600nm of 0.05 and incubated in 
LB at 37 °C for 48 h. The colorimetric analysis of the orcinol reaction was 
adopted from the method described in ref. 56. Briefly, 300 μl of culture super-
natant were extracted twice with diethylether. After evaporation of the pooled 
fraction, the remaining fraction was dissolved in distilled water and incubated 
with 100 μl 1.6% (w/v) orcinol and 800 μl 60% sulfuric acid. After heating 
to 80 °C and shaking at 175 r.p.m. for 30 min, the adsorption at 421 nm was 
determined. In parallel, L-rhamnose at defined concentrations was assayed as 
described above and used as a standard for determining the L-rhamnose in 
the culture samples. Rhamnolipid concentrations were then calculated with the 
assumption that 1 μg of L-rhamnose corresponds to 2.5 μg of rhamnolipid57. 
Rhamnolipids were quantified from at least three independent experiments. 
The significance of the results was determined by applying the two-sided 
Student’s t-test, and results were considered significantly different if P < 0.05.
Molecular modeling. The molecular model for modified EF-Ps on the ribos-
ome was generated using the crystal structure of unmodified T. thermophilus 
EF-P bound to a T. thermophilus 70S ribosome programmed with tRNAfMet at 
the P-site12. The proline residue was modeled onto the CCA-end of the P-site 
tRNA by aligning the structure of the 50S subunit with an aminoacylated tRNA 
substrate in the P-site (PDB1VQN) and by mutagenesis of the amino acid to 
proline using Coot58. The models for EF-P bearing lysinylation or hypusine 
modifications were generated by mutagenesis of Arg32 to lysine of ribosome-
bound T. thermophilus EF-P and then addition of the required modifica-
tion moieties to the ε-amino group of the lysine, whereas for EF-P bearing 
the rhamnosylation modification, an L-rhamnose moiety was added to the 
η2-amino group of Arg32 of ribosome-bound T. thermophilus EF-P. All of the 
models were generated and refined in Coot58, and images were produced using 
the PyMOL Molecular Graphics System (Version 1.5.0.4 Schrödinger, LLC).
33. Eddy, S.R. A new generation of homology search tools based on probabilistic 
inference. Genome. Inform. 23, 205–211 (2009).
34. Katoh, K., Kuma, K., Toh, H. & Miyata, T. MAFFT version 5: improvement  
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(2005).
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Recent technological improvements have advanced mass spectrometry to a stage where
it can be applied to clinical questions. In this fifth and last project, I set out to investigate
a PTM highly relevant in diabetes, called protein glycation. Diabetes, a chronic disease
characterized by abnormal glucose metabolism, is amongst the top ten causes of death
worldwide. Hence new methods for better diagnosis, monitoring and treatment, as well
as a deeper understanding of the disease in order to potentially prevent it, are urgently
needed.
Protein glycation is formed by the non-enzymatic reaction between glucose (or other re-
ducing sugars) with the amino groups of proteins, a reaction commonly known as Mail-
lard reaction. Since the glycation reaction is concentration-dependent, the increased
level of blood glucose in diabetic patients results in an increase of this particular PTM.
Although protein glycation is well understood for hemoglobin, and measuring glycated
hemoglobin (HbA1c) is actually one of the standard procedures to diagnose and mon-
itor diabetes, our knowledge about other glycated proteins is quite limited. Every protein
in contact with glucose is a potential target for this unspecific modification, hence in-
creased knowledge about other glycation targets is highly desirable.
In this project I set out to develop an MS-based method for investigating glycated pep-
tides on the benchtop Orbitrap platforms used in our laboratory, that employ HCD frag-
mentation. I first evaluated the fragmentation behavior of the glycated peptides in HCD
using model proteins, and adapted the data acquisition and analysis accordingly. I then
performed proof-of-principle experiments for detecting glycated proteins in complex
matrices like HeLa lysate and finally human blood plasma. In the future, I plan to fur-
ther optimize this workflow, particularly by implementing a quantification strategy, and
subsequently apply it to investigate protein glycation directly in patient samples.
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ABSTRACT  
 
Protein glycation is a concentration-dependent non-enzymatic reaction of reducing 
sugars with amine groups of proteins to form early as well as advanced glycation 
products (AGEs). Glycation is a highly disease-relevant modification, but is 
typically only studied on few blood proteins. To complement our blood proteomics 
studies in diabetics, we here investigate protein glycation by higher-energy 
collisional dissociation (HCD) fragmentation on Orbitrap mass spectrometers. We 
established parameters to most efficiently fragment and identify early glycation 
products on in vitro glycated model proteins. Retaining standard collision energies 
does not degrade performance if the most dominant neutral loss of H6O3 is 
included into the database search strategy. Glycation analysis of the entire HeLa 
proteome revealed an unexpected intracellular preponderance for arginine over 
lysine modification in early and advanced glycation products. Single-run analysis 
from 1 µl of undepleted and unenriched blood plasma identified 101 early glycation 
sites as well as numerous AGE sites on diverse plasma proteins. We conclude that 
HCD fragmentation is well suited for analyzing glycated peptides, and that the 
diabetic status of patients can be directly diagnosed from single-run plasma 
proteomics measurements.  
 
Keywords: protein glycation, higher-energy collisional dissociation, diabetes, blood 
plasma, AGEs 
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INTRODUCTION 
 
Protein glycation, in contrast to enzyme-mediated glycosylation, it is produced by the non-
enzymatic reaction of glucose molecules or other reducing sugars with amine groups of 
proteins and is also known as Maillard reaction.1 Glucose first attaches to form a Schiff 
base, which then rearranges into the relatively stable Amadori compound2, to which we 
refer here as ‘early glycation product’. Glycated proteins can further react to form 
advanced glycation endproducts (AGEs), or proteins can directly react with glucose-
derived reactive dicarbonyls like methylglyoxal to form AGEs.3 Glucose is an essential 
and omnipresent energy source in humans, and is tightly regulated in a narrow 
concentration band in healthy individuals. Dysregulation of glucose levels is the principal 
feature of diabetes, a growing health epidemic, currently affecting an estimated 415 
million individuals worldwide according to the International Diabetes Federation (IDF) 
Diabetes Atlas (7th edition). The extent of protein glycation and AGEs are increased in 
proportion to the glucose concentration, and the glycation level of one particular blood 
protein, hemoglobin, is routinely assessed in the diagnosis of diabetes as well as for long-
term monitoring of blood glucose levels of diabetes patients. More specifically, glycation 
of the N-terminal valine of the hemoglobin beta-chain is assessed, a clinical parameter 
known as HbA1c.4, 5 Since the lifespan of erythrocytes and hence hemoglobin is around 
120 days, the HbA1c value reflects the average blood glucose concentration of the last 
six to eight weeks2, 6. Hence the HbA1c-test is often more robust than oral glucose 
tolerance tests that can be influenced by various factors such as recent food intake, 
exercise and blood sampling time. If the HbA1c value can be stabilized close to normal 
levels, patients have a much better prognosis and less diabetic complications than those 
with poorly controlled HbA1c values.7 Glycation and AGEs are central to the development 
of typical diabetic complications, and also play a role in ageing and neurodegenerative 
and cardiovascular diseases.8-13  
The current and strong focus on glycated hemoglobin and few more proteins is 
presumably due to a lack of appropriate methods to robustly detect, characterize and 
quantify other glycated proteins. Owing to its extreme complexity and extraordinary 
dynamic range, blood plasma is the most challenging proteome.14-16  However, 
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investigation of other glycated proteins could help to better diagnose, monitor and 
understand metabolic conditions such as diabetes. For example, measuring several 
glycated proteins with different lifespans might yield a more detailed picture of blood 
glucose levels of patients over the last days to weeks.17-19  
Mass spectrometry (MS) is the method of choice to investigate post-translational protein 
modifications (PTMs) in an unbiased manner.20 Analysis of glycation in body fluids has 
been challenging because of its low-stoichiometry and enrichment strategies such as 
boronate affinity chromatography (BAC) are typically employed.21, 22 Sample complexity 
is often additionally reduced by depleting the most abundant plasma proteins and/or 
fractionating the plasma on the peptide level. In this way, and by pooling and fractionating 
a large number of diverse samples, the most comprehensive study to date found evidence 
of around 1100 glycated proteins from human plasma.23 Such elaborate protocols are 
useful for generating glycation site resources, however they are not practical for clinical 
tests. We have recently reported a method called ‘plasma proteome profiling’, that allows 
measuring hundreds of plasma proteins from only 1 µl of plasma in a single-run format 
without depletion or fractionation.24 We therefore wondered if we could complement the 
patient information gained from plasma proteome profiling with the diabetic status by 
determining glycation of plasma proteins. 
Glycated peptides have been studied by MS/MS using various fragmentation techniques.6 
Collision-induced dissociation (CID)25 in ion traps suffers from dominant neutral losses of 
the labile Amadori compound, often leading to insufficient fragmentation of the peptide 
backbone for identification of the peptide sequence and the glycation site.26, 27 Neutral 
loss-triggered MS3 scans partly alleviate this problem, but at the cost of lower throughput 
and sensitivity.28 Electron-transfer dissociation (ETD)29, a technology generally known to 
be well suited for investigating labile modifications, is very effective for glycated peptides. 
Using ETD, no neutral losses and almost complete series of c-and z-ions were 
observed.30 However, ETD is only implemented on specialized mass spectrometers and 
not on the benchtop Orbitrap instruments that are routinely used in many laboratories. 
Initial promising results have also been obtained for higher-energy collisional dissociation 
(HCD)31 fragmentation, however, so far always in combination with other techniques.28 
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As the benchtop Orbitrap instruments (Q Exactive) exclusively feature HCD 
fragmentation, we therefore set out to systematically evaluate how well glycated peptides 
can be fragmented and analyzed with HCD-MS2 scans alone.  
 
 
EXPERIMENTAL SECTION 
 
IN VITRO GLYCATION OF BSA AND HSA 
Both bovine serum albumin (BSA) and human serum albumin (HSA) (human fraction 5 
powder) were purchased from Sigma Aldrich. BSA (100 mg/ml) was incubated with 1 M 
glucose in 50 mM Tris HCl buffer pH 7.5 at room temperature for the indicated times. HSA 
(10 mg/ml) was incubated with 1 M glucose in the same buffer for 48 h. Both BSA and 
HSA were digested with trypsin (Promega) with an enzyme to protein ratio of around 1:20 
to 1:50 in digestion buffer (2 M urea and 1 mM dithiothreitol (DTT) in 50 mM TrisHCl pH 
7.5). After 20 min, 5 mM chloroacetamide (CAA) was added to the samples, then they 
were incubated overnight to ensure a complete digest. On the next day, the digest was 
stopped by addition of 1 µl trifluoroacetic acid (TFA) per sample. The peptides were 
desalted and purified on StageTips (self-made pipette tips containing two layers of C18 
material) according to the standard protocol.32 The StageTips were stored at 4 °C until 
the sample was measured. BSA and HSA samples were eluted from the C18 StageTips 
with 2×20 µl buffer B (80 % acetonitrile (ACN), 0.5 % acetic acid). The organic solvent 
was removed in a SpeedVac concentrator for 20 min, then the peptide mixture was 
acidified with buffer A* (2 % ACN, 0.1 % TFA) to a final sample size of 5 µl. 
 
PREPARATION OF HELA DIGESTS 
HeLa cells were cultured in high glucose DMEM with 10 % fetal bovine serum and 1 % 
penicillin-streptomycin (all from Life Technologies). Around 5x107 cells were harvested 
and lysed in 6 M urea/2 M thiourea. Proteins were reduced with 1 mM DTT for 30 min at 
room temperature, then alkylated with 5mM iodoacetamide (IAA) for 20 min in the dark. 
Proteins were digested overnight with LysC and trypsin. The digest was stopped by 
adding TFA, then peptides were purified on StageTips as described above. 
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PREPARATION OF WHOLE BLOOD AND BLOOD PLASMA SAMPLES: PROTEIN 
DIGESTION AND IN-STAGETIP PURIFICATION.  
Sample preparation for plasma was done as described previously.33 Briefly, 1 µl of plasma 
was mixed with 24 µl of SDC reduction and alkylation buffer34. After protein denaturation 
by boiling for 10 min, LysC and trypsin were added in a 1:100 ratio (µg enzyme to µg 
protein) and digestion was performed for 1 h at 37 °C. Peptides were acidified by adding 
125 µl ethylacetate/1 % TFA and 20 µg were transferred to StageTips, containing two 14-
gauge SDB-RPS plugs. Washing steps included two times 100 µl ethylacetate/1 % TFA 
and one time 100 µl ddH2O/0.2 % TFA. The purified peptides were eluted with 60 µl of 
elution buffer (80 % acetonitrile, 19 % ddH2O, 1 % ammonia) into auto sampler vials. The 
collected material was dried to completion using a SpeedVac centrifuge at 45 °C 
(Eppendorf, Concentrator plus). Peptides were suspended in 2 % acetonitrile, 0.1 % TFA 
and sonicated (Branson Ultrasonics, Ultrasonic Cleaner Model 2510) prior to analysis. 
The sample preparation procedure for whole blood included an additional sonication 
step of 15 min by a Diagenode Bioruptor prior to digestion. 
 
LC-MS/MS MEASUREMENT OF HSA AND BSA 
Samples were analyzed by nanoflow liquid chromatography (LC-MS/MS) on an EASY-
nLC HPLC system (Thermo Fisher Scientific) that was on-line coupled to either an Q 
Exactive plus or a Q Exactive HF mass spectrometer (all Thermo Fisher Scientific) 
through a nanoelectrospray ion source (Thermo Fisher Scientific). A 50 cm column with 
a 75 µm inner diameter in-house packed with 1.9 µm reversed-phase silica beads 
(ReproSil-Pur C18-AQ, Dr. Maisch GmbH) was used for the chromatography. Peptides 
were separated using a linear gradient from 5.6 % to 25.6 % ACN in 0.1 % formic acid at 
a constant flow of 250 nl/min, then directly electrosprayed into the mass spectrometer. 
Overall gradient length was one hour. The column oven (Sonation GmbH) was heated to 
55 °C. The spray voltage was set to 2.4 kV and the heated capillary temperature to 
250 °C.  
BSA/HSA samples were measured using a data-dependent top10 method, the BSA 
glycation time course was measured in a top1 method. Instruments were controlled by 
Tune Plus 2.0 and Xcalibur 2.0. On the Q Exactive plus, full scans (m/z 300–1,650) were 
acquired with a resolution of 70,000 at 200 m/z and an AGC target of 3E06 ions and 
fragmentation scans with a resolution of 17,500 at 200 m/z and an AGC target of 1E05 
ions. Maximum ion accumulation times were 20 ms for the full scans and 120 ms for the 
fragmentation scans. On the Q Exactive HF, full scans (m/z 300–1,650) were acquired 
with a resolution of 60,000 at 200 m/z and an AGC target of 3E06 ions and fragmentation 
scans with a resolution of 16,000 at 200 m/z and an AGC target of 1E05 ions. Maximum 
ion accumulation times were 120 ms for both full scans and fragmentation scans. The 
most intense ions from the full scans were isolated with an isolation width of 1.4 m/z  and 
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fragmented using HCD, with a normalized collision energy (NCE) of 25 % (Q Exactive 
plus) or 27 % (Q Exactive HF) unless specified otherwise in the text. Dynamic exclusion 
was enabled for a duration of 20 s.  
LC-MS/MS MEASUREMENT OF HELA DIGESTS 
Samples were measured on a Q Exactive HF essentially as described for BSA and HSA 
with the following alterations: Gradient length was 2 h, HeLa samples were measured in 
top15 mode and the maximum ion accumulation time for fragmentation scans was 25 ms. 
 
LC-MS/MS MEASUREMENT OF BLOOD PLASMA/ WHOLE BLOOD 
Samples were measured on a Q Exactive HF essentially as described for BSA and HSA 
with the following alterations: Column length was 40 cm and the column oven temperature 
was set to 60 °C. Gradient length was 100 min and samples were measured using a data-
dependent top15 method. Full scans (m/z 300–1,650) were acquired with a resolution of 
120,000 at 200 m/z, an AGC target of 3E06 ions and a maximum injection time of 55 ms. 
An isolation window of 1.5 m/z and a fixed first mass of 100 m/z was used for MS/MS 
scans. HCD fragmentation was performed with an NCE of 27. MS/MS scans were 
acquired with a resolution of 30,000 at 200 m/z with an AGC target of 1E05 ions and a 
maximum injection time of 55 ms. Dynamic exclusion was enabled for a duration of 30 s. 
 
DATA ANALYSIS 
All raw data was analyzed using the MaxQuant35 software environment (version 1.5.3.0). 
The software searched the derived peak list using the built-in Andromeda search engine36 
against either a bovine reference proteome downloaded from Uniprot 
(http://www.uniprot.org/) on February 2016 (24481 sequences) or against a human 
reference proteome downloaded from Uniprot in May 2013 (88847 sequences). In all 
cases, a file containing 247 frequently observed contaminants such as human keratins 
and proteases was included in the search. Trypsin was chosen as the protease with strict 
specificity for cleavage C-terminal to K or R required. Up to two missed cleavages per 
peptide were allowed. The minimum peptide length was set to 7 amino acids. Due to the 
sample preparation, carbamidomethylation of cysteine was set as a fixed modification 
(57.021464 Da). N-acetylation of protein N-termini (42.010565 Da) and oxidation of 
methionine (15.994915 Da) were set as variable modifications. For glycation/AGE 
analysis, the corresponding modification with/without different neutral losses was defined 
in Andromeda configuration and added to the variable modifications as stated in the 
text.(Glycation: 162.052823 Da, CML: 58.005479 Da, CEL: 72.021129 Da, MG-H1: 
54.010565 Da, Argpyr: 80.026215 Da, 3DG-H1: 144.042259 Da) All other parameters 
were left at standard settings. Peptide and protein identifications were filtered at a false 
discovery rate (FDR) of 1 %. The ‘match between runs’ option was used where specified 
in the text with a match time window of 0.7 min and an alignment time window of 20 min.  
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Further analysis of the MaxQuant output tables was performed using the Perseus 
software (version 1.5.3.0), which is part of the MaxQuant environment. Plots were 
produced in R (version 2.15.3). 
 
DATA AVAILABILITY 
 
Raw data and MaxQuant output files are accessible via ProteomeXchange37 with 
identifier PXD004182. 
 
 
 
RESULTS AND DISCUSSION 
 
HCD FRAGMENTATION OF GLYCATED PEPTIDES 
Orbitrap mass spectrometers have proven to be powerful instruments for proteomics in 
general and clinical proteomics in particular, and today are standard in many laboratories. 
The widespread benchtop quadrupole Orbitrap instruments (Q Exactive family) only 
feature HCD as fragmentation method. As previous work on glycated peptides had 
employed ETD or a combination of other fragmentation methods with HCD, we here set 
out to investigate whether glycated peptides can be identified solely on the basis of HCD-
MS/MS scans. As glycation is typically studied in blood plasma, we chose human serum 
albumin (HSA) as a model protein. We glycated HSA in vitro, digested it with trypsin and 
measured the resulting peptides on a Q Exactive HF without optimizing the instrument in 
any way. In the MaxQuant data analysis software35, we included protein glycation 
(C6H10O5; 162.0528 Da) as a variable modification on lysine, which is the major target for 
glycation by glucose, and on arginine. The ‘matching between runs’ algorithm was 
enabled between the three technical replicates, which transfers peptide identifications to 
LC MS/MS runs where the same peptide was present but was not sequenced. 
Surprisingly, in view of the complex experimental set-up previously employed in the 
analysis of glycation, already this first experiment identified 45 unique glycation sites on 
HSA. Most sites (42) were located on lysine, consistent with the fact that this residue is 
the primary target for this type of glycation, and only three sites were found on arginine. 
Thus the large majority of the 59 lysines in mature HSA can be glycated in vitro by 
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incubation with high glucose concentrations. Interestingly, UniProt lists only 20 of the 42 
lysine sites as glycated in vitro or in vivo, while 22 of them were incorrectly annotated as 
‘not glycated’ in UniProt (See Table 1 A). The five strongest glycation sites as indicated 
by the MS intensity of their corresponding glycated peptides were K257, K549, K438, K36 
and K223 (Table 1B). Consistent with our in vitro results, K36, K223, K257 and K549 
have also been reported to be HSA glycation sites in vivo.38 Interestingly, K438 has not 
been reported to be glycated before (only K437), and we found no evidence of two other 
reportedly strong in vivo glycation sites, K305 and K463. The fact that we identified such 
a high number of sites on this widely used model protein suggests that standard HCD-
MS/MS scans are remarkably well suited for the characterization of glycated peptides.  
 
OPTIMIZING THE COLLISION ENERGY FOR GLYCATED PEPTIDES 
 
In addition to backbone fragmentation, glycated peptides can also fragment by losing all 
or part of the Amadori product during CID and HCD fragmentation.27, 39 Therefore collision 
energies for HCD might be different for the identification of glycated peptides compared 
to unmodified peptides, which was suggested by the relatively low identification scores of 
the glycated HSA peptides described above. Using in vitro glycated BSA as a model 
protein, we performed LC-MS/MS runs with six different normalized collision energies 
(NCEs) centered around the standard NCE that we use in our shotgun proteomics 
experiments. Plotting the number of unmodified BSA peptides identified at each collision 
energy confirmed that an NCE of 25 % on the instrument employed (Q Exactive Plus) 
was indeed optimal for these peptides (Figure 1A). The same analysis revealed a broad 
optimum NCE for the number of identified glycated peptides, centered between 20 (43 
sites) and 25 % (42 sites) (Figure 1B). An NCE of 40 %, in contrast, dramatically reduced 
identification success. Next we investigated for each identified glycation site in which of 
the measurements at the different NCEs it was best localized to a particular amino acid 
(localization probability) and where it obtained the maximum database identification 
score. By these measures, an NCE of 20 % appeared to be optimal for both localization 
and identification (Figure 1C, D).  
111
2 Results
9 
 
When we examined the fragmentation spectra of the glycated peptides more closely, we 
found that at higher NCEs, there were typically no fragments carrying the full modification 
of 162.053 Da. Furthermore, b-ions were mostly absent from the spectra, and often a 
number of intense peaks in the higher mass range were unexplained by standard 
backbone fragmentation (for an example, see spectrum in Figure 2A). The Amadori 
compound can lose several water molecules and formaldehyde during CID and HCD 
fragmentation27, 39, resulting in residual modification masses of 144.0423 Da, 126.0317 
Da, 108.0211 Da, 96.0211 Da and 78.0106 Da (Figure 2B). Additionally, we also 
observed loss of the entire glucose moiety from the fragments and the intact peptide. 
After annotating the spectrum in Figure 2A with these reduced forms of glycation using 
the expert system for fragment annotation40, we were able to explain basically all the 
peaks in the spectrum (Figure 2C). Essentially the complete series of backbone 
fragments were represented in at least one of the possible modification states, with the 
exception of cleavage between the N-terminal phenylalanine and the glycated lysine. 
Generally, while the loss of only one water molecule leading to the 144.0423 Da 
modification seemed to occur rarely, other pathways appeared to be more dominant: the 
loss of three water molecules leading to the 108.0211 Da modification, and the loss of 
three water and one formaldehyde molecules leading to the 78.0106 Da modification.  
We reasoned that taking the neutral losses into account, we might be able to use our 
standard collision energy of 25 % (or 27 % on the Q Exactive HF) to both obtain efficient 
backbone fragmentation, as well as confidently identify glycation sites. As the MaxQuant 
software only supports one neutral loss per modification to avoid combinatorial explosion, 
next determined the most common neutral loss in a systematic way. We defined seven 
different versions of glycation for the search engine: without any neutral loss, with a 
neutral loss of H2O, H4O2, H6O3, CH6O3, CH8O4, and finally C6H10O5 corresponding to the 
entire modification. Interrogating the data file obtained at the NCE of 25 % with the seven 
different versions of glycation on lysine, we found that a neutral loss of three water 
molecules (H6O3) leading to a residual mass of 108.0211 Da yielded most glycation sites 
in total (47 sites, see Figure 3A). This search mode also produced most high confidence 
sites, for example 44 sites with an identification score of over 75. CH8O4, with a residual 
modification mass of 78.0106 Da was the next most common neutral loss, followed by 
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loss of the entire glucose moiety. With these optimized collision and search settings, we 
now found an additional 17 glycated lysines on BSA, compared to the search without 
neutral loss (Figure 3A). Figure 3B illustrates that the neutral loss of three water 
molecules explains the majority of peaks in the MS/MS spectra. Having established the 
dominant neutral loss in HCD fragmentation at the standard (and optimal) collision energy 
of 25 % to be the loss of three water molecules, we subsequently routinely included this 
neutral loss in the search for glycated peptides.  
Applying the three water neutral loss analysis to our previous analysis of in vitro-glycated 
HSA increased the number of unique glycation sites increased from 45 to 54. Among 
those are 50 lysine residues, meaning that a remarkable 85 % of all lysine residues in the 
mature HSA sequence can be glycated in vitro. This can be explained by the fact that 
lysine as a charged amino acid is typically surface exposed. The number of glycated 
arginines went up from three to four, and the additional site at R184 has been reported 
before (see Supplementary Table 1). Regarding the previously reported in vivo glycation 
sites, we now additionally identify K305, however we still find no evidence for glycated 
K463. 
Assessing the effect of including the dominant neutral loss on the collision energy 
evaluation, we found that an NCE of 25 % now resulted in the most BSA glycation sites 
and the total number of sites increased from 43 to 60 (Supp. Figure 1A). The best 
localization was now obtained with an NCE of 30 %, while the highest score was clearly 
obtained with an NCE of 25 % (Supp. Figure 1B, C). Thus the overall optimal collision 
energy should be between 25 and 30 %. Considering that 25 % is the optimal setting for 
unmodified peptides and hence peptide backbone fragmentation, and that localization of 
the glycation site is generally not problematic, we recommend an NCE of 25 % as also 
optimal for fragmenting glycated peptides, provided the neutral loss of H6O3 is taken into 
account. (Optimal NCEs depend slightly on the specific model and we find an NCE of 
27 % to be optimal for glycated and non-glycated peptides on the Q Exactive HF ref41).  
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TIME- DEPENDENCY OF PROTEIN GLYCATION  
 
To investigate the increase of protein glycation over time in vitro, we incubated BSA with 
1M glucose for 0-30 days, since after 30 days the equilibrium of the reaction forming the 
Amadori product should have been reached.42 Samples were analyzed in triplicates for 
glycation on K and R allowing for a neutral loss of H6O3 and without matching between 
runs. Interestingly, our results revealed some glycation events already on the purchased 
BSA before in vitro incubation with glucose. These are presumably in vivo glycations that 
have remained stably associated with the protein after purification from bovine blood, 
processing and storage.  We identified 11 such sites in all three replicates: K28, K36, 
K88, K256, K263, K266, K299, K401, K498, K548 and K561. (Note that if comparing BSA 
to HSA sites there is a plus one difference in amino acid position starting from position 
140.) Two of these (K36 and K256) correspond to known HSA in vivo sites.  With longer 
incubation the number of detected glycation sites increased substantially (Figure 4A). 
The figure shows a near doubling of detected sites already after one day. This means we 
are initially detecting the Schiff base adduct, since several days are needed to convert 
the Schiff base to the more stable Amadori product.43 On day 30, almost all sites were 
still found on lysine.  There was also a substantial number of doubly glycated peptides, 
consistent with the fact that glycation inhibits tryptic cleavage (Figure 4B), and a clear 
quantitative increase in glycation over time (Figure 4C).  
 
ANALYZING PROTEIN GLYCATION IN CELL LYSATE AND BLOOD PLASMA 
 
To evaluate the feasibility of detecting glycated peptides in a complex matrix without 
applying any enrichment step, we chose HeLa lysate as a first test matrix. Because 
glucose concentrations in standard cell culture conditions are already around five times 
higher than the physiological concentrations in the body (4.5 mg/mL glucose vs. 0.75-
1.15 mg/ml in normal human blood44), we chose to not further expose the cells to glucose. 
HeLa lysates were trypsin digested in four workflow replicates, measured in single-shot 
2 h measurements on a Q Exactive HF and analyzed for glycation as described before 
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with matching between runs. Even in the absence of any enrichment, we identified 155 
glycation sites on 94 different proteins, with a mean localization probability of 0.95. 
Surprisingly, and in stark contrast to our model plasma proteins, the most frequently 
modified amino acid was arginine (83 sites) and not lysine (72 sites) (Figure 5A). This 
indicates that in an intracellular system, arginine and lysine are about equally reactive as 
targets for glycation by glucose.  
We next investigated possible formation of AGEs in the HeLa proteome. Intracellularly, 
AGEs may not form by reaction with glucose and via the Amadori product, but instead by 
direct reactions with glucose metabolites.45 Therefore, we additionally included some 
major in vivo AGEs derived from glyoxal, methylglyoxal or 3-deoxyglucosone into the 
analysis: carboxymethyllysine (CML), carboxyethyllysine (CEL), methylglyoxal-derived 
hydroimidazolone (MG-H, on arginine), argpyrimidine (on arginine) and 3-
deoxyglucosone-derived hydroimidazolone (3DG-H, on arginine). We indeed found many 
sites for all of those AGEs, and interestingly detected about 5 times more arginine AGEs 
than lysine AGEs (see Figure 5B). This is consistent with what we found for early 
glycation and with the fact that methylglyoxal is more reactive towards arginine than 
lysine.46 Unexpectedly, argpyrimidine was the most common AGE, even though its half-
life under physiological conditions has been reported to be shorter than that of MG-H1 (2-
9 days vs. 2-6 weeks).47 All Hela glycation and AGE sites are listed in Supplementary 
Table 2. 
We next went on to test our method on human blood plasma. Exploiting the high scan 
speed of the Q Exactive HF, we set out to detect glycation sites directly from less than a 
single drop of human plasma, without depletion of high abundance proteins, peptide 
fractionation or enrichment of glycated peptides. We performed the plasma analysis in 
three technical replicates and analyzed the purified peptides in 100 minute gradients 
using a Top15 method. This yielded 101 glycation sites located on 53 proteins. Similar 
numbers were obtained in a 2008 study using immunodepletion and boronate affinity 
enrichment, however, with 5000 times the input material and substantially longer sample 
processing times.48 The protein carrying the most glycation sites was albumin with 16 
sites, 11 of which were identified with very high localization scores (>0.99): K36, K44, 
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K161, K214, K223, K249, K257, K375, K402, K549 and K598. Although identified in a 
direct and relatively straightforward analysis in normal human blood, three of these sites 
have not been reported to be glycated before according to UniProt (see Table 1). Many 
other typical plasma proteins were found to be glycated, among them apolipoprotein A1 
(8 sites), alpha-1-antitrypsin (4 sites), serotransferrin (3 sites), fibrinogen alpha and beta 
chain (1 site each), and interestingly, many antibody chains. Overall, the plasma glycation 
sites had a mean localization probability of 0.95, and a mean absolute mass error of only 
0.12 ppm (Supplementary Table 3). The vast majority of glycations in plasma was found 
to be located on lysine (90 vs. 11 sites; Figure 5C). This was similar to what we observed 
on the model proteins before, but very different from the glycated HeLa proteins (see 
Figure 5A).  Furthermore, while in the cell lysate, the majority of the peptides was 
glycated twice, in plasma the majority of the peptides carried only one glycation. We also 
searched the plasma samples for the five AGEs mentioned above, and found at least 20 
sites for each of them, with CML and 3DG-H1 being the most abundant AGEs at 34 sites 
each (see Supplementary Table 4). In contrast to HeLa cells, lysine and arginine AGEs 
were similarly abundant in plasma (Figure 5D). 
In a final experiment, we measured whole human blood with all cellular components. Thus 
it includes the hemoglobin beta-chain (HBB) and its glycation site on the N-terminal 
valine, which is clinically used to determine the HbA1c value from which diabetes can be 
diagnosed. We digested and measured whole blood as described before for plasma and 
analyzed the resulting samples for glycation on valine as well as on lysine and arginine 
(always including the neutral loss of H6O3). We indeed clearly identified the modified 
valine in position two of HBB (N-terminal position when considering the loss of the 
initiating methionine), on the easily detectable peptide V*HLTPEEK. Additionally, we 
found four of the five known lysine glycation sites on HBB, as well as two additional sites 
that have not been reported before. We also detected all four known lysine glycation sites 
on the hemoglobin alpha chain (HBA) plus two additional ones (See Supplementary 
Table 5 for all hemoglobin sites). If ordered by site intensity, K133 was the strongest site 
on HBB and K41 on HBA. 
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CONCLUSIONS AND OUTLOOK 
 
Blood plasma is one of the most challenging proteomes, spanning more than ten orders 
of magnitude in abundance from the highest to the lowest known plasma protein. 
Furthermore, PTMs on plasma proteins add another layer of complexity to the inherently 
intricate plasma proteome. Previous investigations of glycated plasma proteins had relied 
on extensive sample fractionation, enrichment of glycated peptides and different peptide 
fragmentation methods. 
 In the context of our interest in diabetes, we here asked if modern benchtop Orbitrap 
platforms are capable of the analysis of glycated peptides in plasma. This would be 
particularly attractive if it could be incorporated into a routine and robust workflow for 
plasma proteomics.33  
We evaluated the fragmentation behavior of glycated peptides, and found that HCD-
MS/MS scans with the standard collision energy also used by us in proteome 
measurements are very well suited for identifying and localizing glycation sites. This 
requires that the prevailing neutral loss of H6O3 is taken into account. In this way, we 
developed a straightforward workflow to detect glycated peptides directly from blood 
plasma without applying time-consuming depletion, fractionation or enrichment steps. We 
additionally screened for several well-known AGEs, and found that they can also be 
efficiently detected from plasma.  Our study demonstrates that straightforward plasma 
proteome analysis can identify early and advanced protein glycation in this challenging 
body fluid, as part of the routine plasma proteome profiling workflow. Together, this 
successfully established HCD fragmentation for the investigation of protein glycation in 
general and early glycation in particular. 
It may be interesting to determine the reasons for the marked differences in the glycation 
behavior of intracellular proteomes and the plasma proteome – in particular the 
overwhelming preference for lysine over arginine glycation in plasma in contrast to equal 
occurrence in the cellular proteome.   
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In the future, we plan to implement a quantification strategy for glycated peptides from 
patient material, since this would allow to directly assess the level of blood sugar control 
in any individual in a proteomic study. Clearly, this would be very challenging with label 
free methods, because of the required accuracy: normal HbA1c values of below 5.7 % 
need to be robustly distinguished from the pre-diabetic range (5.7-6.4 %) and diabetic 
values of >6.5 % (Values according to the World health organization report on the use of 
HbA1c in the diagnosis of diabetes, 2011). We envision the use of isotopic labels that can 
be introduced into patient material via chemical labeling strategies, such as iTRAQ or 
TMT. However, ratio compression, which can occur with these techniques, would not be 
clinically acceptable and additional challenges connected to the fact that trypsin or LysC 
do not cleave at glycated lysine residues will have to be overcome.  
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CID –  Collision-induced dissociation 
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DTT –  Dithiothreitol 
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HBB– Hemoglobin beta chain 
HCD –  Higher-energy collisional dissociation 
HPLC –  High-pressure liquid chromatography 
HSA –  Human serum albumin 
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IDF – International Diabetes Federation 
LC-MS/MS –  Liquid chromatography tandem mass spectrometry 
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NCE –  Normalized collision energy 
PTM –  Post translational modification 
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FIGURES 
 
Table 1. Detected glycation sites on HSA (A) Sites ordered by position and their status in UniProt and/or 
in a recent review38 if marked by an asterisk.  (B) All sites with three valid values ordered by their mean 
log2 transformed intensity.  
 
Figure 1. Evaluation of different collision energies. (A) Number of unmodified BSA peptides identified 
with six different normalized collision energies (NCEs) from 15 to 40 %. (B) Glycation sites identified when 
searching for glycation on K and R. (C) Localization score as a function of the NCE. (D) Andromeda 
database identification score36 as a function of the NCE.  
 
Figure 2. HCD fragmentation behavior of glycated peptides. (A) Spectrum of the glycated BSA peptide 
FK*DLGEEHFK with an NCE of 25 % (the asterisk or green color denotes the position of glycation). An 
almost complete y-ion series is apparent, however, not a single b-ion was found and many peaks in the 
spectrum are unexplained. (B) Scheme of proposed pathways generating different neutral losses during 
CID/HCD fragmentation (adapted from ref 39 ) (C) The same spectrum as in (A) now manually annotated 
with the different neutral losses, which explains essentially all fragments. 
 
Figure 3. Evaluation of the different neutral losses. (A) Number of glycation sites identified in seven 
different MaxQuant runs of the same data file with no neutral loss (no NL), neutral loss of H2O (-18 Da), 
two H2O (-36 Da), three H2O (-54 Da), CH6O3 (-66 Da), CH8O4 (-84 Da), and of the entire Amadori 
compound (-162 Da). (B) Same spectrum as in figure 2A and 2C now annotated with an almost complete 
b-ion series due to integrating the neutral loss of three water molecules in the database search. Asterisks 
on the b-ions indicate that they carry the residual modification after neutral loss of H6O3 (standard 
annotation feature in the MaxQuant viewer). 
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Figure 4. The time-dependency of the in vitro glycation reaction. (A) Number of identified glycation 
sites in triplicate analysis of BSA in vitro glycated with 1M glucose for 1-30 days. (B) Analysis of residue 
and multiplicity of all glycation sites identified on day 30. (C) Heatmap of the intensities of those glycated 
lysine sites with more than 50 % valid values over the course of the experiment. 
 
Figure 5. Properties of glycated peptides and AGE analysis. (A) Analysis of glycated peptides identified 
in HeLa lysate, showing the preferred site of glycation and their multiplicity i.e. whether identified peptides 
were glycated one, two or three times. (B) Same analysis for glycated peptides identified in blood plasma. 
(C) Barplot depicting the number of proteins, glycation sites and some major AGE sites identified in the 
HeLa sample. (D) Barplot depicting the number of proteins, glycation sites and some major AGE sites 
identified in the blood plasma sample. 
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3 Conclusion and outlook
Mass spectrometry-based proteomics is today established as the most effective tech-
nique in proteomic research. It is the only method that can identify proteins in a high-
throughput manner from immensely complex samples, and in addition obtain quanti-
tative information about every identified protein. The range of applications in which
MS-based proteomics can give new insights is ever growing. In this thesis, I have shown
three areas where this technology can make tremendous contributions.
Not long ago, members of protein complexes were identified by developing dedicated
multistage biochemical purification schemes for individual stable complexes, a laborious
process easily filling a whole doctorate for one complex. Nowadays, large-scale quantit-
ative interaction studies are straightforward to perform, especially with label-free quan-
tification as implemented in the presented AE-MS pipeline. Such studies are now feasible
within a relatively short time-frame, due to the development of even faster measurement
techniques like the presented double-barrel system. Even though the interaction tech-
niques described in this thesis have been developed for large-scale applications, they are
also extremely powerful for answering defined questions, as I have shown in a small-
scale project on human histone variants.
The second presented application for MS-based proteomics is the investigation of un-
usual posttranslational modifications. Next to the tremendous increase in known sites
that we have gained from MS-based proteomics experiments for certain well-character-
ized PTMs like phosphorylation, the possibility of detecting completely unknown modi-
fications, as presented in the EF-P project, is particularly intriguing. I also investigated
protein glycation, a non-enzymatic and hence rather untypical PTM relevant in diabetes
pathology.
The glycation project is also an example for the third application of MS-based proteomics
presented in this thesis, namely clinical proteomics in general and plasma proteomics in
particular. The great complexity and dynamic range of blood plasma has so far hampered
the successful application of mass spectrometry for investigating plasma proteins. How-
ever, now the prerequisites are changing due to various improvements on the technology
side, and mass spectrometry will surely soon start to impact on clinical questions.
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Interaction proteomics – History, present day and future directions
The global study of protein-protein interactions has only become feasible around the
year 2000, when AP-MS techniques became able to create large-scale interaction data-
sets (see Figure 15). Over the years, the technology has been further refined, with the
most relevant step being the implementation of quantitative mass spectrometry into the
AP-MS workflow. Since then, it is possible to truly distinguish specific interactors from
unspecific background binders. Surprisingly, despite this fact, even today many stud-
ies still rely on outdated non-quantitative techniques. Especially since the maturation
of label-free approaches into highly accurate quantification strategies, quantitative data
can now be acquired in a very straightforward manner. The only requirements for LFQ
interaction studies like the AE-MS-pipeline presented in this thesis are replicates and a
reproducible sample preparation, two prerequisites that are usually anyway given in bio-
logical experiments. When protein quantification finally becomes the standard for in-
teractomics, high confidence large-scale interaction networks will become available for
numerous organisms. Such networks will increase our knowledge about which proteins
interact with each other, and also allow to obtain additional information like complex
topologies and stoichiometries as extremely useful byproducts.
Figure 15: A timeline of some important discoveries and advances in protein research in general
and early interactomics in particular. From [156]
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The next step forward for interactomics will be to investigate interaction networks un-
der various conditions and perturbations. Right now, most datasets are produced from
exponentially growing cells. However, just like the proteome, the interactome is highly
dynamic. Investigating cells under various conditions could lead to the discovery of
completely new protein complexes, that only form under these conditions and hence
could not be detected so far. How interaction networks change in various diseases, and
how such changes can impact on the disease biology, will be of particular interest in this
area.
Endogenous expression of bait proteins is a prerequisite to obtain meaningful interaction
results. So far, true endogenous expression of tagged bait proteins has only been possible
in lower complexity organisms, but not in humans. Although technologies such as the
BAC strategy used in the QUBIC approach are getting very close to that desired goal,
this technique still introduces another copy of the endogenous gene and hence provides
close to, but not completely endogenous regulation and expression. However, recently a
technique that finally allows tagging in the endogenous locus has been described. The so
called CRISPR/Cas system is an acquired immunity mechanism in prokaryotes, that can
be be used to edit the human (or any other) genome at any desired location [157–160].
To do so, an appropriate guide RNA that binds the desired DNA locus, and the Cas9 en-
zyme that recognizes the guide RNA and cleaves the DNA at the targeted position, are
transfected into cells. Libraries of human cells endogenously expressing tagged proteins
are likely being created right now, and will present excellent resources for mapping the
human interactome. With this system, other genetic modifications like the introduction
of point mutations, the removal of protein domains, or the knock-out of entire proteins
are also possible, and can give further insight into the properties of interactions.
Even though classic AP-MS can address many questions in interaction proteomics, sev-
eral powerful complementary MS-based approaches exist. Crosslinking techniques can
determine complex topologies or retain transient interactors. Their successful large-
scale application has been hampered so far by the complex and hard to interpret frag-
mentation spectra that are produced from crosslinked peptides. However, new develop-
ments in this area show great promise, and crosslinking techniques will likely gain mo-
mentum in the future. Recently CID/HCD-cleavable crosslinkers have been developed;
with this technology crosslinked peptides can now be separated into the two linked pep-
tides by applying modest collision energies in the source region of the mass spectrometer.
Subsequently, the now unlinked peptides can be individually isolated and fragmented
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leading to MS2 spectra of ‘normal’ complexity [161]. The recently introduced ‘BioID’
technology takes a completely different approach to investigate weak and/or transient
interactors [162]. In this approach, a biotin ligase is fused to the protein of interest, lead-
ing to biotinylations on proteins in close proximity. The proteins modified in this way
can be isolated by affinity purification and subsequently analyzed by MS. This approach
can also be used to investigate insoluble proteins, and hence complement standard AP-
MS datasets. Some progress has also been made in the field of top-down and native
proteomics. Native MS approaches can now successfully be used to measure whole pro-
tein complexes and even structures as large as virus capsid-antibody conjugates [163].
Collectively, the interaction projects presented in this thesis have demonstrated that MS-
based interaction proteomics is a highly powerful technique, and the described devel-
opments will hopefully contribute to its further success in the future.
Posttranslational modifications – Investigating less characterized modifications
Mass spectrometry-based proteomics has tremendously increased our knowledge about
certain PTMs, however this trend has generally been restricted to modifications with
known composition, and modifications where efficient enrichment strategies are avail-
able.
Since bottom-up MS relies on database searching to identify peptides and modified pep-
tides, it can inherently not discover modifications with unknown mass. In this thesis, I
have applied an interesting search mode that allows for the unbiased detection of com-
pletely unknown modifications from standard shotgun experiments. This ‘dependent
peptide search’ compares all unidentified with all identified peptides, based on the as-
sumption that some of the former could not be identified by the standard search because
they are modified versions of already identified peptides. So far, the dependent peptide
search can only identify dependent peptides when the unmodified counterpart is also
present in the sample, however, this can be resolved by not taking all identified peptides
as basis for the search but all theoretical peptides. In the EF-P project, I have successfully
applied this technique for detecting the modification that activates EF-P, demonstrat-
ing the power of the approach. Especially for relatively specific questions, like the one
presented here investigating one modification on one particular protein, we think that
this search mode can have a big impact in the future.
PTMs on proteins are mostly substoichiometric, hence their successful detection is usu-
ally based on specific enrichment to aid identification by MS. Therefore, the analysis
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of many other highly interesting PTMs, for which no specific enrichment strategy is
available, has lagged far behind. More focus should in the future be put on such under-
investigated PTMs, by either developing the required enrichment methods, or by find-
ing ways to investigate them without enrichment. Recently, several new antibody-based
enrichment strategies have been developed e.g. for ubiquitination [164], histidine phos-
phorylation [165] and arginine-methylation [166]. Due to the increased scanning speed
and dynamic range of modern MS instrumentation, PTMs can in many cases indeed be
detected without enrichment, however naturally not to the same depth.
In this thesis, I have studied protein glycation, an unspecific PTM (i.e. not added by an
enzymatic process) where our knowledge so far is quite restricted. In the case of glyca-
tion, the thorough investigation has not been prevented by a lack of efficient enrichment
strategies, but simply by the fact that is it primarily occurring in blood, the most chal-
lenging sample for MS-based proteomics. We propose that the in-depth study of glyc-
ated proteins will give new insights in the pathology of diabetes, and potentially allow
to better diagnose and/or monitor the disease. Likewise, the investigation of other un-
usual PTMs should yield interesting new physiological or pathological regulatory mech-
anisms.
Clinical proteomics
Despite all the knowledge we have gathered in the natural and medical sciences, the
number of diseases we completely understand down to the molecular level is relatively
small, which hampers the development of new drugs in a targeted manner. Genomic
techniques have in many cases been able to identify the mutations underlying certain
diseases, however, the effects of those mutations often remain elusive. Well-known ex-
amples for such cases include Huntington’s disease and hereditary forms of Parkinson’s
disease. Hence it has become clear, that in order to understand disease pathology, we
should concentrate more of our efforts on investigating the proteome.
Initially hampered by technical issues, proteomics is just beginning to move into the
clinical field. One challenge was to achieve accurate quantification of proteins from pa-
tient samples, which inherently can not be metabolically labeled. However, now patient
samples can easily be quantified using chemical labeling techniques (e.g. [167]), using
specialized metabolically labeled standards as in the super-SILAC approach [59, 168],
or of course using label-free strategies [77]. Another issue was the accessibility of tissue
samples from biobanks, a highly valuable source for clinical proteomics research. Such
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samples are preserved by fixing with formalin and embedding in paraffin. Some years
ago, protocols to efficiently extract peptides from such formalin fixed paraffin embedded
(FFPE) samples for MS analysis have been developed, successfully solving this problem
[169, 170]. Finally, as already discussed in the introduction, one of the most desirable
input materials for clinical studies, namely blood plasma, is also the most challenging
one for proteomics research. To some degree, targeted methods successfully circum-
vent the dynamic range problem in plasma by following only a limited number of ana-
lytes, however, they can only be used when the proteins of interest are already known.
For the unbiased discovery of protein biomarkers, data-dependent shotgun proteomics
is the only way to go. Technical advances on the instrumentation side have expanded
the limits of this technology, and together with sophisticated fractionation techniques
we hopefully soon can reach sufficient depth to measure down to the highly interesting
regulatory plasma proteins and tissue leakage proteins. However, valuable information
is already contained in the top abundant proteins, which we can easily measure today.
These include for example apolipoproteins, some of which are involved in the develop-
ment of vascular diseases and hence heart disease and stroke.
Many challenges still remain to be solved before proteomics can be routinely applied
to diagnose patients. Most importantly, measurements have to become highly repro-
ducible and robust to allow statistically sound conclusions. Nevertheless, at some point
in the future probably not far from now, proteomics will definitely have an enormous
impact on the way we diagnose and monitor diseases, and help to provide patients with
customized and hence maximal effective therapies.
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